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The PI3K-Akt signalling pathway is central to cell proliferation and growth, and hyperactivating 
mutations in this pathway are found in a large number of cancers. Downstream of PI3K, Akt is 
heavily studied, however the highly related SGK family of protein kinases have recently been 
identified as driving cancer cell growth in certain contexts. In particular, my research interest 
and the focus of this thesis is the role these kinases, in particular SGK3, has in resistance to Class 
I PI3K and Akt inhibitors in certain ER+ breast cancers. 
The first major aim of my PhD was to develop a method by which the signalling of SGK3 can be 
specifically modulated in cancer cells. Due to the high homology between the SGK family of 
protein kinases, chemical inhibition of SGK3 specifically has not been possible. Further, model 
cancer cell lines have been intractable to genome modification. I therefore, in collaboration with 
the Ciulli lab, designed and characterised SGK3-PROTAC1, a Proteolysis Targeting Chimera 
(PROTAC) which targeted SGK3 for specific ubiquitylation by VHL E3 ligase and subsequent 
proteasomal degradation. I demonstrated by quantitative Mass Spectrometry that SGK3-
PROTAC1 mediated degradation was highly specific. Rapid, reversible degradation of SGK3 
provided a tool for specifically modulating SGK3 in cancer cells. Further analysis using this 
compound in ZR-75-1 cells suggested some possible, previously unknown functions of SGK3 in 
cAMP signalling and mitochondrial metabolism. On degradation of SGK3, I observed a 
downregulation of the phosphodiesterase PDE4D and upregulation of a host of proteins 
mediating Oxidative Phosphorylation in mitochondria. These effects were observed only on 
degradation of the protein and not inhibition of its kinase activity, suggesting putative kinase-
independent roles of SGK3. These findings would be extremely exciting to follow up in future 
work, and demonstrate the power of the PROTAC approach. 
Given the potential of the PROTAC approach to probe biological systems, I also collaborated with 
the Ciulli lab to generate HaloPROTAC-E. This compound utilizes the bacterial dehalogenase 




I demonstrated that HaloPROTAC-E was able to induce degradation of the entire VPS34 complex 
to impact on downstream biology. This compound will be a useful tool within the unit and wider 
field to study proteins with no known ligands or validate target proteins for potential PROTAC 
development. 
The second aim of my PhD was to study how SGK3 is activated in the context of PI3K inhibition. 
In this thesis, I studied the mTORC2 component mSin1, and provide preliminary data to show 
that certain regions of this protein may explain the differential regulation of Akt and SGK3. I also 
performed a preliminary assay to study interactors regulating the activity of Class III PI3K VPS34. 
Together, these experiments represent important preliminary results in understanding the 
activation of SGK3 and how it mediates Class I PI3K and Akt inhibitor resistance. 
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1.1  Post-Translational modifications, and protein phosphorylation, in 
signal transduction 
For survival, it is critical for cells to be able to respond to signals both internally and from their 
external environment. Sophisticated signalling mechanisms have therefore evolved for cells to 
recognise and appropriately respond to stimuli. Signalling cascades typically result from the 
binding of a signalling molecule, for example external growth factors or internal nutrient levels, 
to a receptor, altering its activity and mediating downstream cellular enzymes. This activation 
results in a cellular response (Figure 1A). A strong advantage to these signalling cascades is that 
sensitivity to subtle changes in the cellular environment can be amplified through the cascade.  
In order to propagate signals, cellular enzymes will frequently modify their substrates through 
mechanisms such as proteolytic cleavage or post translational modifications, for example the 
conjugation of phosphates, carbohydrates or ubiquitin onto substrate proteins (Figure 1.1A). 
These post-translational modifications can dynamically modulate the activity, localisation and 
stability of almost all proteins encoded by the human genome. Additionally, many of these 
cascades are also reversible. For example, as will be discussed further in Chapter 3, 
polyubiquitylation of a target protein can act as a signal for its proteasomal degradation. 
Addition of a carbohydrate moiety to a substrate protein can form a transduction signal or a 
protein interaction motif. Many highly abundant post-translational modifications remain largely 
understudied, due to the lack of tools or analysis to detect them. A recently published study 
used new mass spectrometry analytical techniques to increase known sites of proline 
hydroxylation 10-fold (Devabhaktuni et al., 2019). Another vast class of signal transduction, and 
the focus of this thesis, is protein phosphorylation. 
Protein phosphorylation is the conjugation of a phosphate group to a substrate protein, and is 
a key component of most signal transduction cascades. This is carried out by protein kinases, 




typically occurs on the hydroxyl group of Ser, Thr, or Tyr residues, however other non-canonical 
phosphorylation sites are less well studied (Hunter, 2012). This modification is reversed by the 
action of protein phosphatases. Phosphorylation is an ideal mechanism for signal transduction 
as it is a rapid and reversible process, creating a simple “molecular switch” which does not 
require the synthesis or degradation of any new proteins. Protein phosphorylation results in the 
local addition of 2 negative charges, and therefore a considerable local charge change, which 
often results in conformational change of the substrate protein. This can have a number of 
downstream effects. The most common effect of enzyme phosphorylation is activation or 
deactivation of that enzyme, by revealing or occluding an active site. Alternatively, this 
conformation or charge change can result in altered interaction with downstream substrates 
and binding partners, creating a change in protein localisation, stability or function (Figure 1.1B) 





Figure 1.1 Protein phosphorylation is a reversible switch in signal transduction 
A. Signal Transduction cascades involve a series of enzymes and effectors, which allow internal cellular 
responses to an external or intracellular signal. B. Protein kinases catalyse the transfer of the γ-phosphate 
from ATP to their substrate protein, producing ADP. This modification can be reversed by protein 
phosphatases. Results of protein phosphorylation include activation of an enzyme, or altered interactions, 





‘Canonical’ protein phosphorylation has been extensively studied as the conjugation of 
phosphate to the hydroxyl group of serine, threonine or tyrosine. However, increasing evidence 
suggests that extensive non-canonical phosphorylation also occurs on histidine, arginine, 
asparagine, lysine, glutamate and cysteine residues. The study of these phosphorylation sites 
has remained behind that of canonical phosphorylation due to the lack of tools to study them. 
The bonds formed on phosphorylation of these residues are highly acid- and heat-labile and 
most traditional methods to detect  canonical protein phosphorylation are not suitable 
(Hardman et al., 2019). However, recent development of tools such as monoclonal antibodies 
against pHis have allowed for functional relevance of these phosphorylation events to be 
determined (Besant and Attwood, 2012; Fan et al., 2012; Fuhs et al., 2015; Wieland and Attwood, 
2015; Srivastava et al., 2016; Fuhs and Hunter, 2017). For example, it was recently determined 
that the histidine phosphatase LHPP can act as a tumour suppressor in hepatocellular carcinoma, 
suggesting that deregulated histidine phosphorylation can be oncogenic (Hindupur et al., 2018). 
Phosphorylation of histidine residues is of particular interest, as many enzymes have a catalytic 
histidine in their active site, due to the ability of its sidechain to rapidly transition from a charged 
to uncharged state. The charge change associated with phosphorylation, therefore, could 
strongly impact on catalysis. True to the lack of tools available to study non-canonical 
phosphorylation, little is known about the enzymes which catalyse phosphorylation and 
dephosphorylation of these sites. However elegant work has identified 2 histidine kinases, NME1 
and NME2, and 3 histidine phosphatases, PHPT1, LHPP and PGAM5 (Fuhs and Hunter, 
2017).Recently published work presented a modified mass spectrometry method for detection 
of ‘non-canonical’ phosphorylation, and estimated that these phosphorylation events are far 
more frequent than previously believed, and equal one third of total phosphorylation events 





1.1.1 Protein kinases, their structure and activation 
The human genome encodes 538 known kinases, of which 518 are protein kinases and 20 are 
lipid kinases. This collection of proteins is commonly referred to as the ‘kinome’. Based on 
sequence similarity and functional annotation, the kinome is subdivided into 10 groups. 478 
belong to a single superfamily, the typical eukaryotic protein kinases (ePKs), which evolved to 
share a common kinase domain fold, described further below. A further 40 ‘atypical’ protein 
kinases (aPKs) do not share the typical kinase fold, however do carry kinase activity. One 
example of an atypical protein kinase is mTOR which is described in further detail in section 1.2.5 
(G. Manning et al., 2002). 
The ePKs diverge into 9 groups, namely AGC (PKA, PKG, PKC family), CAMK (Ca2+/Calmodulin-
dependent kinases), CK1 (Casein Kinase 1 family), CMGC (CDK, MAPK, GSK and CLK family), STE 
(homologues of the yeast sterile kinases family), TK (Tyrosine kinase), TLK (Tyrosine kinase-like 
kinase family), RGC (Receptor Guanylate Cyclase), and ‘Other’ protein kinases that do not fit a 
particular group. (G. Manning et al., 2002) (Figure 1.2). Protein kinases within a certain family 
typically have similar substrate preferences, and often also similar methods of activation and 
regulation. Highlighted in Figure 1.2 are the closely related SGK and Akt protein kinases, which 








Figure 1.2 Tree of known human protein kinases  
Protein kinases have evolved from a conserved kinase fold to form 10 kinase groups. Derived from (G. 
Manning et al., 2002). Highlighted in red box are the SGK and Akt protein kinases, the focus of this thesis. 
 
Protein kinases share a remarkably conserved catalytic region, termed the kinase domain. This 
kinase fold of 250-300 residues is highly conserved throughout evolution, however regulatory 




demonstrates the kinase domain of Akt (also known as Protein Kinase B). Akt is a member of the 
AGC protein kinase family, and its kinase domain is typical of this family of kinases. The kinase 
fold consists of 12 subdomains, organised into 2 lobes. The smaller N-lobe is formed of 
subdomains I-IV and contains a 5-stranded β-sheet and the regulatory αC-helix. The remaining 
subdomains V-XII form the largely α-helical C lobe. A hinge region links these 2 lobes, and the 
interface between them forms an important part of the active site. The N lobe is responsible for 
binding and coordination of the ATP for phosphotransfer, whereas the C lobe coordinates 
substrate binding and catalysis. 
 
Figure 1.3 Crystal structure of Akt kinase domain from PDB 1GV1 
The crystal structure of the Akt kinase domain was solved bound to the ATP competitive inhibitor AZD5363 
(Addie et al., 2013). From PDB 1GV1, this structure shows the key structural features of the AGC kinase 
domain. The smaller N-lobe (blue) coordinates ATP (in this case, AZD5363) for transfer to substrate by the 
C-lobe (red). In cyan is demonstrated the Cα-helix, and, in green, the hydrophobic motif residues which 




There are a number of motifs highly conserved in protein kinases that are critical for activation 
and catalytic activity. Motifs within the N lobe are responsible for ATP binding and coordination. 
A GxGxxG motif binds the α and β phosphates of ATP, which are not transferred during 
phosphorylation, meanwhile the VAIK motif binds and positions the ATP. The lysine of this VAIK 
motif is the catalytic lysine critical for phosphorylation activity. Motifs within the C lobe are 
responsible for substrate binding and phosphotransfer. The HRDxxxxN motif contributes an Asp 
as proton acceptor for the catalytic reaction and the Asn coordinates one Mg2+ ion, while the 
DFG motif, which coordinates the second Mg2+ ion and its responsible for orientation of the ATP 
γ-phosphate. In addition, in this region an APE motif forms a salt bridge to subdomain XI for 
stabilization of the C lobe. In between these two motifs lies the critically important activation 
region of the T loop. 
Surprisingly, 10% of the kinome comprises pseudokinases. These proteins are structurally 
related to kinases, and have maintained the typical protein kinase fold, however have lost 
residues critical for catalysis (Kwon et al., 2019). Pseudokinases are well conserved and evolved 
alongside active kinases, likely evolving from gene duplication, which implies they still have, 
currently unknown, functional roles in signal transduction. For example, pseudokinases may act 
through regulating the activity of an active kinase, of through dynamic scaffolding functions 
(Rajakulendran and Sicheri, 2010; Shaw et al., 2014). For example, pseudokinase FAM20A has 
no catalytic activity, however is a regulator of its counterpart FAM20C (Cui et al., 2015, 2017). 
Some predicted pseudokinases bind nucleotides in different binding modes. For example, the 
SelO pseudokinase was found to bind ATP in an inverted conformation, and instead ‘AMPylate’ 
its substrate proteins (Sreelatha et al., 2018). Further the bacterial pseudokinase SidJ was found 
to use a protein kinase fold to glutamylate the SidE family of E3 ligases and inhibit their activity 




Protein kinases are molecular switch proteins which can rapidly be activated or inactivated 
through phosphorylation. AGC protein kinases are typically activated by phosphorylation on two 
important residues, the T-loop (or activation loop) and the C-terminal hydrophobic motif 
residues. In the case of Akt, these residues are Thr308 and Ser473 respectively. The T loop of 
Akt is phosphorylated by 3-phosphoinositide dependent protein kinase-1 (PDK1) (Alessi, Deak, 
et al., 1997; Alessi, James, et al., 1997; Mora et al., 2004). Phosphorylation of this residue allows 
for the displacement of the Cα-helix  and  stabilisation  of  the  N- and  C-lobes  in  the  active  
conformation,  permitting  the  proper  orientation  of  the  substrate (Hanks and Hunter, 1995; 
Johnson et al., 1998). In figure 1.3, the T loop of AKT is observed to orientate the Cα-helix in 
cyan. Another critical activation residue of the AGC protein kinases is the hydrophobic motif 
residues. In AKT, this is Ser473 as is phosphorylated by mTORC2 (Sarbassov et al., 2005). The 
hydrophobic motif residues interact with the N lobe of the protein, for further stabilization. In 
Figure 1.3 this is shown for AKT in green. For AKT, this additional phosphoactivation event 
maximally activates the kinase towards certain additional substrates (Guertin et al., 2006; 
Jacinto et al., 2006). For other kinases, such as the Serum and Glucocorticoid regulated protein 
kinases (SGKs), prior phosphorylation of this residue is critical for subsequent phosphorylation 
of the T-loop residue by PDK1 (Garcia-Martinez and Alessi, 2008). This mechanism is described 
in greater detail in section 1.4.1. 
 
1.1.3 Protein phosphorylation in disease 
Protein phosphorylation regulates a vast array of cellular processes. It is therefore unsurprising 
that mutations of the enzymes regulating phosphorylation cascades are linked to a wide 
spectrum of human diseases. Hereditary conditions linked to mutations of kinases have been 
extensively reviewed by Lahiry et al, and Alessi and Cohen. Inactivating and activating mutations 
in protein kinases can impact on a wide range of pathologies, including neurological disorders, 




(Lahiry et al., 2010; Cohen and Alessi, 2013). For example, activating mutations in Leucine Rich 
Repeat Kinase 2 (LRRK2) are a risk factor for familial Parkinson’s Disease (PD) (Alessi and 
Sammler, 2018). Although the mechanism by which LRRK2 mutations lead to PD are not yet 
known, all known pathogenic mutations result in an increase in kinase activity, therefore LRRK2 
inhibitors are being investigated as a possible therapeutic in the clinic. Another example is the 
WNK1 (with-no-K(Lys)) and WNK4 kinases, which phosphorylate 2 downstream kinases 
STE20/SPS1-related proline/alanine-rich kinase (SPAK) and oxidative stress-responsive kinase 1 
(OSR1) in the regulation of blood pressure, and mutation of these kinases can lead to 
hypertension (Vitari et al., 2005; Richardson and Alessi, 2008). Activated SPAK/OSR1 
phosphorylate and activate ion cotransporters such as the Na+/Cl- co-transporter (NCC) to 
regulate salt homeostasis (Gamba, 2005). Therefore, targeting of these kinases is an attractive 
target in lowering blood pressure.  
The importance of protein phosphorylation in human disease is highlighted by the significant 
effort that has been devoted for the development of protein kinase inhibitors for the clinic, to 
treat a range of conditions (Cohen and Alessi, 2013). There are currently 52 kinase inhibitors 
approved for clinical use by the Food and Drug Administration (FDA), with many more in clinical 
development (See www.kinase-screen.mrc.ac.uk).  
In addition, both hereditary and sporadic mutations of protein and lipid kinases are commonly 
found in human cancers. A current list of kinases implicated in oncogenesis by somatic or 
hereditary mutations is summarised in Table 1.1. This dataset is summarised from the COSMIC 
Cancer Gene Census (CGC), and describes ‘Tier 1’ genes with substantial evidence as a driver in 
tumorigenesis (Forbes et al., 2011; Sondka et al., 2018). A primary driver in many cancers is 





Table 1.1 Protein and Lipid kinases mutated in cancer. 
Protein and Lipid kinases implicated in cancer, with either somatic or germline mutations. Adapted from 
the COSMIC Cancer Gene Census (CGC), described in (Forbes et al., 2011; Sondka et al., 2018) Only Tier 1 
census genes, with extensive evidence demonstrating a functional role in cancer, are listed. OG = 
oncogene, TSG = Tumour suppressor gene, T = translocation, Mis = missense mutation, N = nonsense 
mutation, D = deletion, F = frameshift mutation, S = splice site mutation 
 








ABL2 AML     OG, fusion T 
ALK 
ALCL, NSCLC, neuroblastoma, inflammatory 
myofibroblastic tumour, Spitzoid tumour neuroblastoma familial neuroblastoma OG, fusion T, Mis, A 
ATR 
endometrial, gastric, epithelial ovarian, 
myeloma oropharyngeal 
familial cutaneous telangiectasia 
and cancer syndrome TSG F; Mis 
BTK CLL, mantle cell lymphoma, WM     OG, TSG Mis 
CDK12 serous ovarian     TSG Mis, N, F 
CDK4   melanoma familial malignant melanoma OG Mis 
CDK6 ALL     OG, fusion T 
CDKN1B breast, small intestine neuroendocrine tumours pituitary, parathyroid 
multiple endocrine neoplasia type 
IV TSG F 
CDKN2A melanoma, multiple other tumour types melanoma, pancreatic familial malignant melanoma TSG 
D, Mis, N, F, 
S 
CDKN2C glioma, MM     TSG D 
ERBB3 colon, gastric, head and neck, bladder, skin     OG Mis, N 
ERBB4 melanoma, gastric, NSCLC     OG, TSG Mis, N 
ETNK1 aCML, CMML, SM-AHD, HES     TSG Mis 
FES HNSCC, ovarian carcinoma     OG, TSG Mis, F 
FLT3 AML, ALL     OG Mis, O 
FLT4 soft tissue sarcoma     OG A 
IKBKB SMZL     OG Mis 
ITK peripheral T-cell lymphoma     fusion T 
JAK1 ALL     OG, TSG Mis 
JAK2 ALL, AML, MPN,  CML     OG, fusion T, Mis, O 
JAK3 acute megakaryocytic leukaemia, ETP ALL     OG Mis 
LATS1 skin basal cell carcinoma     TSG Mis, N 
LATS2 malignant mesothelioma     TSG D, F, N 
LCK T-ALL     OG, fusion T 
MAP2K1 NSCLC, melanoma, colorectal     OG Mis 
MAP2K2 NSCLC, melanoma     OG Mis 
MAP2K4 pancreatic, breast, colorectal     OG, TSG D, Mis, N 
MAP3K1 luminal A breast     OG, TSG 
N, F, Mis, 
O, S 
MAP3K13 breast     OG, TSG F 
MAPK1 CLL, ovarian mixed germ cell tumour, cervical carcinoma     OG Mis 
NTRK1 papillary thyroid, Spitzoid tumour     
OG, TSG, 
fusion T, A 
NTRK3 congenital fibrosarcoma, secretory breast     OG, fusion T 
PIK3CA colorectal, gastric, glioblastoma, breast     OG Mis 
PIK3CB SCC, NSCLC     OG Mis 
PIK3R1 glioblastoma, ovarian, colorectal     TSG Mis, F, O 
PRKACA 
fibrolamellar hepatocellular carcinoma, cortisol 
secreting adrenal adenoma     OG T, Mis, N 
PRKAR1A papillary thyroid 
myxoma, endocrine, 
papillary thyroid Carney complex 
OG, TSG, 
fusion 
T, Mis, N, F, 
S 
PTK6 renal, gastric, head and neck, ovarian, others     OG, TSG Mis, N 
SRC colorectal cancer, endometrial carcinoma     OG Mis, N 
STK11 NSCLC, pancreatic 
jejunal hamartoma, 
ovarian, testicular, 
pancreatic Peutz-Jeghers syndrome TSG 
D, Mis, N, 
F, S 




1.2 PI3K-mTOR pathway hyperactivation in breast cancer 
1.2.1 Phosphatidylinositol signalling is mediated by phosphatidylinositol 
kinases and phosphatases. 
As demonstrated in Figure 1.4, Phosphatidylinositol (PtdIns) is a glycerophospholipid, containing 
a glycerol backbone, two nonpolar fatty acid tails and a phosphate group linked to an inositol 
polar headgroup. This inositol headgroup is phosphorylated on various sites to produce a range 
of phosphatidylinositides (PtdInsP). These molecules form a minority of phospholipids on 
biological membranes, and yet are central in cellular signalling and as anchors for peripheral 
membrane proteins.  Phosphorylation occurs on one of three hydroxyl groups (positions 3, 4, 
and 5) on the inositol ring, either alone or in combination to generate seven known PtdInsP. 
These phosphorylation events are performed by phosphatidylinositol kinases (PIKs) and 
removed by lipid phosphatases (Figure 1.4) (Bishé, Syed and Siddiqui, 2012). 
Much of the work in this thesis focusses on the PI3Ks, which phosphorylate the 3-OH on the 
inositol headgroup of PtdIns on cellular membranes. These phospholipids then act as 
recruitment signals for effector proteins carrying, for example, PH domains (PtdIns(3,4,5)P2) or 
PX and FYVE domains (PtdIns(3)P). As will be discussed in this section, the PI3K signalling 
pathway is a central pathway by which cells can detect and respond to external signals and 
regulate functions such as glucose metabolism and cell proliferation. The roles in growth and 






Figure 1.4 7 varieties of PtdInsP formed from phosphatidylinositol. 
PtdInsP is modulated by phosphatidylinositol kinases (PIKs), represented in black,  and lipid phosphatases, 
in red. From (Bishé, Syed and Siddiqui, 2012) 
PI3Ks are grouped into 3 classes based on their domain organisation, however all contain a 
structurally related lipid kinase domain. Figure 1.5 describes the classification and domain 
structure of the PI3K family. The class I PI3Ks are the largest class and most highly studied, using 
phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) as a substrate to generate PtdIns(3,4,5)P3. 
The generated PtdIns(3,4,5)P3 has an important role in activating the PI3K-Akt-mTOR signalling 
axis, which will be discussed further below. Class II PI3Ks are less well understood, and contain 
a catalytic core similar to Class I, however contain a C-terminal PX-C2 domain and a variable N-
terminal region. The Class III PI3K family consists of just one member, VPS34. VPS34 is present 
in all eukaryotes and is therefore considered the ancestral PI3K. Overall the domain structure of 




heterotetrameric complexes (Vanhaesebroeck et al., 2010; Vanhaesebroeck, Stephens and 
Hawkins, 2012).  
 
Figure 1.5 The catalytic subunits of the PI3K lipid kinase family. 
The kinases are classified into three different classes based on their structural and biochemical features. 
The common, core catalytic domain consists of a C2 domain, a helical domain, and the catalytic kinase 
domain. Class I PI3K also contain a Ras-binding domain and a domain for binding to regulatory subunits. 
Class II PI3K, also known as PI3K-C2, contain an additional C-terminal PX and C2 domain. In addition, 
variable N-terminal Proline rich domains may mediate protein interactions, localisation and regulation. 
The sole Class III PI3K member, VPS34, is much simpler and contains just the catalytic core. Activity of 
VPS34 is regulated by a large complex. P = Proline rich region, PX = Phox Homology Domain. Adapted from 
(Vanhaesebroeck et al., 2010) 
1.2.2 Class I PI3K 
PI3K Class I act as heterodimers in cells. These dimers consist of a catalytically active p110 
subunit, of which there are α, β, γ and δ variants, and a regulatory subunit. PI3K p110α, β and δ 
form a dimer with regulatory p85 subunits and are activated by Tyrosine autophosphorylation 
of Receptor Tyrosine Kinases (RTKs) (Figure 1.6A). There are 5 different regulatory subunits 
which activate class I PI3K under different stimuli (Vanhaesebroeck, Stephens and Hawkins, 
2012). Docking of the p85 SH2 domain to pTyr allows for allosteric activation of the dimer. PI3K 
p110γ binds to either p101 or p84 regulatory subunits and is activated downstream of G-protein-
coupled receptors (GPCR) signalling. p101 links p110γ to Gβγ subunits released from 
heterotrimeric G proteins downstream of GPCRs (Stephens et al., 1994). Additionally, 
interaction of p110 with the small G-protein Ras can also contribute to the activation of PI3K 





Class I PI3K form the major axis of canonical PI3K signalling, and the subsequent activation of 
Akt and mTORC1 in response to growth factor signals recognised by RTKs (Figure 1.6). 
Dimerization and autophosphorylation of RTKs generates phosphotyrosine for the recruitment 
of p85 by its SH2 domain (Escobedo et al., 1991; Skolnik et al., 1991). This process recruits PI3K 
to the plasma membrane and also relieves autoinhibition of p110 by p85 (Yu et al., 1998). The 
preferred substrate for Class I PI3K is PtdIns(4,5)P2, which is phosphorylated at the 3-OH position 
to generate PtdIns(3,4,5)P3 (Whitman et al., 1988; Stephens and Downes, 1990). This action is 
reversed by the tumour suppressor, lipid phosphatase PTEN (phosphatases and tension 
homolog deleted on chromosome 10) (Maehama and Dixon, 1998; Myers et al., 1998; Stambolic 
et al., 1998) (Figure 1.6A). 
Production of PtdIns(3,4,5)P3, and its immediate product PtdIns(3,4)P2, results in the 
recruitment of pleckstrin homology (PH) domain-containing effector proteins. Two critical 
proteins in the pathway containing a PH domain are 3-phosphoinositide-dependent protein 
kinase-1 (PDK1) (Alessi, Deak, et al., 1997) and Akt (James et al., 1996). This recruitment allows 
for the phosphorylation of Akt by PDK1 on its activation loop Thr308 and therefore its activation 
(Alessi, James, et al., 1997). Activated Akt phosphorylates a number of substrates in the cell 
effecting biological processes such as cell growth and proliferation (Figure 1.6B). 
1.2.3 Class II PI3K 
Unlike Class I PI3K, Class II PI3K do not constitutively associate with regulatory subunits. There 
are 3 members of the PI3K Class II, PI3K-C2α, β or γ, which contain variable N- and C-terminal 
regions which may regulate their activity. In particular, all PI3K-C2 isoforms contain an additional 
C-terminal C2 domain (Gulluni et al., 2019). Unlike the Class I and Class III PI3K, Class II PI3K 
isoforms are active as monomers, with no known obligatory regulatory subunits (MacDougall, 








Figure 1.6. Activation and downstream effect of PI3K Class I 
A. Class I PI3K are activated by external stimuli such as growth factors, cytokines or hormones binding to 
Receptor Tyrosine Kinases (RTK) or G-protein coupled receptors (GPCR). Phosphorylated RTKs bind to 
regulatory p85, relieving inhibition of p110α,β,δ. p110γ is activated by binding to Gβγ proteins released 
from GPCRs. p110 preferentially uses PtdIns(4,5)P2 as a substrate to generate PtdIns(3,4,5)P3 on the 
plasma membrane B. PtdIns(3,4,5)Ps rich regions on the plasma membrane recruit Akt and PDK1 by virtue 
of their PH domains. mTORC2 is also recruited to the membrane by the PtdIns(3,4,5)P3 signal. 
Colocalization of Akt with its activating kinases allows for its phosphorylation and activation, stimulating 
cell growth and survival signals. Modified from (Vanhaesebroeck et al., 2010; Yang et al., 2019). 
Until recently, the PI3K-C2 kinases were largely understudied, however recent findings suggests 
roles in both cell signalling and vesicle trafficking (Gulluni et al., 2019). The Class II Isoforms each 
have the enzymatic capability to produce both PI(3)P and PI(3,4)P2 in vivo, depending on their 
cellular context. Each isoform carries distinct and non-overlapping cellular roles in different 




PI3KC2α on early endosomal membranes will produce PtdIns(3)P from readily available PtdIns 
containing membranes, and mediates vesicle trafficking (Yoshioka et al., 2012; Franco et al., 
2014). However, this isoform can also produce PtdIns(3,4)P2 from PtdIns(4)P-rich areas of the 
plasma membrane to regulate clathrin-mediated endocytosis (Posor et al., 2013). 
PI3KC2β, however, primarily synthesises PtdIns(3)P both in vitro and in vivo (Maffucci and 
Falasca, 2014). Enzymatic activity of PI3KC2β has been linked to cell migration and formation of 
actin-rich lamellipodia (Domin et al., 2005). PI3KC2β has also been linked to insulin sensitivity 
and regulation of mTORC1 (Alliouachene et al., 2015; Marat et al., 2017). PI3KC2α and PI3KC2β  
both have essential roles in clathrin-mediated pinocytosis, however PI3K-C2β was required for 
actin filament formation at the clathrin-coated structures (Aung et al., 2019). PI3KC2γ can 
produce both PtdIns(3)P and PtdIns(3,4)P2 in vitro, however in vivo primarily produces a pool of 
PtdIns(3,4)P2 on endosomal membranes in response to insulin (Braccini et al., 2015). 
1.2.4 Class III PI3K 
Class III PI3K, VPS34, generates PtdIns(3)P from PtdIns and is found in two distinct complexes 
within cells. The catalytically active VPS34 subunit forms a constitutive heterodimer with VPS15. 
VPS15 is myristoylated at Gly2, acting as a member anchor. This dimer forms 2 major complexes 
in cells, with different biological roles (Figure 1.7). In VPS34 Complex I, VPS34/VPS15 form a 
heterotetramer with Beclin1 and ATG14L. This complex is primarily on Rab7-containing 
membranes and involved in the activation and regulation of autophagy, and response to 
nutrient starvation (Kihara et al., 2001; Itakura et al., 2008; Matsunaga et al., 2009). Complex II 
is formed with UVRAG in place of ATG14. This complex is found on Rab5- and Rab9-containing 
endosomal membranes and is critical for endocytic sorting, lysosome recycling and LC3-
mediated phagocytosis (Liang et al., 2008; Thoresen et al., 2010; Martinez et al., 2015; Munson 






Figure 1.7 Complexes formed by Class III PI3K VPS34. 
VPS34, VPS15 and Beclin1 form a heterotetramer with either ATG14L or UVRAG to form complex I or 
complex II respectively. More transient, accessory interactors include Rubicon and Rab5 interacting with 
Complex II, and NRBF2 and Rab7 interacting with Complex I. AmbraI has been observed to form very 
transient interactions with both complexes. 
Differing complexes and localisation allows for the independent regulation of many distinct 
pathways controlled by PtdIns(3)P in the cell. For example, in the context of amino acid 
starvation, complex I is activated to regulate autophagy while other complexes are inhibited. 
This is due to the recruitment of ATG14L by ULK1, which phosphorylates Beclin1 for activation 
of the complex (Russell et al., 2013). Differing activity of the complexes can also be regulated by 
curvature of the target membrane, therefore differentiating between different intracellular 
organelles. While, in vitro, both complexes I and II displayed similar activity on high curvature 
membranes, complex I had no measurable activity in flat membranes (Rostislavleva et al., 2015). 
Structural information on VPS34 complex 
 
Figure 1.8 Domain structure of the core VPS34 complex members. 
 VPS34 interacts and dimerises with the WD40 domain of VPS15 via its N-terminal C2 domain. Binding to 
substrate membranes is via the kinase domain of VPS34 and the BARA domain of Beclin1. The core complex 




Comprehensive structural studies of the VPS34 complexes has revealed additional information 
on the mechanisms of VPS34 activation. Both complexes form a “Y” shape on the target 
membrane. VPS34/VPS15 form as an obligate dimer and form a catalytic arm of the “Y” 
(Baskaran et al., 2014; Rostislavleva et al., 2015; M. Ma et al., 2017). Beclin1 with ATG14 or 
UVRAG form a second, regulatory arm of the “Y”. These 2 arms bind to target membranes via 
the BARA domain of Beclin1 and the kinase domain of VPS34. Myristoylation of VPS15 at Gly2 
also acts as a membrane anchor (Herman, Stack and Emr, 1991). In vitro studies of the human 
protein have also observed a high mobility of the VPS34 kinase domain relative to the rest of the 
complex (M. Ma et al., 2017; Stjepanovic et al., 2017). 
VPS34 has a similar domain structure to the other PI3Ks, with an N-terminal C2 domain, Helical 
domain and a C-terminal Kinase domain (Figure 1.8). However, this domain structure is very 
simple in comparison to the Class I and Class II PI3K and the polypeptide does not contain other 
regulatory elements, as regulation is mediated by its complex members. The C2 domain is critical 
for interaction with the WD40 domain of VPS15 (Rostislavleva et al., 2015). Also, residues of this 
domain can be phosphorylated by CDK1, CDK5 and AMPK which causes a reduction in VPS34 
activity, possibly due to weakened complex stability (Furuya et al., 2010; Kim et al., 2013). 
Additionally, cleavage of this domain by caspase 8 causes decreased affinity for Beclin1, and 
reduced activity, demonstrating how critical this region is for VPS34 activity (Jiang et al., 2017). 
VPS15 is composed of an N-terminal pseudokinase domain, followed by a Helical domain, linker 
region and C-terminal WD40 domain critical for binding to VPS34 (Figure 1.8). Despite having no 
known kinase activity, the pseudokinase domain of VPS15 has been demonstrated to be critical 
for complex formation and VPS34 activation (Nemazanyy et al., 2013). Somatic mutations in the 
pseudokinase domain have also been detected in cancer (Herman, Stack and Emr, 1991; Shull et 
al., 2012). Beclin1 is extensively decorated with posttranslational modifications, which mediate 
its localization, binding partners and stability. For example, as described above, phosphorylation 




Russell et al., 2013; Egan et al., 2015). Generally, autophagy-promoting modifications are largely 
found in the N-terminus and BH3 domain. Conversely, autophagy-inhibiting modifications are 
commonly found in its CC domains and membrane-binding BARA domain (Zalckvar et al., 2009; 
Shi and Kehrl, 2010; Maejima et al., 2013). 
ATG14L completes VPS34 complex I, and contains 3 coiled coil domains, a C-terminal domain 
and a Barkor/Atg14L autophagosome targeting sequence (BATS) domain. At the N-terminus of 
ATG14L, two heavily conserved CXXC motifs are critical for localisation of ATG14 to the ER 
(Matsunaga et al., 2010). Additionally, an N-terminal extension, present only in metazoans, 
contains a phosphorylation site at S27. Phosphorylation of this site by Ulk1 is triggered by amino 
acid starvation or inhibition of mTORC1 and activates VPS34 complex I activity, however it is 
currently unclear how this activation occurs (Park et al., 2016). UVRAG is the subunit found 
exclusively in complex II. UVRAG-contained complexes are found to localise to Rab5- and Rab9-
positive endosomes, and UVRAG is not found with autophagic complexes. Instead, the function 
of UVRAG-containing complexes is in endocytic trafficking and potentially autophagosome 
maturation (Knaevelsrud et al., 2010; Takats et al., 2014).  Importantly, Rab5-positive 
endosomes have only UVRAG-containing complexes, not ATG14. 
In addition to these stable complex members, there are several accessory subunits which bind 
to the complex more transiently. NRBF2 binds specifically to complex I, and boosts activity of 
the complex (Ohashi et al., 2016; Young et al., 2016). Phosphorylation of NRBF2 by mTORC1 
decreases binding to complex I and reduces VPS34 activity (X. Ma et al., 2017). Rubicon, 
alternatively, binds specifically to complex II and regulates its activity, however it has been 
reported to both increase and decrease activity of the complex and its role is not entirely clear 
(Matsunaga et al., 2009; Matsunaga, Noda and Yoshimori, 2009; Zhong et al., 2009; Martinez et 
al., 2015). Additionally, AMBRA1 (activating molecule in Beclin-1-regulated autophagy) is an 
adaptor molecule which weakly associates with both complexes (Antonioli et al., 2014). It is a 




and regulate mTOR signalling. It has been demonstrated to interact with Beclin1 and increase 
VPS34 complex activity (Cianfanelli et al., 2015). 
Posttranslational modifications regulating VPS34 activity 
Binding of regulatory subunits to VPS34 is critical for mediating its subcellular activity. However, 
a range of post translational modifications also vastly regulate its activity. As described above, 
Beclin1 is heavily decorated with modifications which alter its localisation and activity of the 
VPS34. In addition, VPS34 itself can also be regulated by PTMs. For example, VPS34 can be 
acetylated by p300 at K29, K771 and K781. K771 is situated in the activation loop of VPS34 kinase 
domain and, importantly, binds to substrate PtdIns. Acetylation at this site by p300 substantially 
reduces VPS34 activity. Additionally, acetylation at K29 has been observed to reduce Beclin1 
interaction and increase Rubicon interactions, potentially activating and deactivating VPS34 
under the appropriate conditions. Within the helical domain of VPS34, two highly conserved 
lysine residues are poly-ubiquitinated by the UBC-13/UEV-1/CHN-1 complex. This 
polyubiquitylation stabilizes VPS34 and increases autophagosome maturation. 
1.2.5 mTOR signalling downstream of PI3K 
The mammalian target of rapamycin (mTOR) is a Ser/Thr protein kinase, and central integrator 
of a wide variety of cellular signals that control cell growth and homeostasis. It is an atypical 
protein kinase of the PI3K-like Kinase (PIKK) family. mTOR is the mammalian homolog of yeast 
target of rapamycin (TOR). It is inhibited by the macrolide Rapamycin, discovered due to its anti-
proliferative properties (Heitman, Movva and Hall, 1991; Brown et al., 1994; Sabatini et al., 1994; 
Sabers et al., 1995). mTOR exists in at least two distinct complexes termed mTOR complex 1 
(mTORC1) and mTORC2,  shown in figure 1.9. Both complexes contain mTOR and accessory 
proteins termed mammalian lethal with sec-13 protein 8 (mLST8, also known as GβL) (Kim et al., 
2003; Jacinto et al., 2006), DEP domain containing mTOR-interacting protein (Deptor) (Peterson 
et al., 2009) and Tti1/Tel2 complex (Kaizuka et al., 2010). mTORC1 is completed by regulatory- 




2002), and proline-rich Akt substrate 40 kDa (PRAS40) (Sancak et al., 2007; Thedieck et al., 2007; 
Vander Haar et al., 2007; Wang et al., 2007). mTORC2 uniquely contains Rapamycin-insensitive 
companion of mTOR (Rictor) (Jacinto et al., 2004; Sarbassov et al., 2004), mammalian stress-
activated map kinase-interacting protein 1 (mSin1) (Frias et al., 2006; Jacinto et al., 2006) and 
protein observed with Rictor 1 and 2 (Protor1/2) (Pearce et al., 2007; Thedieck et al., 2007; Woo 
et al., 2007). 
Activity of these 2 distinct complexes can be delineated with Rapamycin. mTORC1 is acutely 
sensitive to rapamycin whereas mTORC2 is only affected by chronic rapamycin treatment 
(Sarbassov et al., 2004, 2006; Phung et al., 2006). Cryo-EM advances have allowed the structure 
of both complexes to be solved, providing insights into their differential activity and regulation 
(Aylett et al., 2015; X. Chen et al., 2018). 
 
Figure 1.9 mTOR forms two complexes in cells 
 mTORC1 is formed of mTOR, Raptor and mLST8, with PRAS40 and Deptor. mTORC2 is formed of mTOR, 
Rictor and mLST8, with Deptor and Protor. These two complexes are activated by different cellular signals 





mTORC1 is the better characterised complex of mTOR and coordinates a vast array of upstream 
signals relating to cell growth and metabolism. mTORC1 has been demonstrated to be regulated 
by a) growth factor signalling, b) cellular stress, c) cellular energy status, d) oxygen, and e) amino 
acids. Downstream of these signals, mTORC1 regulates cell growth and proliferation by 
promoting anabolic processes and by inhibiting the catabolic process of autophagy (Figure 1.9) 
(Saxton and Sabatini, 2017). 
 
Figure 1.10 Activation of mTORC1 in response to growth factors and cellular energy through TSC2. 
On activation of the PI3K signalling pathway, Akt is activated by phosphorylation by PDK1 and mTORC2. 
Active Akt phosphorylates TSC2, relieving its inhibition on Rheb. Activation of Rheb allows the activation 
of mTORC1 signalling. Akt also phosphorylates PRAS40, releasing the inhibitory factor from the mTORC1 
complex. Other signals of cellular energy mediate mTORC1 activation through TSC2, via AMPK or MAPK 
and cytokine signalling. 
 
A key signal for mTORC1 activation is in response to Growth Factors, and cellular energy levels, 
mediated through tuberous sclerosis 2 (TSC2). Within the PI3K-Akt-mTOR signalling axis, Akt 
mediates the activation of mTORC1 via phosphorylation of TSC2 and PRAS40. Akt 




heterodimer from the GTPase Ras homolog enriched in brain (Rheb) (B. D. Manning et al., 2002; 
Inoki et al., 2002). In its GTP-bound state, Rheb will directly bind to and activate mTORC1. TSC1/2 
complex acts as a GTPase-activating protein (GAP) for Rheb, therefore its dissociation allows 
accumulation of Rheb-GTP to activate mTORC1 (Inoki et al., 2003; Tee et al., 2003). The TSC1/2 
is also phosphorylated at alternative sites  and inactivated by other effector kinases of growth 
factor signalling pathways, such as the extracellular-signal-regulated kinases 1/2 (ERK1/2) and 
cytokines (Ma et al., 2005; Lee et al., 2007; Laplante and Sabatini, 2012). Akt also phosphorylates 
PRAS40 at Thr246, triggering its dissociation from mTORC1, relieving its inhibition of the 
complex (Sancak et al., 2007; Thedieck et al., 2007; Vander Haar et al., 2007; Wang et al., 2007) 
(Figure 1.10). 
However, it is important that mTORC1-mediated anabolism only occurs under conditions of 
sufficient cellular energy and substrates for macromolecular synthesis. Glucose deprivation and 
hypoxia activate the AMP-regulated protein kinase AMPK, which will phosphorylate and activate 
TSC2 (Brugarolas et al., 2004; Kalender et al., 2010; Efeyan et al., 2013), leading to inhibition of 
mTORC1 activity. Further, exquisite mechanisms have evolved by which mTORC1 senses cellular 
amino acid levels, and activation of mTORC1 by Rheb-GTP only occurs in the presence of amino 
acids (Figure 1.10). 
This has been shown to be mediated by the Rag GTPases, vacuolar v-ATPase and Ragulator (E. 
Kim et al., 2008; Sancak et al., 2008, 2010; Zoncu et al., 2011; Bar-Peled et al., 2012). 
Accumulation of amino acids in the lysosomal lumen promotes the loading of the RagA/B 
heterodimer with GTP, allowing its interaction with the mTORC1 subunit Raptor, and 
translocation of mTORC1 from the cytosol to the lysosomal surface (Laplante and Sabatini, 2012; 
Jewell, Russell and Guan, 2013). On the lysosomal surface, the RagA/B dimer docks onto 
Ragulator, and mTORC1 can interact with Rheb-GTP, located throughout the endomembrane 




are available, irrespective of other positive signals. Interaction of the v-ATPase with Ragulator is 
also believed to be important for mTORC1 activation on lysosomal membranes (Zoncu et al., 
2011). 
More recent advances have also determined how Rag-mediated activation of mTORC1 senses 
cytosolic amino acid levels, through the GATOR1/GATOR2 complexes. The GATOR1 complex acts 
as a GTPase-activating protein (GAP) for RagA/B, and therefore inhibits mTORC1 activation on 
the lysosomal membrane. GATOR2, on the other hand, is a positive regulator of mTORC1 
signalling, as it interacts with and inhibits GATOR1 (Bar-Peled et al., 2013; Wolfson et al., 2017). 
The activity of GATOR2 is then regulated by cytosolic amino acid sensors, which bind and inhibit 
GATOR2 in the absence of amino acids. Sestrin2 is a cytosolic leucine sensor, which binds 
GATOR2 in the absence of leucine, and releases it upon leucine binding (Chantranupong et al., 
2014; Parmigiani et al., 2014; Saxton, Knockenhauer, et al., 2016; Wolfson et al., 2016). CASTOR 
similarly binds and inhibits GATOR2, dissociating upon binding of cytosolic arginine 
(Chantranupong et al., 2016; Saxton, Chantranupong, et al., 2016). 
mTORC2 
mTORC2 is insensitive to nutrients, however is also regulated by growth factors via relatively 
poorly understood mechanisms mediated by PI3K. mTORC2 has also been shown to associate 
with ribosomes following PI3K activation and the activation of mTORC2 is suggested to be 
dependent on ribosomes, but not protein synthesis (Zinzalla et al., 2011) 
PI3K-dependent activation of mTORC2 may be mediated by PtdIns(3,4,5)P3 itself. Increased 
PtdIns(3,4,5)P3 levels correlate with increased mTORC2 activity and recent studies suggest a 
direct activation of mTORC2 by PtdIns(3,4,5)P3 (Gan et al., 2011; Liu et al., 2015). Liu et al., 
recently proposed that PtdIns(3,4,5)P3 is activating mTORC2 via the PH domain of mSin1. Their 
proposed model suggested an autoinhibition of mTOR by the PH domain of mSin1, which was 




The best-characterised substrates of mTORC2 are the AGC protein kinases, phosphorylating 
their hydrophobic motif residues leading to their activation. Akt activity against certain 
substrates appears to be modulated by mTORC2 activity, whereas hydrophobic motif 
phosphorylation of SGK is critical for its activation (Guertin et al., 2006; Jacinto et al., 2006; 
Garcia-Martinez and Alessi, 2008). Through phosphorylation of its substrates, mTORC2 has roles 
in controlling cell survival and proliferation, as well as cytoskeletal organisation (Laplante and 
Sabatini, 2012). 
1.2.6 Hyperactivation of the PI3K pathway in breast cancer 
Due to its role in mediating many processes in cell growth and metabolism, aberrant activation 
of the PI3K pathway is frequently observed in breast cancer.  It is estimated that 70% of all breast 
cancer cases harbour hyperactivated PI3K signalling (Miller et al., 2011). This hyperactivation of 
the pathway can be achieved in a number of ways. Frequently observed alterations include, but 
are not limited to, amplification of RTKs, loss of PTEN or INPP4B (inositol polyphosphate-4-
phosphatase) function, activating mutations of p110 catalytic subunit of PI3K, inactivating 
mutations of p85 regulatory subunit of PI3K or activating mutations of Akt or Ras. Mutations of 
the pathway in breast cancer was extensively reviewed by McKenna et al., and is summarised in 
table 1.2 below. 
The most frequent pathway mutations, and the most important in the context of therapy, are 
PI3K and PTEN. The PI3KCA gene, encoding the p110α catalytic subunit, is the most frequently 
mutated PI3K pathway component in breast cancer (Zardavas, Fumagalli and Loi, 2012). 80% of 
these mutations occur in 1 of three hotspot regions, described by Samuels et al., which modulate 
PI3K regulation and activity (Samuels et al., 2004). One hotspot is the E545K mutation in exon 9, 
located in the helical domain, which interferes with inhibitory binding of the p85 subunit. 
Mutations around H1047 in the kinase catalytic domain increase interaction of the kinase with 




et al., 2018). These mutations act by different mechanisms and therefore can combine for a 
synergistic effect on PI3K pathway activation (Zhao and Vogt, 2008). Additionally, important 
activating mutations also occur in the C2 domain (Croessmann et al., 2018). Gene mutations in 
PTEN are relatively uncommon, and loss of function of PTEN frequently occurs through loss of 
heterozygosity at the 10q23 locus.  This occurs in 30-40% breast cancer tumours, and results in 
constitutive activation of Akt (Li et al., 1997; Liaw et al., 1997; Wang et al., 2014; C.-Y. Chen et 
al., 2018). These alterations also occur in 80% of Cowden’s syndrome patients, a condition which 




Table 1.2 Mutations within the PI3K pathway associated with breast cancer, stratified by subtype. 
Modified from (McKenna, McGarrigle and Pidgeon, 2018). HR+ = hormone-receptor positive. HER2+ = 
human epidermal growth factor receptor 2 positive, TNBC = triple negative breast cancer. Data extracted 
from a = (Miller, 2011), b = (Kriegsmann et al., 2014), c = (Gonzalez-Angulo and Blumenschein, 2013), d = 
(Ellis and Perou, 2013), e = (Stern et al., 2015), f = Cancer Genome Atlas Network (CGAN, 2012), g = (Chin 
et al., 2014) 
  











EGFR Amplification Activation of EGFR 
signalling 
0.8 0.8 0.8-0.9 a, b 
ERBB2 Amplification/Overexpression Activation of ErbB2 
signalling 
10 100 0-3.8 a, b 
FGFR1 Amplification/Activating 
mutation 





5.4 5.6 a 
IGF1R Activating 
mutation/Amplification 












23-42 8-25.9 a, c, b 
PIK3CB Amplification Unknown 5 5 5 a 
PIK3R1 Inactivating mutation 





2-5 0-2 a, c, d 
PIK3R3 Activating mutation 
(p55γ) 




0 0 c 
Lipid phosphatases 




5.4-22 4.8-67 a, b, e, f 




30-54 30-53 a, c 
Akt 
AKT1 Activating mutation Activation of AKT 
signalling 
2-4 0-2 0-0.9 a, c, b 




0-2.8 0-2.8 a, c 
AKT3 Activating mutation/ 
Amplification 




0 1-28 c, g 
Other regulators 
KRAS Activating mutation Hyperactivation of 
PI3K and MEK 
4-6 4-6 0.9-6 a, b 




- - a 
PDK1 Amplification/Overexpression Activation of AKT 
signalling 
22 22 38 a 












1.2.7 PI3K Inhibitors to treat cancer 
Due to the hyperactivation of PI3K-signalling being frequently observed in breast cancer, a wide 
range of inhibitors have been developed targeting this pathway with the aim of therapeutically 
targeting cancer. These inhibitors commonly target either PI3K, Akt or mTOR. In addition, PI3K-
mTOR dual inhibitors have been developed, as well as isoform specific PI3K inhibitors. Current 
inhibitors in clinical trials are summarised in Figure 1.11. P110α inhibitor BYL719 from Novartis 
has recently been approved by the FDA for treatment of advanced ER+ PI3KCA mutant breast 
cancer under the brand name Piqray. The drug has been approved in combination with 
Fulvestrant, after their SOLAR-1 study demonstrated the combination almost doubled 
progression-free survival (PFS) compared to Fulvestrant alone, extending PFS to 11 months 
compared to 5.7, and more than doubled the overall response rate to 38% from 16% (André et 
al., 2019). Targeting p110α specifically reduced off target toxicity associated with pan inhibitors 
which also target the p110β/δ isoforms (Baselga et al., 2018). 
 
Figure 1.11 Inhibitors of the PI3K-Akt-mTOR pathway in clinical trials against Breast Cancer. 




1.3 Akt protein kinases 
The Akt isoforms are members of the AGC family of Ser/Thr protein kinases. As discussed above, 
Akt is critical in the activation of mTORC1 by phosphorylation of PRAS40 and TSC2. As well as 
mTORC1 activation, Akt phosphorylates a wide array of substrates involved in regulating 
metabolism, and cell survival and proliferation (Manning and Cantley, 2007).  
1.3.1 Activation of Akt 
Akt is activated downstream of PtdIns(3,4,5)P3 production by Class I PI3K on the plasma 
membrane.  Akt is recruited to PtdIns(3,4,5)P3 rich membranes by virtue of its N-terminal PH 
domain, where it is phosphorylated on its activation loop residue Thr308 by PDK1, and its 
hydrophobic motif residue Ser473 by mTORC2 (James et al., 1996; Alessi, Deak, et al., 1997; 
Alessi, James, et al., 1997; Sarbassov et al., 2005). Many AGC protein kinases, such as the SGK 
family, require prior phosphorylation on their hydrophobic motif residue for subsequent 
phosphorylation of the activation loop by PDK1. This occurs via a PDK1-interacting fragment 
(PIF)-dependent mechanism by which a conformational change allows the protein to dock to the 
PIF-pocket of PDK1, leading to its activation loop phosphorylation. Akt, however, can be 
phosphorylated by PDK1 by a PIF-independent mechanism, through co-recruitment to 
PtdIns(3,4,5)P3 rich plasma membranes. 
Akt is also autoinhibited in the cytosol, through allosteric inhibition by its PH domain in the 
absence of PI(3,4,5)P3. On engagement with PtdIns(3,4,5)P3 on the membrane, this 
autoinhibition is relieved. The autoinhibited form of Akt in the cytosol is also held more 
susceptible to phosphatase mediated inactivation (Ebner, Lučić, et al., 2017; Lučic et al., 2018). 
 
The precise mechanism of Akt activation in response to membrane binding and hydrophobic 
motif phosphorylation is still unclear, with 2 recent papers proposed differing mechanisms by 
which Akt is fully activated. Lučic et al proposed a model whereby PtdIns(3,4,5)P3 binding of the 




binding in the active site, also maintaining Akt in a conformation more open to cytosolic 
phosphatases. They also propose that phosphorylation of Akt on its activation sites does not 
override occlusion of the active site by the PH domain in the absence of membrane binding  
(Lučic et al., 2018). Alternatively, Chu et al used protein semisynthesis to study purified Akt 
phosphorylated on its hydrophobic motif. They demonstrated motif phosphorylation relieves 
auto-inhibition of the PH domain on the kinase domain by interaction with a hydrophobic patch 
on the PH-kinase linker (Chu et al., 2018). 
1.3.2 Downstream substrates of Akt 
Once activated, Akt phosphorylates a wide array of substrates, which through different 
mechanisms drive cellular metabolism, as well as proliferation and survival. It is currently under 
debate whether Akt must remain at the membrane to phosphorylate its substrates, or once 
activated it can phosphorylate substrates elsewhere in the cell (Ebner, Lučić, et al., 2017; Chu et 
al., 2018; Lučic et al., 2018). Akt has a very well characterised RXRXXpS/T substrate motif, which 
it shares with the SGK family of protein kinases, discussed further in section 1.4 (Pearson and 
Kemp, 1991; Alessi et al., 1996). More recent data has demonstrated that Akt prefers large 
hydrophobic residues at its +1 site, whereas the SGK kinases can tolerate a wider range of 
residues at this site (Murray et al., 2005; Malik et al., 2019). The first identified substrate of Akt 
was the protein kinase Glycogen Synthase Kinase 3 (GSK3) (Cross et al., 1995), which when 
phosphorylated is inhibited, allowing cell cycle progression. Since then, a variety of substrates 
have been identified, by which Akt mediates cell growth and metabolism, cell proliferation, and 
cell survival (Manning and Cantley, 2007). These are summarised in Figure 1.12 and discussed in 






Figure 1.12 Schematic of Akt activation downstream PtdIns(3,4,5)P3, and examples of its downstream 
substrates in cell growth and survival. 
 
Cell growth and metabolism 
The most well characterised role of Akt is in its activation of mTORC1, and subsequent driving of 
protein and lipid synthesis and other anabolic processes. It was described in section 1.2.4 how 
Akt activates this process through phosphoinactivation of PRAS40 and TSC2. Once activated, 
mTORC1 is a promotor of translation initiation and ribosome biogenesis. mTORC1 is therefore 
critical in enhancing protein and lipid synthesis to mediate cellular growth and metabolism 
through phosphorylation of its substrates. 
Akt is a major regulator in glucose metabolism, through regulation of plasma membrane 
transporters. A primary glucose transporter in cells is GLUT1 and is regulated largely through its 
expression levels. Activation of mTORC1 can promote expression of GLUT1 through Hif1α-
dependent transcription of the GLUT1 gene and cap-dependent translation of its mRNA (Zelzer 
et al., 1998; Taha et al., 1999). In addition, activation of Akt has been associated with increased 




glucose uptake (Kohn et al., 1996). It has been proposed that this translocation is mediated by 
direct phosphorylation by Akt of the Rab GTPase-activating protein AS160 (Sano et al., 2003; 
Eguez et al., 2005), and alanine mutation of target sites blocked insulin-stimulated GLUT4 
translocation (Sano et al., 2003). Akt is also proposed to regulate expression of other nutrient 
transporters in an mTORC1-dependent manner (Edinger and Thompson, 2002). 
Cell proliferation 
A number of Akt substrates regulate the process of cell proliferation and cell division, and 
phosphorylation by Akt can promote these processes. Phosphorylation of GSK3 by Akt inhibits 
its activity, leading to the stabilization of proteins that play key roles in G1-S transition (Cross et 
al., 1995). Phosphorylation of cyclin D and cyclin E, as well as transcription factors c-jun and c-
myc, targets them for degradation and inhibits the cell cycle (Diehl et al., 1998; Welcker et al., 
2003; Yeh et al., 2004; Wei et al., 2005). Therefore, inhibition of this pathway by Akt-mediated 
phosphorylation of GSK3 promotes cell proliferation. Activation of mTORC1 by Akt also 
promotes activation of eIF4E, promoting cap-dependent translation of cell cycle promoters such 
as cyclin D1 and c-Myc (Mamane et al., 2004). 
Additionally, Akt phosphorylates p27, the Cyclin-dependent kinase inhibitor, at T157, creating a 
14-3-3 binding site and blocking nuclear localisation (Liang et al., 2002; Shin et al., 2002; Viglietto 
et al., 2002; Sekimoto, Fukumoto and Yoneda, 2004). This impedes its inhibitory effects and 
promotes progression through the cell cycle. Akt can also inhibit expression of p27 through 
FOXO inhibition (Medema et al., 2000), discussed in further detail below. Similarly, Akt has been 
found to phosphorylate cyclin-dependent kinase inhibitor p21, again leading to its cytosolic 
localisation (Zhou, Liao, Xia, Spohn, et al., 2001). 
Cell survival 
Finally, phosphorylation of substrates by Akt blocks the function or expression of many pro-
apoptotic proteins, and as a result Akt actively promotes cell survival. Akt regulates the 




will directly phosphorylate FOXO transcription factors, leading to their binding to 14-3-3 proteins, 
and nuclear export and degradation (Tran et al., 2003). This therefore results in reduced 
expression of FOXO target genes such as the proapoptotic cytokine FasL (Brunet et al., 1999) 
and BH3-only protein BIM, which stimulates cell death upon cytokine withdrawal (Dijkers et al., 
2002). Akt also phosphorylates and inhibits BAD, a pro-apoptotic Bcl-2 family member. 
Phosphorylation of BAD at S136 again creates a binding site for 14-3-3 proteins, and triggers the 
release of BAD from its target proteins (Datta et al., 1997, 2000; del Peso et al., 1997). Finally, 
Akt will directly phosphorylate MDM2, an E3 ligase which mediates degradation of p53. 
Phosphorylated MDM2 translocates to the nucleus and there negatively regulates p53 function 
(Mayo and Donner, 2001; Zhou, Liao, Xia, Zou, et al., 2001) resulting in the downregulation of 
proapoptotic p53 targets such as Puma and Noxa (Villunger et al., 2003). 
Akt mutation and cancer 
Given the role Akt plays in a vast array of pro-survival pathways, it is unsurprising that activating 
mutations in Akt or its upstream regulators are frequently found in a numerous cancers. For 
example, a Glu17Lys mutation within the PH domain of Akt1 causes constitutive Akt1 plasma 
membrane association and activation (Carpten et al., 2007), and the analogous mutation has 
also been reported in Akt2 and Akt3 (Davies et al., 2008; Stephens et al., 2012). Glu17Lys has 
been identified as a hotspot mutation in a wide range of cancer types (Bleeker et al., 2008; Do 
et al., 2008; M. S. Kim et al., 2008; Cohen et al., 2010; Chang et al., 2016; Rudolph et al., 2016). 
Studies by Parikh et al. suggested the majority of activating Akt mutations disrupt autoinhibitory 
PH-kinase domain interactions (Parikh et al., 2012). For example, L52R mutation is predicted to 
severely weaken PH domain interactions with V270, V271, Y326 and R328 of the kinase domain. 
Additionally, Q79K mutant PH domain exhibited weaker interaction with the kinase domain (Kan 
et al., 2010; Parikh et al., 2012; Yi et al., 2012; Yi and Lauring, 2015). Ebner et al also observed 
that a somatic cancer mutation (D323A) drives Akt hyperactivation by relieving autoinhibition, 




1.4 SGK Protein kinases and Akt-independent oncogenic signalling 
The serum- and glucocorticoid-regulated kinase (SGK) family of protein kinases are AGC protein 
kinases carrying very high homology to Akt. Their kinase domains share 45-55% identity and they 
share an overlapping RxRxxS/T substrate recognition motif (Webster et al., 1993; Alessi et al., 
1996; Murray et al., 2005). They are therefore able to phosphorylate a shared pool of substrate 
proteins and likely perform overlapping functions. Although their kinase and regulatory domains 
are highly similar, the SGKs differ from Akt as they lack the N-terminal PH domain which 
mediates Akt localisation and activation. Therefore, SGK1/2 are localised and activated 
cytosolically. SGK3 is unique within the SGK family and known protein kinases, as it contains an 
N-terminal PX domain, which alternatively localises it to PtdIns(3)P produced on early 
endosomal membranes for its activation (Figure 1.13). 
Although the SGK family are highly conserved at the sequence level, they display differences in 
tissue distribution and expression. SGK1 was the first discovered member of the Serum- and 
Glucocorticoid-regulated kinase family. It was initially identified as a gene regulated by 
glucocorticoids and serum, due to a glucocorticoid response element in its gene promoter 
(Webster et al., 1993). In contrast, SGK2 and SGK3 expression in not induced in response to 
serum or glucocorticoids, but were named by sequence similarity to SGK1 (Kobayashi et al., 
1999). Both SGK1 and SGK3 are ubiquitously expressed in heart, brain, liver, lung, kidney, 
placenta, skeletal muscle and pancreas but SGK2 showed more restricted expression in liver, 





Figure 1.13 Domain structure of the SGK family of protein kinases. 
SGK protein kinases are very similar in domain structure to Akt. They contain an AGC family kinase domain 
and C-terminal regulatory domain (CTD). SGK protein kinases are phosphorylated, like Akt, on their T loop 
by PDK1 and H-motif by mTORC2 for their activation. SGK3 also contains an N-terminal PX Domain. The 
SGK protein kinases, like Akt, phosphorylate substrates within an RxRxxpS/T recognition motif. 
1.4.1 Regulation of the SGK Protein kinases 
The activation and regulation of Akt was discussed in section 1.3.1. As with Akt and many other 
AGC protein kinases, the SGK family of protein kinases are similarly activated by PI3K signalling, 
mediated by phosphorylation on their T Loop by PDK1 and Hydrophobic motif by mTORC2. 
However, as these kinases lack a PH domain, they are  not recruited to PDK1 on the plasma 
membrane as Akt. Therefore, activation of the SGK family of kinases is reliant on a PIF-
dependent mechanism, whereby phosphorylation first occurs by mTORC2 on the hydrophobic 
motif (Garcia-Martinez and Alessi, 2008), which induces a conformational change in this 
hydrophobic region, promoting interaction with the PDK1 interacting fragment (PIF) pocket of 
PDK1. This enables PDK1 to dock, allowing phosphorylation of the activation loop residue (Biondi 
et al., 2001; Collins et al., 2003). 
The protein kinase SGK3 is unique among the SGK3 isoforms, as it has an N-terminal PX-domain. 
Similarly to the recruitment of Akt to PtdIns(3,4,5)P3 rich membranes, the PX-domain of SGK3 
anchors it to PtdIns(3)P rich membranes for its subsequent phosphorylation and activation by 




domain of SGK3 completely ablated localisation to PtdIns(3)P-containing structures, and also its 
activity (Bago et al., 2016). By shRNA knockdown of the mTORC2 subunit Rictor, Bago et al. 
demonstrated that SGK3 activation and hydrophobic motif phosphorylation is mTORC2 
dependent (Bago et al., 2016). Recent research has revealed that SGK3 can be activated through 
PtdIns(3)P production by the Class III PI3K VPS34, but also by Class I PI3K, via the lipid 
phosphatases SHIP2 and INPP4B (Bago et al., 2016; Malik et al., 2018). Comparison of the 
activation mechanisms of the Akt and SGK isoforms is shown in Figure 1.14. 
 
Figure 1.14 Activation mechanisms of Akt, SGK1/2 and SGK3. 
Akt can be activated in a PIF-independent mechanism, by colocalization to the plasma membrane with 
PDK1, or a PIF-dependent mechanism by prior phosphorylation by mTORC2. It is currently contested 
whether PH-binding to PtdIns(3,4,5)P3 is required for Akt activation. SGK3 is activated by recruitment to 
PtdIns(3)P on endosomal membranes by phosphorylation by mTORC2 in a PIF-dependent manner, then 
PDK1. SGK1/2 are activated by a PIF-dependent mechanism. 
 
SGK1 is also regulated by rapid protein turnover, with a half-life of only 30 minutes. This a 




degradation (Brickley et al., 2002; Bogusz et al., 2006). This protein-level regulation appears to 
be in part mediated by SGK1 through feedback regulation. Phosphorylation of Neural Precursor 
Cell-Expressed Developmentally-Downregulated Protein 4-2 (Nedd4-2) by SGK1 increases 
Nedd4-2-mediated ubiquitylation of SGK1 (Zhou and Snyder, 2005). 
1.4.2 Physiological roles of the SGK Protein Kinases 
SGK1 
As discussed above, SGK1 was first identified as a gene upregulated in response to serum and 
glucocorticoids (Webster et al., 1993; Webster, Goya and Firestone, 1993). SGK1 has also been 
demonstrated to be transcriptionally induced by the mineralocorticoid aldosterone (Chen et al., 
1999; Naray-Fejes-Toth et al., 1999) and a range of other factors such as transforming growth 
factor beta (TGF-β), cytokines, and external stress (Lang et al., 2006; Lang, Artunc and Vallon, 
2009). 
SGK1 has been linked to multiple cellular and physiological processes including regulation of 
solute transport, control of blood pressure, memory consolidation and cell survival (Lang et al., 
2006). SGK1 gene variants have been associated with elevated blood pressure (Busjahn et al., 
2002; Rao et al., 2013), increased incidence of ischaemic stroke and type II diabetes (Schwab et 
al., 2008; Dahlberg et al., 2011) and increased body mass index (Dieter et al., 2004), and SGK1 is 
thought to be a driver in the pathophysiology of these conditions. SGK1 has been reported to 
regulate the activity of a vast number of channels and transporters including sodium, potassium, 
calcium and chloride channels and amino acid and glucose transporters (Lang et al., 2006; Lang 
and Voelkl, 2013). 
SGK1 is highly expressed in the kidney, and the best mechanistically characterised role of SGK1 
is in regulation of the epithelial sodium channel (ENaC), through which SGK1 contributes to the 
control of renal tubular Na+ reabsorption. Co-expression of SGK1 with ENaC in Xenopus oocytes 




membrane (Chen et al., 1999; Naray-Fejes-Toth et al., 1999; Alvarez de la Rosa et al., 2003). 
Additionally, phosphorylation of Nedd4-2 by SGK1 was found to upregulate levels of ENaC at the 
plasma membrane. Downregulation of Nedd4-2 activity by SGK1-mediated  phosphorylation 
reduces binding to ENaC and stimulates Nedd4-2 binding to 14-3-3 chaperone proteins, leading 
to increased levels of ENaC at the cell surface (Debonneville et al., 2001; Snyder, Olson and 
Thomas, 2002; Bhalla et al., 2005; Ichimura et al., 2005). SGK1 has additionally been suggested 
to regulate ENaC via WNK4 (Ring et al., 2007) and transcriptionally (Boyd and Naray-Fejes-Toth, 
2005; Zhang et al., 2007).  
As expected from these findings, SGK1 knockout mice exhibit an impaired ability to regulate 
urinary Na+ and water excretion when placed on a low sodium diet (Wulff et al., 2002; Fejes-
Toth et al., 2008; Faresse et al., 2012). SGK1-/- mouse kidneys also failed to eliminate acute K+ 
load (Huang et al., 2004), and mice were resistant to increases in blood pressure, either induced 
by dexamethasone or by high salt intake in combination with a high fat diet (Huang, Boini, 
Friedrich, et al., 2006; Huang, Boini, Osswald, et al., 2006; Boini et al., 2008). However, a 
surprising result from these knockout mice was that expression of ENaC channels was only 
modestly reduced, with a greater deficiency in Na+Cl- cotransporter (NCC) (Fejes-Toth et al., 
2008; Vallon et al., 2009; Faresse et al., 2012). These findings suggest that the primary target of 
SGK1 may actually be NCC, with mechanisms proposed via Wnk4 (Rozansky et al., 2009) and 
Nedd4-2 (Arroyo et al., 2011). 
SGK1, as well as SGK3, may impact cellular metabolism, as expression in Xenopus oocytes, was 
shown to stimulate the activity of the Na+-glucose cotransporter SGLT1, which serves to absorb 
intestinal glucose (Dieter et al., 2004). Consequently, SGK1 knockout mice exhibited reduced 







Of all the SGK isoforms, SGK2 is the least studied. SGK2 is not transcriptionally induced by 
glucocorticoids or serum in cells (Kobayashi et al., 1999), and its physiological roles are not yet 
clear. A handful of studies have implicated SGK2 signalling in regulation of human organic anion 
transporters 1 and 4 (hOAT1/4) via phosphorylation of Nedd4-2 (Wang et al., 2016; Xu et al., 
2016; Wang, Zhang and You, 2019). 2 recent papers have suggested a role for SGK2 in bladder 
and renal cell carcinoma proliferation (Liu et al., 2017, 2019; J.-B. Chen et al., 2018). 
SGK3 
SGK3 was first identified as a novel isoform of SGK1 (Kobayashi et al., 1999). It was identified as 
a mediator of interleukin 3 (IL3)-dependent survival in haematopoietic cells (Liu, Yang and 
Songyang, 2000). SGK3 can be recruited via its PX domain to PtdIns(3)P at the early endosomal 
membrane generated by VPS34 (Virbasius et al., 2001; Bago et al., 2014, 2016). As SGK3 is 
commonly observed on Rab5-positive endosomes, its activation is likely mediated by complex II 
of VPS34. Additionally, the accessory subunit Rubicon has been associated with growth factor 
recognition and solely interacts with VPS34 complex II. Unlike SGK1, SGK3 expression is not 
induced by serum and glucocorticoids and is constitutively expressed (Kobayashi et al., 1999). 
However, its gene promoter contains oestrogen binding regions and its transcription can be 
induced by oestrogen (Wang et al., 2011). Additionally, elevated levels of SGK3 have also be 
observed in ER positive breast cancer cells (Xu et al., 2012). 
Like SGK1, SGK3 has been observed to phosphorylate and regulate the activity of the E3 Ligase 
Need4-2 (Dieter et al., 2004; Lamothe and Zhang, 2013). A role has also been proposed for SGK3 
in regulation of  vesicular trafficking and receptor sorting at the endosome, through regulation 
of E3 ligase atrophin-1 interacting protein 4 (AIP4) (Slagsvold et al., 2006). 
An additional substrate of SGK1 and SGK3, shared with Akt, is N-myc downstream-regulated 




phosphorylation event remains unknown. Phosphorylation at this site is extensively used as a 
measure of SGK activity in this thesis. Recent data from our lab has identified SGK3-specific 
endosomal substrates (Malik et al., 2019). It was determined that the identity of the +1 site in 
the substrate motif was critical in specificity between Akt and SGK3 substrates and may provide 
a bioinformatic tool for identifying further SGK3-specific substrates. 
SGK3 knockout mice display impaired postnatal hair growth due to a hair bulb keratinocyte 
proliferation defect (McCormick et al., 2004; Alonso et al., 2005). SGK3-/- mice also display a mild 
growth defect, normal renal salt handling, subtly decreased locomotion, defective mast cell 
function, increased gastric acid secretion and decreased intestinal glucose transport (McCormick 
et al., 2004; Sandu et al., 2005; Zemtsova et al., 2010; Pasham et al., 2011). 
Combination with SGK1 or Akt deletion models reveals redundancies and unique roles for the 
kinases in this pathway. For example, depletion of SGK3 further worsens the glucose handling 
phenotype of Akt2 knockout mice (Yao et al., 2011). SGK1-/-SGK3-/- double knockout mice share 
the hair growth defect of the SGK3 knockouts and the renal salt retention defect of SGK1 
knockouts without showing any novel more severe phenotypes (Grahammer et al., 2006). This 
suggests these kinases are playing independent physiological roles. 
1.4.3 SGK family of kinases in cancer, and Akt and PI3K inhibitor resistance. 
As discussed, the high degree of homology between the Akt and SGK protein kinases results in 
an overlapping substrate-specificity motif and therefore shared substrates between these 
kinases. These kinases were therefore  proposed as possible candidates for mediating Akt 
independent signalling, considering their regulation by PI3Ks and the similarity in substrate 
specificity with Akt (Bruhn et al., 2010, 2013) 
As Akt, SGK1 has been proposed to phosphorylate and inhibit the pro-apoptotic FoxO 
transcription factors (Brunet et al., 2001). SGK1 has also been linked to dexamethasone and 




Wu et al., 2004), and a role for SGK1 in cell invasion and migration has also been reported 
(Eylenstein et al., 2011; Schmidt, Gu, et al., 2012; Schmidt, Kraemer, et al., 2012). In multiple 
myeloma SGK1 was identified as a transcriptional target of cytokines that promote proliferation 
(Fagerli et al., 2011). It has recently been observed, in a panel of breast cancer cell lines carrying 
PI3K pathway mutations, that high expression of SGK1 confers resistance to Akt inhibitors 
(Sommer et al., 2013). It was also recently shown that a set of colorectal cancer tissues exhibited 
high expression of SGK1 in comparison to neighbouring healthy tissue. In addition, targeting of 
SGK1 by shRNA or kinase inhibition reduced colorectal cancer cell proliferation and migration, 
and induced apoptosis (Liang et al., 2017). A recent study of diffuse large B cell lymphomas found 
shRNA knockdown of SGK1 sensitised these cells to Akt inhibition (Lu et al., 2019). SGK1-/- mice 
were observed to develop significantly fewer chemically induced colonic tumours than their 
wildtype littermates, and this was determined to be at least partially due to stabilization of 
FOXO3a and BIM (Nasir et al., 2009). Additionally, crossing these mice with an adenomatous 
polyposis coli (APC)-deficient background resulted in reduced spontaneous tumorigenesis, and 
reduced β-catenin abundance was detected by western blot and confocal microscopy (Wang et 
al., 2010) 
It has recently been shown that SGK3 can also be implicated in resistance to inhibition of the 
PI3K-Akt signalling pathway. Bago et al., published that, in certain breast cancer cell lines, SGK3 
can be induced to provide acquired resistance after prolonged treatment with PI3K or Akt 
inhibitors. SGK3 is transcriptionally upregulated and activated independently of Class I PI3K to 
phosphorylate substrates in the place of Akt. This leads to Akt-independent activation of 
pathways such as mTORC1-driven proliferation (Figure 1.15). The focus of this thesis will be on 
this role of SGK3 in resistance to Class I PI3K and Akt inhibitors. In xenograft models of BT474 
cells treated with Akt inhibitors alone or in combination with an inhibitor of SGK (14H), it was 
determined that the combination treatment caused a much better growth arrest and even 




mediate liver cancer stem cell expansion after prolonged inhibition of PI3K Class I, through 
activation of the GSK-3β/β-catenin signalling (Liu et al., 2018). 
 
Figure 1.15 Akt-independent activation of mTORC1 via SGK3. 
When Class I PI3K or Akt are inhibited, SGK3 can be activated via Class III PI3K VPS34. In the absence of 
Akt activity, SGK3 can phosphorylate TSC2 leading to the activation of mTORC1. 
SGK3 has also been proposed as a driver of cancer cell proliferation itself. SGK3 was originally 
identified as a mediator of interleukin 3 (IL3)-dependent survival in hematopoietic cells, and 
again was suggested to inhibit FOXO-mediated transcription and to inhibit pro-apoptotic Bcl-2 
family members in a manner similar to Akt (Liu, Yang and Songyang, 2000). A study by Vasudevan 
noted that growth of breast cancer cells carrying the PIK3CA E545K mutation was promoted 
through activation of SGK3, with relatively low Akt phosphorylation (Vasudevan et al., 2009). A 
recent study also used SGK3 KO mice to determine that SGK3 was critical for hepatocarcinoma 




1.5 Thesis Aims 
My PhD project aimed to further explore the role that SGK3 plays in resistance to PI3K/Akt 
inhibition. In order to investigate the regulation and downstream signaling of SGK isoforms, 
work on the project has been based on 2 key aims. 
1. The Development of tools to induce degradation of SGK3 in sensitive cancer cell lines 
a. An SGK-specific PROTAC derived from Sanofi inhibitor compounds (Chapter 3) 
b. Mass-Spectrometry analysis of the impact of PROTAC-mediated degradation in 
cancer cells (Chapter 4) 
c. A Generalizable HaloPROTAC approach (Chapter 5) 
2. Determining the mechanism by which SGK3 can be activated in the context of PI3K 
inhibition 
a. How is mTORC2 activated against SGK3 under Class I PI3K inhibition? In 
particular, is this mediated by mSin1? (Chapter 6) 





2. Materials and Methods 
2.1 Materials  
2.1.1 Commercial Reagents   
Reagents used in this report are categorised into 5 main parts for: bacterial transformation, 
tissue culture, cell lysis, Immunoblotting (IB),  Immunoprecipitation (IP) & Kinase assay, and 
gDNA extraction and subcloning (Table 2.1).  
Table 2.1 Commercial Reagents 
Reagent Company Origin  
Bacterial transformation 
Ampicillin Sigma-Aldrich Poole, UK 
Plasmid Maxiprep kit Qiagen Ltd Crawley, UK 
Plasmid Midiprep kit Qiagen Ltd Crawley, UK 
Tissue culture  
Blasiticidin InVivoGen San Diego, USA 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich Poole, UK 
Doxycycline Sigma-Aldrich Poole, UK 
Dulbecco’s modified eagle medium Invitrogen Paisley, UK 
Foetal bovine serum (FBS) Labtech Brambleside, UK 
Hygromycin InVivoGen San Diego, USA 
L-glutamine Invitrogen Paisley, UK 
Pen/Strep Invitrogen Paisley, UK 
Phosphate buffered saline (PBS) Invitrogen Paisley, UK 
Polyethyleneimine (PEI) Polyscience Warrington, PA 
Puromycin Sigma-Aldrich Poole, UK 
Trypsin/EDTA Invitrogen Paisley, UK 
Zeocin Invivogen San Diego, USA 
IGF-1 (carrier free) New England 
Biolabs 
Ipswich, MA 




Benzamidine Sigma-Aldrich Poole, UK 
Dithiothreitol (DTT) Formedium Norfolk, UK 
EDTA Sigma-Aldrich Poole, UK 
EGTA Sigma-Aldrich Poole, UK 
Protease inhibitor cocktail Roche Lewes, UK 
Sodium b-glycerophosphate Sigma-Aldrich Poole, UK 
Sodium fluoride Sigma-Aldrich Poole, UK 




Triton-X-100 Sigma-Aldrich Poole, UK 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich Poole, UK 
IB, IP & Kinase Assay 
3MM paper Whatman Maidstone, UK 
40% (w/v) 29:1 Acrylamide Flowgen 
Bioscience 
Nottingham, UK 
Ammonium persulphate (APS) Sigma-Aldrich Poole, UK 
Bovine serum albumin (BSA) Sigma-Aldrich Poole, UK 
Coomassie protein assay kits Thermo Scientific Essex, UK 
Dimethyl pimelimidate (DMP) Sigma-Aldrich Poole, UK 
Enhanced chemiluminescence (ECL) GE Healthcare Piscataway, NJ 
Glycine Sigma-Aldrich Poole, UK 
Immobilon PVDF membrane (0.45μm) Sigma-Aldrich Poole, UK 
Isopropanol Sigma-Aldrich Poole, UK 
Methanol Sigma-Aldrich Poole, UK 




NuPAGE LDS sample buffer Invitrogen Paisley, UK 
NuPAGE MOPS running buffer Invitrogen Paisley, UK 
NuPAGE Novex SDS Bis-Tris gels Invitrogen Paisley, UK 
Photographic developer (LX24)  Kodak Liverpool, UK 
Photographic fixer (FX40) Kodak Liverpool, UK 
Ponceau S Sigma-Aldrich Poole, UK 
Precision Plus Protein unstained standards BioRad Herts, UK 
Skimmed milk (Marvel) Premier 
Beverages 
Stafford, UK 
Sodium tetraborate Sigma-Aldrich Poole, UK 
Sucrose BDH Lutterworth, UK 
Tris(hydoxymethyl)methylamine (Tris) BDH Lutterworth, UK 
Super sensitive X-ray films GE Healthcare Buckinghamshire, UK 
Tween-20 Sigma-Aldrich Poole, UK 
X-ray films Konica 
Corporation 
Japan 
[γ32P]‐labelled ATP GE Healthcare Buckinghamshire, UK 
P81 paper GE Healthcare Poole, UK 
Acetone Sigma Aldrich Poole, UK 
Orthophosphoric Acid Sigma Aldrich 
 
Magnesium Acetate Sigma Aldrich Crawley, UK 
gDNA extraction and subcloning 
DNeasy Blood and Tissue Kit Qiagen Essex, UK 
dNTP Mix Thermo Scientific Ipswich, MA 
Taq Polymerase New England 
Biolabs 
Paisley, UK 
Custom Primers Invitrogen Essex, UK 




Strataclone PCR cloning kit Agilent Santa Clara, CA 
X-Gal Formedium Norfolk, UK 
 
2.1.2 In-house Reagents    
Calcium competent E. coli DH5α cells and Crosstide Peptide were kindly provided by MRC PPU 
Reagents and Services. Luria Bertani (LB) broth and agar plates were kindly supplied by the 
Media Kitchen of the University of Dundee. PROTAC compounds were produced by the Ciulli Lab 
(BCDD, University of Dundee) and dissolved in DMSO to a 10mM solution. In-house antibodies 
were provided by MRC PPU Reagents and Services are described in section 2.1.5 
2.1.3 DNA constructs   
Cloning and mutagenesis of cDNA constructs was performed by Dr R Toth, Mrs M Wightman, Mr 
T. Macartney and Ms S Weidlich (Table 2.2). All DNA constructs were verified by DNA sequencing 
performed by Sequencing Service of the University of Dundee using DYEnamic ET terminator 
chemistry (GE Healthcare, Little Chalfont, UK) on automated DNA sequencers (Applied 
Biosystems, Foster City, CA). All constructs encoded the human version of the gene. 
Table 2.2 cDNA constructs 
Expressed Plasmid Vector Type DU# 
Chapter 3  
SGK3 pcDNA5 FRT/TO Mammalian 42866 
SGK3 K191A pcDNA5 FRT/TO Mammalian 44432 
SGK3 T320A pcDNA5 FRT/TO Mammalian 62503 
SGK3 S486A pcDNA5 FRT/TO Mammalian 62504 
SGK3 Q125-end pcDNA5 FRT/TO Mammalian 62559 
SGK3 R50A/R90A pcDNA5 FRT/TO Mammalian 44990 
HA-SGK1 pcDNA5 FRT/TO Mammalian 44437 
HA-SGK1 K129A pcDNA5 FRT/TO Mammalian 44426 
Chapter 4 




shSGK3 #2 pLKO puro Viral 62768 
shRNA scramble pLKO puro Viral 62719 
Gag/Pol-Rev pCMV Mammalian  Addgene 
VSVG pCMV Mammalian Addgene 
SGK3 shRNA#1 resistant pcDNA5 FRT/TO Mammalian 44539 
SGK3 K191A shRNA#1 resistant pcDNA5 FRT/TO Mammalian 44540 
SGK3 shRNA#2 resistant pcDNA5 FRT/TO Mammalian 44496 
SGK3 K191A shRNA#2 resistant pcDNA5 FRT/TO Mammalian 44538 
Chapter 5 
SGK3 Cter Gly5 Halo IRES GFP KI Donor pMK-RQ Mammalian 52689 
SGK3 Cter KI antisense guide + Cas9 
D10A 
pX335 Mammalian 52662 
SGK3 Cter KI sense guide pBabeD Mammalian 52684 
VPS34 Nter Halo KI Donor pMK-RQ Mammalian 57077 
VPS34 Nter KI antisense guide + Cas9 
D10A 
pX335 Mammalian 52082 
VPS34 Nter KI sense guide pBabeD Mammalian 52071 
SGK3 pcDNA5 FRT/TO Mammalian 42866 
SGK3-Flag pcDNA5 FRT/TO Mammalian 42884 
SGK3-GFP pcDNA5 FRT/TO Mammalian 42883 
SGK3-Gly5-Halo   pcDNA5 FRT/TO Mammalian 50748 
SGK3-Gly5-HaloD106A pcDNA5 FRT/TO Mammalian 50763 
SGK3-Gly10-Halo pcDNA5 FRT/TO Mammalian 26756 
SGK3-Gly15-Halo pcDNA5 FRT/TO Mammalian 26769 
SGK3-Gly20-Halo pcDNA5 FRT/TO Mammalian 26812 
SGK3-Gly5-ATG-Halo pcDNA5 FRT/TO Mammalian 54586 
SGK3-Lys5-Halo pcDNA5 FRT/TO Mammalian 50749 
SGK3-Lys5-HaloD106A pcDNA5 FRT/TO Mammalian 50764 
SGK3-Gly5-HaloMUT1 * pcDNA5 FRT/TO Mammalian 26553 
SGK3-Gly5-HaloMUT2 * pcDNA5 FRT/TO Mammalian 26566 
SGK3-Gly5-HaloMUT3 * pcDNA5 FRT/TO Mammalian 26575 
SGK3-Lys5-HaloMUT1 * pcDNA5 FRT/TO Mammalian 26527 
SGK3-Lys5-HaloMUT2 * pcDNA5 FRT/TO Mammalian 26541 




*MUT1 = R21K, R86K, R204K, R254K, R288K  
MUT2 = MUT1 + R30K, R146K, H230K  
MUT3 = MUT2 + R199K  
Chapter 6 
mSin1 KO antisense guide + Cas9 D10A pX335 Mammalian 52297 
mSIN1 KO sense guide pBabeD Mammalian 52278 
mSIN1 Cter GFP KI Donor pMK-RQ Mammalian 57431 
mSIN1 Cter KI antisense guide A + Cas9 
D10A 
pX335 Mammalian 57354 
mSIN1 Cter KI sense guide A pBabeD Mammalian 57348 
mSIN1 Cter KI antisense guide B + Cas9 
D10A 
pX335 Mammalian 57353 
mSIN1 Cter KI sense guide B pBabeD Mammalian 57349 
Rictor NTer GFP KI Donor pMK-RQ Mammalian 57430 
Rictor Nter KI antisense guide A + Cas9 
D10A 
pX335 Mammalian 57356 
Rictor Nter KI sense guide A pBabeD Mammalian 57350 
Rictor Nter KI antisense guide B + Cas9 
D10A 
pX335 Mammalian 57355 
Rictor Nter KI sense guide B pBabeD Mammalian 57351 
HA-mSin1 TV1 pcDNA5 FRT/TO Mammalian 26852 
HA-mSin1 TV2 pcDNA5 FRT/TO Mammalian 26882 
HA-mSin1 TV3 pcDNA5 FRT/TO Mammalian 26952 
HA-mSin1 TV4 pcDNA5 FRT/TO Mammalian 26853 
HA-mSin1 TV5 pcDNA5 FRT/TO Mammalian 26886 
HA-mSin1 TV1 R393C K428A K464A pcDNA5 FRT/TO Mammalian 26854 
HA-mSin1 TV1 M1-Q375 pcDNA5 FRT/TO Mammalian 26862 
HA-mSin1 TV1 M1-S356 pcDNA5 FRT/TO Mammalian 27342 
HA-mSin1 TV1 R312L pcDNA5 FRT/TO Mammalian 26992 
HA-mSin1 TV1 R312A pcDNA5 FRT/TO Mammalian 26991 
HA-mSin1 TV1 K307D pcDNA5 FRT/TO Mammalian 26993 
HA-mSin1 TV1 R312L R393C K428A 
K464A 
pcDNA5 FRT/TO Mammalian 27329 
HA-mSin1 TV1 T86A pcDNA5 FRT/TO Mammalian 27795 




HA-mSin1 TV1 T86A T398A pcDNA5 FRT/TO Mammalian 27814 
HA-mSin1 TV1 T86E T398E pcDNA5 FRT/TO Mammalian 27788 
HA-mSin1 TV1 Q68H pcDNA5 FRT/TO Mammalian 27538 
HA-mSin1 TV2 R393C K428A K464A pcDNA5 FRT/TO Mammalian 59340 
HA-mSin1 TV2 M1-Q375 pcDNA5 FRT/TO Mammalian 59186 
HA-mSin1 TV2 T86A pcDNA5 FRT/TO Mammalian 59104 
HA-mSin1 TV2 T86E pcDNA5 FRT/TO Mammalian 59103 
HA-mSin1 TV2 T86A T398A pcDNA5 FRT/TO Mammalian 59282 
HA-mSin1 TV2 T86E T398E pcDNA5 FRT/TO Mammalian 59132 
GST-SGK3 D304A pEBG Mammalian 2257 
GST-SGK1 60-end K127A pEBG Mammalian 143 
GST-PKB A K179A pEBG Mammalian 6191 
Flag-TurboID-aGFP6M pBabeD Mammalian 29702 
Gag/Pol pCMV Mammalian Addgene 
VSV/G pCMV Mammalian Addgene 
 
2.1.4 Buffers and solutions  
Mammalian cell lysis buffer: 25 mM Tris (pH 7.5), 1 mM EDTA, 1 mM EGTA, 0.27 M sucrose, 50 
mM NaF, 5 mM sodium pyrophosphate, 1mM sodium orthovanadate, 10 mM sodium 
βglycerophosphate, 1 mM benzamidine, 1mM DTT, one mini Complete protease inhibitor 
cocktail tablet per 10 ml of lysis buffer and 1% Triton X-100  
Glutamate Lysis Buffer: 25mM HEPES (pH 7.4), 2.5mM Mg Acetate, 5mM EGTA (pH 8), 150mM 
K-Glutamate, 25mM KCl 
Tris-Glycine running buffer: 25 mM Tris-HCl (pH 8.3), 192 mM glycine, 0.1% (w/v) SDS  
Tris-Glycine transfer buffer: 48 mM Tris-HCl (pH 8.3), 39 mM glycine, 20% (v/v) methanol 
TBST buffer: 50 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.1% (v/v) Tween-20 




RIPA Buffer: 50mM Tris-HCl (pH 8), 150mM NaCl, 1mM EDTA, 0.1% SDS, 1% sodium 
deoxycholate, 1% NP-40, 50mM NaF, 5mM sodium pyrophosphate, one mini Complete protease 
inhibitor cocktail tablet per 10 ml of lysis buffer. 
2.1.5 Antibodies  
In-house antibodies (Table 2.3) were raised in sheep and affinity purified with respective 
antigens by the DSTT and were used at 1 µg/mL in 5% (w/v) skimmed milk in 0.1% TBST. 
Phospho-specific antibodies were supplemented with 10 µg/ml of the relevant non-phospho 
peptide to increase specificity and decrease background. Commercial antibodies (Table 2.4) 
were diluted 1:1000 in 5% (w/v) BSA in 0.1% TBST.  
Table 2.3  In-house antibodies produced by MRC PPU Reagents and Services 
Antibody Immunogen Sheep # Bleed # 
PKB-alpha Human 466-480 S695B 3rd 
NDRG1 Human Full Length S771D 3rd 
PRAS40 Human 238-256 S115B 1st 
pPRAS40 (Thr246) Human 240-251 S114B 2nd 
SGK3 SGK3 PX Domain 
(Human 1-130) 
S848D 6th 
VPS15 Human 433-667 R1737 2nd 
VPS34 Human Full Length S672B 3rd 
Beclin1 Human Full Length S900B 2nd 
UVRAG Human Full Length S232D 3rd 
P70S6K1 Human 25-44 S417B 2nd 
mSin1 Human Full Length S008C 3rd 
mTOR Human 2-20 S683B 1st 
Rictor Human 6-20 S654B 3rd 
  
Table 2.4 Commercial antibodies.  
Antibody Catalogue Number Company Species 




pAkt (Ser473) 9271 CST Rabbit 
pAkt (Thr450) 9267 CST Rabbit 
pSGK3 (Thr320) 5642 CST Rabbit 
pSGK1 (Ser422) Sc-16745 Santa Cruz Rabbit 
SGK S5188 Sigma Rabbit 
pNDRG1 (Thr346) 5482 CST Rabbit 
GAPDH (6C5) Sc-32233 Santa Cruz Mouse 
HaloTag7 mAb G9211 Promega Mouse 
HaloTag7 pAb G9281 Promega Rabbit 
pTSC2 S929 3615 CST Rabbit 
pTSC2 T1462 3617 CST Rabbit 
TSC2 3612 CST Rabbit 
pPRAS40 2997 CST Rabbit 
pS6 S240/244 2215 CST Rabbit 
S6 Total 2317 CST Mouse 
pp70S6K1 T389 9205 CST Rabbit 
p70S6K1 9202 CST Rabbit 
pFOXO3a (Ser253) 9466 CST Rabbit 
p4EBP1 S65 9451 CST Rabbit 
4EBP1 9452 CST Rabbit 
PDE4D Ab171750 Abcam Rabbit 
RPL14 ab181200 Abcam Rabbit 
TRAF3IP2 NB100-56740SS Novus Rabbit 
ZNF512B A303-236A-T Bethyl Rabbit 
RSAD1 ab104051 Abcam Rabbit 
GHITM 16296-1-AP Proteintech Rabbit 
COX6C ab150422 Abcam Rabbit 
COXIV 4844 CST Rabbit 
ATPb ab15730 Abcam Rabbit 
MT-CO1 ab14705 Abcam Rabbit 




mSin1 12860 CST Rabbit 
pmSin1 T86 14716 CST Rabbit 
Rictor 3806 CST Rabbit 
ATG14 PD026 MBL Rabbit 
 
2.1.6 Inhibitors and compounds 
PROTAC compounds were synthesised by Andrea Testa and Chiara Maniaci in Alessio Ciulli’s lab. 
Large amounts of Sanofi 290-R and 308-R were synthesised by Natalia Shpiro for production of 
the SGK3-PROTAC compounds. Natalia Shpiro also synthesised the inhibitors available in house 
at MRC PPU Reagents and services. 
Table 2.5 Inhibitors 
Inhibitor Target Source Ref 
AZD5363 Akt AstraZeneca (Davies et al., 
2012) 
14H SGK In House (Halland et al., 
2015) 
GDC0941 Class I PI3K In house (Folkes et al., 
2008) 
VPS34IN1 VPS34 In house (Bago et al., 2014) 
MLN4924 Nedd8 E3 In house (Brownell et al., 
2010) 
VH298 pVHL Ciulli lab (Frost et al., 2016) 
MG132 Proteasome Calbiochem (Lee and 
Goldberg, 1998) 
MK2206 Akt SelleckChem (Hirai et al., 2010) 
Bafilomycin A Vacuolar H+-ATPase Enzo Life Sciences (Ohkuma et al., 
1993) 
 
2.1.7 Cell lines 
ZR-75-1, CAMA-1, CAMA-R, BT-474 and JIMT-1 cell lines were provided by AstraZeneca. All other 




2.2 Methods  
2.2.1. Amplification of cDNA constructs. 
cDNA constructs used in this study were produced by MRC PPU Reagents and Services as 
described in section 2.1.3. Amplification of the constructs for use in experiments was performed 
in DH5α cells. 
2.2.1.1 Transformation of competent E. coli DH5α cells  
1 µl DNA was added to 50 µl of competent E. coli DH5α cells and incubated on ice for 20 min 
followed by a heat shock for 45 seconds at 42°C. The cells were placed back on ice for 5 min and 
then streaked onto LB agar plates containing ampicillin or kanamycin for selection and incubated 
overnight at 37°C. 
2.2.1.2 Purification of plasmids from E. coli and measurement of DNA concentration   
Transformed E. coli DH5α cells were cultured in 250 mL LB containing 200 µg/mL ampicillin or 
kanamycin. After an incubation time of about 16 h at 37°C, shaking at 180rpm, the samples were 
pelleted by centrifugation at 6000 x g. Plasmid purification was performed by Maxiprep kit 
according to the manufacturer’s instructions. Finally, DNA concentrations were measured using 
NanoDrop based on DNA absorption at 260 nm. Absorbance at 230 nm and 280 nm was also 
measured as a measure of purity.    
2.2.2 gDNA Sequencing  
gDNA was extracted from HEK293 cells using DNeasy Blood and Tissue Kit according to 
manufacturer’s instructions for Blood. Polymerase Chain Reaction (PCR) was performed in a 25µl 
reaction, containing 2 ul Buffer, 0.8µM primers, 200µM dNTPs, 1 µl DNA and 1 µl Taq Polymerase. 
The reaction was performed on the following thermal cycle, using primers described in Table 
2.6: 96 °C for 3, 35 cycles of [95 °C for 30’’, Tm for 30’’, 72 °C for 30’’], then 72 °C for 10’’ before 
storage at 4 °C. 5µl PCR product was analysed on a 2% Agarose gel in TAE buffer to detect the 




according to manufacturer’s instructions. DNA Sequencing was performed using the M13 
Forward Primer by DNA Sequencing and Services (www.dnaseq.co.uk) using Applied Biosystems 
Big-Dye v 3.1 chemistry on an Applied Biosystems model 3730 automated capillary DNA 
sequencer.   
Table 2.6 PCR primer sequences 








VPS34 Exon 1 AGCTCAAGCTCAAATGATAGCG CATCTGCCTGTGTCTACCTCTC 
mSin1 Exon 5 TCCATGGTCACAGTAGGTCT GCTGATTCTCTGAGATGCACA 
  
2.2.3 Cell culture methods 
Cells were maintained in an incubator at 37°C and 5% CO2. The passaging of  cells was performed 
by washing the cells with PBS followed by incubation with Trypsin/EDTA. Detached cells were 
resuspended in cell culture medium and split at 1:2 – 1:8 ratios. HEK293, HEK293FT, HEK293T 
and U2OS cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) in the presence of 
10% (v/v) FBS, 2 mM  L-glutamine, 100 U/mL penicillin and 0.1 mg/mL streptomycin in DMEM. 
Stable HEK293 TREx cell lines were grown in selection media containing 100 µg/ml Hygromycin 
and 15 µg/ml Blasticidin. Virally transfected stable cell lines were grown in media containing 2 
µg/ml Puromycin until plating for experiments. ZR-75-1, CAMA-1, BT-474 and JIMT-1 were 
grown in RPMI-1640 media without phenol red and supplemented as above with the exclusion 
of penicillin and streptomycin. 




Detached cells were centrifuged at 300 x g for 5 min and resuspended in FBS with 10% DMSO. 1 
mL aliquots were stored in cryovials at -80 ˚C. Cells were thawed in a 37 ˚C water bath, 
resuspended in growth medium and allowed to adhere overnight prior to medium change.  
2.2.3.2 Transfection of cells using polyethyleneimine (PEI)   
For transfection of cells grown in 10cm dishes, 5µg DNA was mixed with 20µl 1mg/ml PEI and 
1mL serum-free DMEM and left for 20-30 min at room temperature before being added to cells. 
For transient transfection, cells were harvested 24 hr post transfection. For generation of 
HEK293 TREx stable cell lines, media was changed 24 hr post transfection, and media containing 
Hygromycin and Blasticidin added 48 hr post transfection. 
2.2.3.3 Transfection of cells using retroviral and lentiviral constructs. 
i. Transfection with pBABE constructs for stable overexpression 
Stable expression of the FLAG-TurboID-aGFP6M plasmid was performed using a pBABE retroviral 
expression vector. To generate retroviral particles, HEK293T cells grown on 10 cm dishes were 
transfected with 6 µg pBABE construct, 3.8 µg pCMV Gag-Pol and 2.2 µg pCMV VSVG, with 36 µl 
Lipofectamine 2000 in Optimem. Virus-containing medium was collected 48 and 72 h post-
transfection and filtered with a 0.45 µM filter. Cells were transfected at a 5:1 ratio in full media, 
with 8 µg/ml polybrene. Media was changed after 24 h, and after 48 h selection for transfected 
cells was performed with media supplemented with 2 µg/ml puromycin.  
ii. RNA interference by small hairpin RNAs (shRNA) 
shRNA knockdown of SGK3 was performed using pLKO shRNA lentiviral constructs previously 
optimised in the lab for SGK3 knockdown in a range of cell lines. shRNA sequences are shown in 
table 2.4 below. To generate lentiviral particles, HEK293T cells grown on 10cm dishes were 
transfected with 3 µg pLKO plasmid and 3 µg each of the lentiviral packaging plasmids from 




and filtered with a 0.45 µM filter. Cells were transfected at a 5:1 ratio in full media, with 8 µg/ml 
polybrene. Media was changed after 24 h, and after 48 h selection for transfected cells was 
performed with media supplemented with 2 µg/ml puromycin. 
Table 2.7 shRNA sequences 
shRNA Sequence insert 
shSGK3#1 CCGGGCAGGACTAAACGAATTCATTCTCGAGATAAGAGAAACCAACGAATGCTTTTT 





2.2.3.4 Treatment of cells with Growth Factors, Inhibitors or PROTACs  
PROTAC compounds and inhibitors were added to cell culture medium at the time and 
concentration described in text, to a DMSO concentration of 0.1%. In IGF1 stimulation 
experiments, cells were deprived of serum for 16hr to induce basal conditions prior to 
stimulation with 50 ng/mL IGF1 for 15 min. 100 µg/mL stock of IGF1 was prepared in 20mM 
citrate pH 3. In the case of prolonged inhibitor treatments of cancer cell lines, RPMI medium and 
compounds were replenished every 3 days. 
2.2.3.5 Cell lysis  
Cells were washed with PBS and lysed on ice using 1 mL of cell lysis buffer per 15 cm dish. Lysates 
were clarified by centrifugation at 14,000 x g for 15 min at 4 ˚C.  
2.2.3.6 Quantification of protein concentration with Bradford assay   
The protein concentration of lysates was measured using the Bradford assay in a 96 well plate. 
5 µl of a 1:10 diluted sample was added in duplicate to 200 µl of Bradford reagent (Coomassie 
Brilliant Blue). The standard curve was measured by plotting absorbance at 595 nm against BSA 




2.2.4 Western Blotting 
2.2.4.1 Resolution of protein samples via SDS-PAGE and transfer to nitrocellulose membranes   
To separate proteins according to their electrophoretic mobility, polyacrylamide gel 
electrophoresis (PAGE) was used. Home-made isogradient or commercial 4-12% Bis-Tris gels 
were used to resolve different proteins. Samples were made in 1x LDS buffer with 5% β-
mercaptoethanol and heated at 70 ̊ C for 15 min. 2-30 µg of lysate or 10% of immunoprecipitates 
were loaded per lane alongside protein standards. In-house gels consist of a resolving gel (375 
mM Tris-HCl (pH 8.6), 0.1% SDS and 8/10/12 % acrylamide) and a stacking gel (125 mM Tris HCl 
pH 6.8, 0.1% SDS, 4% acrylamide). TEMED and APS were used to initiate polymerisation. The 
electrophoresis was initiated at 80 V until the dye front entered the resolving gel and was then 
increased to 160-180 V until the dye front reached the end of the resolving gel. Pre-cast gels 
were run at 160 V for 1 h.   
For protein transfer, gels were sandwiched between nylon sponges, Whatman 3MM filter 
papers and nitrocellulose soaked in transfer buffer. The transfer cell was submerged in transfer 
buffer and transfer was carried out at 80 V for 80 min.   
2.2.4.2 Immunoblotting (IB)  
After transfer, membranes were blocked with 5% (w/v) skimmed milk in TBST for 1 h at room 
temperature. Next, membranes were incubated with primary antibodies diluted in either 5% 
(w/v) milk or BSA in TBST at 4 ˚C overnight. Membranes were washed four times with TBST at 
room temperature followed by the incubation with IR-680 or IR-800 dyes, diluted 1:10,000 in 
TBS/T, for 1 hour at room temperature. The membranes were then washed four times with 
TBS/T, and fluorescent signal captured with an Odyssey Infrared Imaging System and Quantified 
in Image Studio.  
Where indicated, signals were visualised using Horseradish Peroxidase (HRP)-conjugated 





2.2.5.1 Covalent coupling of antibodies   
Protein G-beads were washed in PBS four times followed by coating with 1 µg of antibody per 1 
µl of resin for 1 h at 4 ̊ C. Beads were then washed 4 times with PBS to remove unbound antibody, 
followed by 4 washes with 100 mM sodium tetraborate (pH 9.3). Beads were incubated with 20 
mM DMP in 100 mM sodium tetraborate twice for 30 min at room temperature followed by four 
washes with 50 mM glycine (pH 2.5) to remove any non-covalently coupled antibody. To 
neutralise the pH, two washes were performed with 200 mM Tris-HCl (pH 8). Finally, beads were 
incubated in 200 mM Tris-HCl (pH 8) at 4 ˚C overnight, before storage in PBS at 4˚C.   
2.2.5.1 Immunoprecipitation (IP) of proteins  
Covalently coupled antibody was mixed with 0.5-3 mg of lysate, at a ratio of 1µg antibody to 
1mg lysate, for 2.5 h at 4 ˚C on a rotating wheel. Beads were then washed once with lysis buffer 
containing 500mM NaCl and once with lysis buffer containing 150 mM NaCl, followed by 2 
washes with Buffer A. The immunoprecipitates were eluted by resuspending the beads in 2x 
NuPAGE LDS sample buffer, boiled at 70 ˚C for 15 min followed by filtering through 0.22 µM 
Spin-X columns.  
2.2.6 Kinase assays employing a peptide substrate  
In vitro kinase activities were measured using Cerenkov counting of incorporation of radioactive 
32P from [γ32P]‐labelled ATP into a peptide substrate. The following conditions were used: 10 
mM Magnesium Acetate, 0.1 mM [γ32P]‐ATP, 30 µM Crosstide Peptide (GRPRTSSFAEG) in Buffer 
A to a final volume of 40 µl. Control reactions contained a pre-immune IgG precipitate. Reactions 
were incubated at 30˚C for 30 min, shaking at 1100rpm, and terminated by adding 10µl 0.1M 
EDTA.  
40 µl of the reaction mixture was then spotted onto P81 phosphocellulose paper, which 




orthophosphoric acid to remove any radioactivity not associated with the phosphorylated 
peptide. Papers were then incubated in acetone for 3 min and air-dried. Cerenkov counting was 
performed on a scintillation counter for 1 minute per sample and counts normalised to 1ul of 
the kinase assay reaction mix. One unit of protein kinase activity is defined as the amount of 
enzyme that catalyses the incorporation of 1 nmol phosphate into the substrate in 1 min. 
Protein kinase profiling 
Protein kinase profiling against Dundee panel of 140 protein kinases was undertaken at the 
International Centre for Protein Kinase Profiling. The result for each kinase was presented as a 
mean kinase activity of the reaction taken in triplicate relative to a control sample treated with 
DMSO. Assay conditions and abbreviations are available at http://www.kinase-screen.mrc.ac.uk. 
IC50 determination was performed with MRC PPU International Centre for Protein Kinase 
Profiling, according the protocol previously described (Hastie, McLauchlan and Cohen, 2006; 
Bain et al., 2007) 
2.2.7 mTORC2 kinase assays 
Cells were lysed in CHAPS lysis buffer. Lysates were incubated with 15 µL HA-conjugated 
sepharose beads at 4 °C for 1 h. Immunoprecipitates were washed six times with CHAPS lysis 
buffer and twice with HEPES kinase assay buffer. Assays were carried out in a final volume of 25 
µL HEPES kinase assay buffer containing 1µg of substrate (GST-Akt1, GST-ΔN-SGK1, or GST-SGK3) 
and kinase reactions were initiated upon addition of 0.1 mM ATP and 10 mM Magnesium 
acetate. Reactions were carried out for 30 min at 30°C and terminated by SDS sample buffer. 
Samples were heated to 70°C for 5 min, passed through a Spin-X column and subjected to 
immunoblot analysis.  
2.2.8 Generation of knock-in cells via CRISPR/Cas9  
A detailed description of the CRISPR/Cas9 mechanism is described in Chapter 5. A modified Cas9 




SGK3–HaloTag7 knock–in mutation, as well as knockout of msin1. Optimal sgRNA pairs were 
identified [as close as possible to point of HaloTag7 insertion, with a low combined off–targeting 
score; (VPS34–sgRNA1: GCTACATCTATAGTTGTGACC (DU52071); sgRNA2: 
GCCCCATCGCACCGTCTGCAA (DU52082); SGK3–sgRNA1: GAGCAAAATAAGTCTATAGA 
(DU52684)); sgRNA2: GAAAAATAAGTCTTCTGAAGG (DU52662), mSin1-sgRNA1: 
GCCCGATCAGGTCCTGCACCC; sgRNA2: GTGCTGGCAGTATACAAGCGA] using the Sanger Institute 
CRISPR web tool (http://www.sanger.ac.uk/htgt/wge/find_crisprs). Complementary oligos with 
BbsI compatible overhangs were designed for each, annealed and the dsDNA guide inserts 
ligated into BbsI–digested target vectors; the antisense guides (sgRNA2) were cloned onto the 
spCas9 D10A–expressing pX335 vector (Addgene plasmid no. 42335) and the sense guides 
(sgRNA1) into the puromycin–selectable pBABED P U6 plasmid (Dundee–modified version of the 
original Cell Biolabs pBABE plasmid). Donor constructs (VPS34–DU57077 and SGK3–DU52689) 
consisting of HaloTag7 or HaloTag7–IRES2–GFP flanked by ∼500 bp homology arms were 
synthesized by GeneArt (Life Technologies); each donor was engineered to contain sufficient 
silent mutations to prevent recognition and cleavage by Cas9 nuclease. 
1 µg each of the sense, antisense and donor plasmid were transfected into cells of 70% 
confluency using 20µl 1mg/ml PEI. Media was changed 24hr post transfection and puromycin 
selection (2µg/ml) initiated 48 hr post transfection. Untransfected cells served as negative 
control since these were not puromycin resistant. After another 48 h, media was changed to 
normal growth media for recovery. Due to the low efficiency of knockin, the transfection process 
was performed twice. After 2 rounds of transfection cells were split into two dishes. One half 
was lysed and used for the immunoblot (IB) screen of the cell pool to assess KI efficiency. The 
other half of the cells was prepared for single cell sorting by centrifugation at 300 x g for 3 min 
at room-temperature and resuspending in 1 mL DMEM containing 1% FBS. After single cell 
sorting into 96 well plates, each plate was centrifuged at 350 x g for 3 min at room-temperature 




plates and expanded until enough cells were obtained to screen by for IB. Possible positive 
clones were identified by western blot before validation by gDNA sequencing, as described in 
section 2.2.3 
2.2.9 Immunofluorescence 
Immunofluorescent imaging was used in this study to determine the correct localisation 
of proteins of interest, and to measure production of PtdIns(3)P on endosomal 
membranes. 22x22 cm coverslips were sterilised in ethanol before placing in a well of 6 
well plates and allowing to dry. When working with HEK293 cells or using the Freeze-
Thaw method of cell permeabilization, cover slips were coated with Poly-L-Lysine to 
improve adherence of cells to coverslips in later washing steps. Cells were plated on 
coated coverslips and allowed to adhere overnight, before cell treatments were 
performed as indicated.  
2.2.9.1 Formaldehyde fixation of cells 
The goal of fixation is to maintain cells in their current state and to preserve the cells 
over an extended period. Chemical cross-linkers such as formaldehyde crosslink proteins 
via their free amino groups and cellular morphology is generally well conserved in this 
way. Following cell treatments, media was removed, and coverslips immediately 
incubated with 4% paraformaldehyde for 10 minutes at room temperature to fix the 
cells. After fixation, coverslips were quenched by 3x 5’ washes with 0.2% BSA in PBS. 
2.2.9.2 Permeabilization 
i. 1% Nonidet P40 method 
Permeabilization of cells were performed by incubating coverslips for 10’ in 1% Nonidet 




accessible to antibodies, which otherwise would not be able to pass the lipid membranes 
of the cell. 
ii. Freeze-Thaw method 
Following cell treatments as described in figure legends, and prior to fixation with 
paraformaldehyde, cells were placed on ice and washed twice with ice-cold PBS. Cells were then 
washed twice with glutamate lysis buffer before snap freezing in liquid nitrogen. Coverslips were 
quickly thawed and washed twice more with glutamate buffer, prior to fixation with 4% PFA for 
30 minutes at room temperature. After fixation, cover slips were quenched by two washes and 
10’ incubation with DMEM + 10 mM HEPES, pH 7.4. 
2.2.9.3 Immunostaining 
Following permeabilization, cover slips were washed 2 x 5’ with 0.2% BSA in PBS, then incubated 
in blocking buffer (1% BSA in PBS) for 15’ at room temperature. As with immunoblotting, this 
blocking minimises non-specific binding of primary antibodies to  off-target antigens within the 
cell. After blocking samples were incubated with a dilution of the primary antibody ranging from 
1:500 – 1:1000 for 1 hour at room temperature to specifically target the intracellular protein 
structure of interest. Following three 10 minute washes with 0.2% BSA to remove unbound 
antibody, coverslips were incubated with secondary antibodies conjugated to AlexaFluor-488 or 
AlexaFluor-594 fluorescent dyes (Life Technologies), diluted 1:500 in 0.2% BSA in PBS for 1 hour 
at room temperature. At the stage of adding fluorescent antibodies samples were protected 
from light to prevent photobleaching. Surplus antibody was again removed by three further 
washes for 10 min in 0.2% BSA. Subsequently coverslips were briefly washed with ddH2O to 
remove PBS salt crystals prior to mounting onto coverslips with ProLong gold® antifade 
mountant with DAPI (Life Technologies). DAPI stains the nuclei and can assist in orientation of 




2.2.9.4 PtdIns(3)P staining and HaloTag7-staining. 
PtdIns(3)P was localised by use of recombinant 2xFYVE domain probes, kindly gifted by Ian 
Ganley. In brief, probes were produced by expression of a tandem 2xFYVE domain of the 
endocytic Hrs protein (DU45781), which specifically binds PtdIns(3)P. Proteins were cloned, 
expressed and purified by MRC PPU Reagents and Services. This probe was then conjugated to 
AlexaFluor 488 (A30006 – Life Technologies) or Alexa-Fluor-594 (A30008 – Life Technologies) 
according to the manufacturer’s protocol. The probes were stored at 1mg/ml in 50 % (v/v) 
Glycerol at -80 °C. 
For detection of PtdIns(3)P inside cells, coverslips were permeabilised by the freeze-thaw 
method before paraformaldehyde fixation. The freeze-thaw method is necessary for use of 
these probes to remove cytosolic proteins while preserving membrane-bound proteins to give 
a clean signal. After blocking, coverslips were incubated with the 2xFYVE probe for 1 hour at 
room temperature, alongside any endosomal counterstains. After secondary staining, if 
required, coverslips were briefly washed in ddH20 to remove any PBS crystals and mounted on 
microscope slides with ProLong gold® antifade mountant with DAPI (Life Technologies). Slides 
were imaged under the microscope to examine localisation and the probe intensity quantified 
to determine intracellular PI(3)P levels. 
Localisation of HaloTag7 was identified using the HaloTag7-TMR Ligand from Promega, 
according to the manufacturer’s instructions. This ligand contains the 594-fluorescent TMR-dye 
conjugated to a chloroalkane moiety, which will specifically and covalently bind to HaloTag7. In 
brief, 5 µM HaloTag7-TMR ligand was added to live cells for 15 minutes, and washout performed 
for 30 minutes, before fixation and counterstaining for endosomal markers. 




All images were collected on an LSM710 laser scanning confocal microscope (Carl Zeiss) using 
the x63 Plan - Apochromat objective (NA 1.4), using a pinhole chosen to provide a uniform 0.8um 
optical section thickness in all the fluorescence channels. For quantitation of PtdIns(3)P 
production, images from the microscope were imported into Volocity image processing 
software (Perkin-Elmer) and batch processed using the same custom written programmes for all 
the images in an experimental group. The graphs show the sum of signal intensity per cell in 
arbitrary units.  
2.2.10 Measurement of cell growth and viability 
2.2.10.1 Quantification of cell growth by Incucyte S3 Assay. 
To measure the rate of growth of cancer cell lines, cells were seeded into 96-well plates and 
allowed to adhere overnight. The next morning, cells were treated in triplicate with the 
compounds indicated and placed in an Essen Incucyte S3, incubated at 37 ˚C. 4 images per well 
were taken every 4 hours, and cell confluency estimated from these images for the length of 
time indicated. 
2.2.10.2 Quantification of cell number by Sytox Green Assay 
Sytox Green is a nucleic acid stain which gives a >500-fold fluorescent enhancement when 
binding to nucleic acid. However, the stain is also impermeable to live cells. Therefore, dead cells 
can be measured by brief incubation of a cell population with Sytox Green and excitation of the 
dye by a 488 nm laser, with an emission peak of 523 nm. After measuring dead cells, adding the 
mild detergent saponin to a cell population overnight will permeabilise the cells allowing a total 
cell count. Live cell number can then be calculated by subtracting dead cell count from the total 
cell count. 
This approach can be used to measure sensitivity of a cell population to compound treatment. 
After seeding 2 plates in parallel and allowing cells to adhere overnight, one plate was taken at 




and remaining surviving cells measured by Sytox Green Assay. Subtracting ‘Day 0’ counts from 
the final cell count provides a proxy of cell growth and survival in the presence of the tested 
compound. The multi-well plate format allows a large number of compounds to be tested over 
a range of concentrations in parallel. Plates were read using the Acumen laser scanning plate 
reader, using the 488nm argon-ion laser to excite the dye. 
2.2.10.3 Estimation of cell viability by MTS assay. 
MTS assay was performed using the CellTiter 96® AQueous One Solution Cell Proliferation Assay 
kit from Promega. This kit provides a colorimetric method to measure cell viability, as it contains 
the tetrazolium compound MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt] which reacts with the electron coupling reagent PES 
(phenazine ethosulfate) to form a formazan product in live, proliferating cells. This can be 
measured in a multi-well assay, measuring production of formazan by absorbance at 490 nM. 
While this assay is in fact a measure of metabolism, it is often used at a proxy for cell viability 
and proliferation. The production of formazan product, as measured by absorbance at 490nm, 
is directly proportional to the number of living cells in culture. 
For this assay, cells were seeded in 96-well plates and allowed to adhere overnight. The next 
morning, cells were treated with compounds as indicated in the figure. DMSO treatment was 
used as a positive control and 0.1% Triton was used as a 100% death negative control. After 48 
h treatment, cell viability was measured by addition of MTS reagent for 4 h, and measurement 
on an optical plate reader at 490 nm. Absorbance was normalised to DMSO control to determine 
any impact of the compound on cell viability. 
2.2.11 Mass Spectrometry Methods 
2.2.11.1 Global Proteome Analysis 




Cell pellets were lysed with 2 ml of lysis buffer (8 M Urea, 50 mM Ammonium bicarbonate 
containing protease inhibitor and phosphatase inhibitor).  Samples were incubated on ice for 15 
min then sonicated for 5 min (30 sec on/off) in ice-cold water bath. After sonication, benzonase® 
endonuclease (Merck Millipore) was added 1:100  to degrade DNA and RNA. Lysates clarified by 
centrifugation at 12,000 rpm, 15 min at 4 °C, and supernatants were transferred into new 
Eppendorf tubes. Protein concentration was measured with BCA assay (Pierce™ BCA Protein 
Assay Kit, Thermo).  Each sample was reduced with 5 mM DTT at 45 °C for 30 min, before 
alkylation for 30 min at RT with 10 mM iodoacetamide. Alkylation was quenched by the addition 
of 5 mM DTT. 
Samples were digested by Lys-C  (1:200 w/w) for 4 h at 30 °c. Samples were diluted with 50 mM 
ammonium bicarbonate to 1.5 M Urea concentration. Samples were then digested with trypsin 
(Pierce trypsin, Thermo) at an enzyme to protein ratio of 1:50 (w/w) at room temperature with 
gentle shaking overnight. The digest was stopped by the addition of 1% TFA (v/v), centrifuged at 
10,000 g for 10 min at room temperature.  The supernatants were desalted on 200 mg SepPak 
C18 cartridge (Waters), and dried by vacuum centrifugation using Speedvac (Thermo).  
TMT labelling and Basic C18 reverse phase (bRP) chromatography fractionation 
200 μg peptides was re-suspended in 100 μL 100 mM TEAB buffer. The TMT labelling reagents 
were equilibrated to room temperature and 41 μL anhydrous acetonitrile was added to each 
reagent channel and softly vortexed for 10 min. Peptides were transferred to the corresponding 
TMT channels and incubated for 1 h at room temperature. The reaction was quenched with 8 μL 
of 5% hydroxylamine. To ensure complete labelling, 1 µg of labelled samples from each channel 
were analysed by LC-MS/MS prior to mix. After evaluation, the complete TMT labelled 9 samples 
were then combined, acidified and dried. Sep-Pak desalting was then performed, and the elution 




Pooled peptides were separated by basic reverse phase (bRP) chromatography fractionation. 
With Ultimate 3000 high-pressure liquid chromatography (HPLC) system (Dionex) operating at 
569 µL/min with two buffers: buffer A (10 mM ammonium formate, pH 10) and buffer B (80% 
ACN, 10 mM ammonium formate, pH 10). Peptides were resuspended in 200 µL of buffer A (10 
mM ammonium formate, pH10) and separated on a C18 reverse phase column. A total of 90 
fractions (1 min per fraction) were collected before further concatenation into 30 final fractions. 
Each fraction was then dried and desalted over a C18 StageTip prior to analysis by mass 
spectrometry. 
LC-MS/MS and Data Analysis 
LC-MS/MS was performed by Dr Houjiang Zhou at the MRC PPU. Liquid Chromatography (LC) 
separations were performed with a Thermo Dionex Ultimate 3000 RSLC Nano liquid 
chromatography instrument. Approximately 1 µg of concatenated peptides (Peptides 
quantitation by Nanodrop) from bRP chromatography were dissolved in 0.1% formic acid and 
then loaded on C18 trap column with 3 % ACN/0.1%TFA at a flow rate of 5 μL/min. Eluted 
peptides were analysed on an Orbitrap Fusion Lumos (Thermo Fisher Scientific, San Jose, CA) 
mass spectrometer. 
All the acquired LC-MS/MS data were analysed using Proteome Discoverer software v.2.2 
(Thermo Fisher Scientific) with Mascot search engine. Data were searched against a complete 
UniProt Human (Reviewed 20,143 entry downloaded at Nov 2018). Reporter ions were 
quantified from MS3 scans. Protein ratios were calculated from medians of summed sample 
abundances of replicate groups. Standard deviation was calculated from three biological 
replicate values. The standard deviation of three biological replicates lower than 25% were used 
for further analyses. To determine the significant differences between different treatments, 
ANOVA model is used for statistical significance analysis. 





Cell lysates were prepared and desalted as described for total proteomics above. The  desalted 
peptides were resuspended in 1 ml of 2 M lactic acid/50% acetonitrile (ACN) and centrifuged at 
15,000 x g for 20 min. Supernatants were transferred to an Eppendorf tube containing 18 mg of 
titanium dioxide (TiO2) beads (GL sciences, Japan) and vortexed for 1 h at room temperature. 
The TiO2 beads were washed three times (10 min per wash) with 2 M lactic acid/50% ACN 
following by three washs with 0.1%TFA/50% ACN. Phosphopeptides were eluted twice with 150 
μl of 50 mM ammonia solution (NH4OH) (pH ~10). The combined eluent were dried using 
vacuum centrifugation and then desalted using a C18 StageTip (3M Empore™). TMT labelling 
was performed as described for total proteomics. 
LC-MS/MS and Data Analysis 
LC-MS/MS was performed by Dr Houjiang Zhou at the MRC PPU. The desalted TMT labelled 
phoshopeptides were dissolved in 0.1% formic acid and then loaded on C18 trap column with 3 
% ACN/0.1%TFA at a flow rate of 5 μl/min. Eluted peptides were analysed on an Orbitrap Lumos 
Tribrid platform with instrument control software version 3.0. 
Maxquant was used for processing the collected MS Raw data. The raw data were searched 
against Uniprot human database (70,947 entries, downloaded on March 10, 2017) using Mascot. 
The phosphopeptides were quantified using the intensity of TMT reporter ions. Data were 
further analysed with Perseus software and figures were made using PRISM software.  
2.2.11.1 Analysis of biotinylated proteins by TurboID and streptavidin pulldown. 
Cell culture and proteomic sample preparation  
After stimulation, cells were washed 5 times with ice cold PBS to remove exogenous biotin and 
lysed in RIPA buffer. Lysates were clarified by centrifugation and quantified using Pierce 660 nM 




with 20ul Streptavidin-conjugated sepharose beads. Streptavidin-IP was washed 3x each in RIPA 
buffer, 500 mM Tris-HCl and Urea Buffer. To prepare proteins for digest, the samples were 
reduced with 1 mM DTT for 30 minutes, alkylated in the dark with 10 mM iodoacetamide for 
30minutes, and quenched with 10 mM DTT for 10 minutes. Samples were first digested with 
200ng Trypsin per sample, at 32°C with gentle shaking for 16 h.  The digest was stopped by the 
addition of TFA to a final concentration 1% TFA (v/v), centrifuged at 10,000 g for 10 min at room 
temperature.  The supernatant was desalted on SCX membrane and desalted peptides airdried 
by vacuum centrifugation using a SpeedVac (Thermo Scientific)  
TMT labelling 
Each sample was re-suspended in 20 μL of 100 mM TEAB buffer. The TMT labelling reagents 
were equilibrated to room temperature and 7 ul TMT reagent added with 3 ul  anhydrous 
acetonitrile. Labelling reactions were incubated for 1 h at room temperature with gentle shaking. 
The reaction was quenched with 0.1% v/v hydroxylamine. To ensure complete labelling, 10% 
labelled samples from each channel were analysed by LC-MS/MS prior to mix. After evaluation, 
the complete TMT labelled 9 samples were then combined, acidified and dried. Samples were 
desalted and fractionated on C18 membrane prior to analysis by mass spectrometry. 
LC-MS/MS and Data Analysis 
LC-MS/MS was run by MRC PPU Proteomics Facility (Robert Gourley). Peptides were analysed 
on Orbitrap Fusion Lumos (Thermo Fisher Scientific, San Jose, CA) mass spectrometer. All the 
acquired LC-MS data were analysed using MaxQuant software v.1.6.6.0. Volcano plots  were 
produced in Perseus 1.6.2.3.  
2.12. Statistical Analysis 
With the exception of Mass Spectrometry Analysis, described above, all figures are 
representative of at least n=2 replicate experiments.  Statistical analysis  was performed in 




3. SGK3-PROTAC1 induces degradation of SGK3 in cancer cell 
lines 
3.1 PROTACs – Proteolysis Targeting Chimeras for targeted protein 
degradation 
Proteolysis Targeting Chimeras (PROTACs) have recently gained momentum as a new 
therapeutic axis in targeting erroneous signalling axes. These compounds act by ‘hijacking’ the 
ubiquitin-proteasome system, allowing target proteins to be ubiquitylated and targeted for 
degradation by the cells’ own degradation machinery. As will be discussed further in section 
3.2.1, this approach has numerous benefits over chemical inhibition. I therefore chose as a major 
aim of my thesis to develop a PROTAC compound targeted against SGK3, designed to degrade 
the protein from cancer cell lines and modulate PI3K inhibitor resistance. 
3.1.1 Ubiquitin-Proteasome mechanism of protein degradation 
Like protein phosphorylation, protein ubiquitylation is an evolutionarily conserved 
posttranslational modification critical to numerous cell signalling processes. It requires the 
transfer of a 76 amino acid protein Ubiquitin to, typically, lysine residues on substrate proteins. 
Ubiquitin can be conjugated to substrates in a variety of topologies resulting in different cellular 
responses. Substrate proteins can be monoubiquitylated, polymonoubiquitylated, or decorated 
with polyubiquitin chains. Further specificity of the pathway is mediated by different 
polyubiquitin chain types being formed, from different lysines of ubiquitin. Chains can be formed 
from K6, K11, K27, K29, K33, K48, and K63, in addition to the N terminal Methionine M1. These 
chain types signal for different cellular responses, for example, K63 and linear ubiquitin chains 
can have both scaffolding and signalling roles, regulating many biological processes, including 
inflammation (Newton et al., 2008; Walczak, Iwai and Dikic, 2012). K48  and K11 chains on 
substrate proteins specifically target the ubiquitylated protein for degradation via the 
proteasome (Jin et al., 2008; Newton et al., 2008; Wickliffe et al., 2011). It is this proteasomal 




3.1.2 E3 Ubiquitin Ligases 
 
Figure 3.1 Mechanism of substrate ubiquitylation. 
Ubiquitin is activating by formation of a thioester bond onto an E1 enzyme, in an ATP dependent manner. 
Ubiquitin is conjugated onto the E2 conjugating enzyme. E3 ligases catalyse the transfer of ubiquitin from 
the E2 to the substrate protein 
Ubiquitylation is mediated by three families of enzymes. E1 activating enzymes catalyse the 
formation of an E1-Ub thioester in an ATP-dependent manner (Schulman and Harper, 2009). E2 
conjugating enzymes are then ‘charged’ with the ubiquitin, generating a E2-Ub thioester 
(Komander, 2009). E3 ubiquitin ligases catalyse the final step of the substrate ubiquitylation 
cascade. These enzymes interact with both the E2-Ub conjugate and a target protein to catalyse 
the transfer of Ubiquitin to the substrate. While there are just 2 E1s, UBE1 and UBE1L2, and over 
40 E2s, complexity and specificity in the pathway is mediated by the E3. There are >600 E3 ligases, 
grouped into 3 families, based on their structure and mechanism of ubiquitin transfer (Li et al., 
2008). These are the Really Interesting New Gene (RING)-E3 ligases, the HECT-E3 ligases and 
RING-between-RING (RBR)-E3 ligases. One subset of the RING E3 ligases is the Cullin-RING (CRL) 
E3 ligases. These enzymes are large E3 ligase complexes, built on a Cullin scaffold. This scaffold 
then binds adaptor proteins to substrate receptors, and the E3 ligase protein itself. Through this 
scaffold mechanism, substrate proteins are recruited into proximity of the E3, where transfer of 
Ubiquitin from the E2 can be catalysed. 
An example of such an E3 is the CUL2VHL E3 ligase. Built from a Cullin2 scaffold, the pVHL 
substrate adaptor protein is joined to the complex by Elongin1/Elongin2. pVHL recognises its 
substrate, Hif1α, via a hydroxyproline residue on Hif1α. Under normoxic conditions, Hif1α is 




and ubiquitylated by VHL, and targeted for degradation (Figure 3.2). Under conditions of hypoxia, 
PHD enzymes are inhibited, and Hif1α is stabilized, accumulates and triggers the transcription 
of hypoxia related genes. Also bound to Cullin2 is the RBX1 E3 ligase, and recruitment of Hif1α 
to the complex by VHL allows ubiquitin transfer to the substrate from an associated E2. Similar 
mechanisms of ubiquitin transfer are utilised by CUL4CRBN and CUL1SKP2. 
3.2  PROTAC mechanism - Proximity-based ubiquitylation 
The mechanism of action of CRL E3 ubiquitin ligases, identifying substrate proteins for 
ubiquitylation via an adaptor protein, has recently been exploited for targeted degradation of 
alternative proteins. As ubiquitylation of substrate proteins by CRL E3 ligases  is proximity driven 
through the substrate receptor, with no specific ubiquitylation motifs, this mechanism can be 
hijacked to target protein degradation to desired target proteins. By recruiting the target protein 
of interest to the target E3 ligase, this protein can be ubiquitylated in the place of the 
endogenous substrate. 
One example of this is Proteolysis Targeting Chimeras (PROTACs). PROTACs are chimeric 
molecules, consisting of an E3 ligase-binding headgroup joined to a protein-targeting headgroup 
joined by a short linker sequence (Pettersson and Crews, 2019). For example, in order to target 
VHL E3 Ligase, the ligand VH032 designed as a Hif-1α mimic and a high affinity binder of VHL, 
has been conjugated to a range of known inhibitors to target a vast array of proteins (Zengerle, 
Chan and Ciulli, 2015; Gadd et al., 2017; Maniaci et al., 2017; Smith et al., 2019). Similarly, 
CUL4CRBN E3 ligase has been utilised using compounds derived from pomalidomide and a number 
of other phthalidomide-related inhibitors (Lu et al., 2015; Winter et al., 2015; Lai et al., 2016; 
Olson et al., 2018). 
To date, PROTAC compounds have been developed targeting a range of protein kinases, such as 
RIPK2 (Bondeson et al., 2015) BCR-ABL(Lai et al., 2016; Shibata et al., 2018), CDK9 (Olson et al., 




kinases for targeted degradation evades numerous issues with conventional kinase inhibition 




Figure 3.2 Mechanism of action of PROTAC compounds. 
A PROTAC consists of an E3 binding motif and target protein binding motif, joined by a short linker. 
PROTACs act by recruiting a protein of interest to the targeted E3 ligases. The CUL2 VHL E3 Ligase complex 
typically induces ubiquitylation and degradation of Hif1a under conditions of normoxia. Formation of an 
E3-PROTAC-target ternary complex results in the polyubiquitylation of the target protein, leading to its 
proteasomal degradation in cells. 
3.2.1 Benefits of targeted degradation over chemical inhibition of protein kinases 
The importance of protein phosphorylation to cell signalling and disease means that kinases are 
commonly the target of therapeutic avenues. Kinase inhibitors have been developed for a wide 
range of diseases; however, issues arise in resistance and off target effects. Many of these 
problems with kinase inhibition can be solved by targeted protein degradation. Firstly, chemical 
inhibition of kinases requires 1:1 occupation of the binding site, and therefore fairly high 
concentrations of compound are required for a biologically significant, therapeutic effect. This 
can result in either on-target or off-target toxicity. The catalytic mechanism of action of a 




lower amounts are required. This reduces off target effects and is an advantage as both a 
methodological tool and a potential therapeutic. Additionally, chemical inhibition of a kinase will 
only remove one function of a protein, its kinase activity. Many kinases also carry additional 
functions such structural and scaffolding roles, which would not be removed by chemical 
inhibition. Conversely, targeted degradation of the protein will remove it from the cell 
completely, therefore removing all its potential roles. Depending on whether these additional 
functions are beneficial or deleterious, it may be advantageous to remove the entire protein 
from cells. There is also an additional advantage that these tools allow us to delineate between 
kinase and non-kinase functions of proteins in disease. 
Finally, a common mechanism of resistance to chemical inhibition is for the cell to upregulate a 
target protein at the transcriptional level, to overcome loss of function. However, this is 
circumvented by the PROTAC as any newly translated protein can be rapidly degraded (reviewed 
in (Ferguson and Gray, 2018)).  
‘Drugging the undruggable’ 
A large benefit of PROTAC compounds is the ability to target proteins previously considered 
‘undruggable’. A large portion of the human proteome is implicated in disease, however most 
cannot be targeted by conventional chemical therapeutic methods. Many identified proteins 
important in oncogenesis have so far failed to be inhibited by conventional approaches, and 
therefore deemed ‘undruggable’ (Huang and Dixit, 2016). In particular, proteins such as Myc, β-
catenin and MCL1 have been particularly difficult to target (Nero et al., 2014). Targeted protein 
degradation opens a whole new realm of potential for interrogating protein function 
3.3 Designing a PROTAC compound targeting SGK3 for degradation. 
Given the powerful potential of PROTACs as a tool to investigate protein function, and as a new 
therapeutic modality, one of the leading aims of my thesis was to develop a tool compound for 




previously generated using CRISPR/Cas9 technology, and this cell line has been successfully used 
to expand our knowledge of how SGK3 is activated by growth factor signaling (Malik et al., 2018). 
However, a caveat to this genome level knockout is that compensatory pathways may replace 
the role of SGK3 over time, and the effects of the knockout may be diminished. In addition, 
attempts in the lab to generate a genome level knockout of SGK3 in relevant model breast 
cancer cell lines, such as the ZR-75-1 and CAMA-1 cell lines have so far been unsuccessful. Use 
of PROTAC compounds to induce rapid, reversible knockout of SGK3 at the protein level in these 
cells is a promising solution to these caveats. I therefore aimed, in the first two chapters of my 
thesis to develop tool compounds to induce degradation of SGK3. 
The strategy chosen for this approach involved designing compounds derived from a series of 
SGK inhibitors recently published by Sanofi (Halland et al., 2015). Because a crystal structure of 
the SGK3 kinase domain is not yet available, either alone or in complex with an inhibitor, we 
could not use structure-guided design to build a series of degraders. The Ciulli lab inspected the 
structure activity relationship (SAR) of the series of SGK inhibitors described in the Sanofi Patent 
(Halland et al., 2015) (International Patent WO2014140065), to identify potential strategies to 
elaborate PROTACs.  
3.4 Two rounds of compound screening revealed optimal compound 
SGK3-PROTAC1 
A series of inhibitors that have a pyrazolopyrimidine scaffold appeared to tolerate aliphatic and 
cyclic substituents at the position 4 of the pyrazolopyrimidine core, suggesting that such portion 
of the molecule could be solvent exposed. Two SGK inhibitors, termed 290 and 308 (Fig 3.3A), 
were judged particularly amenable for linker conjugation, as the morpholine ring can be 
selectively N-alkylated by means of reductive amination protocols. (Fig 3.3A). As the inhibitors 
described in the patent were racemic, we synthesized both the R and S epimers of these 




(data available at http://www.kinase-screen.mrc.ac.uk/kinase-inhibitors). The specificity of 
these compounds was profiled against 140 kinases at 1 M concentration, revealing that they 
were relatively selective (Figure 3.3, 3.4 and Appendix Table 1), with S6K1 being a key off target 
that was most potently inhibited. Further profiling determined that the IC50 of these 
compounds for SGK1 and SGK3 were between 5 to 40 nM, with S6K1 again being a key off-target 







Figure 3.3 In vitro selectively screening of 1 M Sanofi 308(R). 
Kinase selectively profiling was performed by the National Centre for Protein Kinase Profiling (www.kinase-screen.mrc.ac.uk) against 140 protein kinases. Data are presented 
as mean (n=3) kinase activity remaining in the presence of 1 M Sanofi 308(R), in comparison to a DMSO control. Raw data is available in Appendix Table 1, and data for the 






Figure 3.4 In vitro selectively screening of 1 M Sanofi 290(R). 
Kinase selectively profiling was performed by the National Centre for Protein Kinase Profiling (www.kinase-screen.mrc.ac.uk) against 140 protein kinases. Data are presented 
as mean (n=3) kinase activity remaining in the presence of 1 M Sanofi 290(R), in comparison to a DMSO control. Raw data is available in Appendix Table 1 and data for the 




Design of 1st Generation compound DAT1 
For the first round of compound screening, 4 compounds were developed by the Ciulli lab, with 
290-R or 308-R conjugated to either the well characterised VHL ligand VH032 (Galdeano et al., 
2014; Frost et al., 2016) or the Cereblon ligand pomalidomide (Lu et al., 2015) (Fig 3.5B). For this 
first series of compounds, a medium length linker, composed of 3 PEG units, was used (Fig 3.5C). 
In order to examine the potency and specificity of the compounds, I administered them to 
HEK293 cells for 48 hours at concentrations of up to 10 M and analysed the effect of PROTAC 
treatment on expression of endogenous SGK isoform or S6K1 expression (Fig 3.3C). Of the four 
compounds tested only DAT1, composed of 308-R conjugated to VH032, markedly reduced SGK3 
expression. Additionally, this reduction in SGK3 occurred without significantly impacting levels 
of SGK1, SGK2 or S6K1 (Fig 3.5D). DAT1 reduced SGK3 expression by 69% at 1 µM and 77% at 10 





Figure 3.5 Design and cellular activity of first generation SGK3 PROTACs. 
A. Structure of compound 14H, previously published by Sanofi as an inhibitor of SGK3. B. Starting material 
for SGK PROTACs. PROTACs were derived from SGK inhibitors 308-R or 290-R linked to either VH032 or 
Pomalidomide to target the VHL or Cereblon E3 ligases respectively. C. Structures of first generation SGK 
PROTACs, generated by the Ciulli lab. SGK and E3 ligase targeting motifs were joined by a 3xPEG linker to 
produce the PROTACs D. HEK293 cells were treated for 48 hours with increasing concentrations of each 
PROTAC compound from 0.1 nM to 10 µM. Cell lysates were subjected to immunoblot analysis with the 
indicated antibodies, and SGK3 protein levels quantified in Image Studio Lite software (Licor). 
Conjugation of 308-R to E3 ligase ligands for the elaboration of PROTACs markedly decreased 
the inhibitory activity for SGK isoforms and S6K1 in biochemical kinase assays (5 nM to 440 nM 
for SGK3 and 1 nM to 160 nM for S6K1) (Table 3.1). We found no correlation between potency 
of PROTACs for inhibiting SGK3 and ability to induce degradation of SGK3 in cells. For example, 
DAT2 which does not impact SGK3 protein levels in HEK293 cells, inhibited SGK1 and SGK3 2-4-




Table 3.1. IC50 values of SGK inhibitors and first generation PROTACs. 
The structures of the compounds are shown in Figure 3.5B&C. For degradation efficiency “-“ = No 
Degradation, “+” = >50% Degradation at 10 µM. 




290 (R) 35 19 10 / 
308(R) 5 10 1 / 
DAT1 440 1600 160 + 
DAT2 190 400 180 - 
DAT3 640 1000 240 - 
DAT4 540 600 190 - 
 
Treatment with 1 M DAT1 maximally reduced SGK3 expression by 12 hours (Fig 3.6A) and a 
dose response analysis revealed that 2 M DAT1 maximally reduced SGK3 expression at an 8 h 
time point (Fig 3.6B). To validate that this degradation occurred, as expected, via the CUL2VHL E3 
Ligase complex and the proteasome, I pre-treated cells with inhibitors of the pathway (Fig 3.7) 
and measured blockade of DAT1-induced degradation. MLN4924 is an inhibitor of the 
Neddylation enzyme which conjugates NEDD8 onto the CRL E3 ligases (Brownell et al., 2010). 
Inhibition of this Neddylation process inactivates the complex. MG132 is an inhibitor of the 
proteasome and therefore blocks the degradation of ubiquitylated proteins (Lee and Goldberg, 
1998). As expected, pre-treatment with MLN4924 (3 M) or proteasome inhibitor MG132 (50 
M) successfully blocked DAT1-induced degradation of SGK3 (Figure 3.6C). These data 
demonstrate that DAT1 degradation of SGK3 is both neddylation and proteasome dependent, 
and therefore acting via the expected mechanism. I therefore selected DAT1 to analyse further 






Figure 3.6 Mechanistic characterization of DAT1 
 A. HEK293 cells were treated for up to 48h with 1 µM DAT1, and lysates analysed by western blot for SGK3 
expression B. HEK293 cells were treated for 6 h with increasing doses of DAT1, and lysates analysed by 
western blot. C. HEK293 cells were pre-treated with the indicated inhibitors before treatment for 6 h with 





Figure 3.7 Inhibitor treatments for mechanistic validation of SGK PROTACs. 
MG132 is an inhibitor of proteasome activity, and blocks degradation of polyubiquitylated proteins. 
Neddylation inhibitor MLN4924 restricts activity of the CUL2VHL complex, and therefore reduces CUL2VHL 
E3 activity and blocks ubiquitylation of target proteins. 
Design of 2nd Generation compound DAT8 (SGK3-PROTAC1) 
The next series of compounds were analogues of DAT1, produced by shortening the linker length 
from 3 to 2 PEG units (DAT5) or extending the linker length to 4 and 5 PEG units (DAT6-7).  (Fig 
3.8A). As before, I tested the ability of each of these compounds to decrease SGK3 expression 
after 48 h treatment in HEK293 cells (Fig 3.8C). From this data I determined that the optimal 
linker length was 4 PEG units (13 atoms), with DAT6 displaying significant improvements both in 
terms of potency and amount of reduction of SGK3 observed compared to the original DAT1 (Fig 
3.6C). DAT6 induced 55% degradation of SGK3 at 1 µM, and 80% degradation at 10 µM. DAT7 
(16 atoms) also induced potent degradation of SGK3. We then changed the composition of the 
linkers for more lipophilic alkylic moieties of 13 (DAT8) and 16 atoms (DAT9,10). For this set of 
compounds, we also conjugated the inhibitor 290-R (DAT11,12). This was to determine whether, 
with an optimized linker, the 290-R derived compounds may show some activity.  
DAT8 possessed the best potency for inducing degradation of SGK3, with 65% degradation at 
0.1 µM and 75% degradation achieved at 1 µM after treatment for 48 h. This represents a >10-
fold increase in potency for DAT8 over DAT6, and is likely a result of increased cell penetrance 




degradation was specific for SGK3 with no effect on SGK1/2 or S6K1. At concentrations >1 µM, 
however, a slight reduction in S6K1 expression can be observed. DAT8 was therefore selected 
for further use in this thesis and renamed SGK3-PROTAC1 (Fig 3.8D). SGK3-PROTAC1 possesses 
a linker of 13 atoms, the same as DAT6, however carries 1 less oxygen atom, creating a more 
lipophilic compound (Fig 3.8A). 
At this stage I also decided to generate a control compound for SGK3-PROTAC1 that would bind 
and inhibit SGK3, but not induce recruitment of the CUL2-VHL E3 ligase complex. We therefore 
synthesized a version of SGK3-PROTAC1 termed cisSGK3-PROTAC1 that contains a hydroxyl 
epimer of VH032 moiety that previous work showed ablates binding to VHL (Fig 3.8B) (Bondeson 
et al., 2015; Zengerle, Chan and Ciulli, 2015; Frost et al., 2016). 
In in vitro assays, SGK3-PROTAC1 inhibited SGK3 with an IC50 of 300 nM and S6K1 with an IC50 
of 1800 nM (Table 3.2). SGK1 was inhibited with an IC50 of 220 nM, however, was not degraded 
by the compound. The specificity of SGK3-PROTAC1 at 1 M was assessed in a panel of 140 
kinases. This revealed a surprising increase in specificity over the original 308-R compound, with 
SGK1 and S6K1 the only kinases most potently inhibited by this compound in vitro (Figure 3.9 
and Appendix Table 1). As expected, cisSGK3-PROTAC1 inhibited our panel of kinases similarly 





Figure 3.8 Design and cellular evaluation of second and third generation SGK PROTACs.  
A. Chemical structure of compounds DAT5-12, expanding upon DAT1. B. Chemical structure of cisSGK3-
PROTAC1 C. HEK293 cells were treated for 48 hours with increasing concentrations of each PROTAC 
compound from 1 nM to 10 µM. Cell lysates were subjected to immunoblot analysis with the indicated 
antibodies, and SGK3 protein levels quantified in Image Studio Lite software. D. HEK293 cells were treated 
for 48 hours with increasing concentrations of each PROTAC compound from 1 nM to 10 µM. Cell lysates 
were subjected to immunoblot analysis with the indicated antibodies, and SGK3 and S6K1 protein levels 
quantified in Image Studio Lite software. 
 
 




The structures of the compounds are shown in Figure 3.6A. “-“ = No Degradation, “+” = >50% Degradation 
at 10 µM. “++” = >50% Degradation at 1 µM. “+++” = >50% Degradation at 0.1 µM. “++++” = >60% 
Degradation at 0.1 µM. 




DAT1 0.44 1.6 0.16 + 
DAT5 >10 >10 >10 + 
DAT6 >10 >10 >10 ++ 
DAT7 >10 >10 >10 ++ 
DAT8 0.3 0.22 1.8 ++++ 
DAT9 1.79 8.99 4.53 ++ 
DAT10 >10 >10 >10 ++ 
DAT11 0.73 1.34 1.80 +++ 






Figure 3.9 In vitro selectively screening of 1 M SGK3-PROTAC1. 
Kinase selectively profiling was performed by the National Centre for Protein Kinase Profiling (www.kinase-screen.mrc.ac.uk) against 140 protein kinases. Data are presented 






Figure 3.10 In vitro selectively screening of cisSGK3-PROTAC1. 
Kinase selectively profiling was performed by the National Centre for Protein Kinase Profiling (www.kinase-screen.mrc.ac.uk) against 140 protein kinases. Data are presented 




 3.5 Cellular characterisation of SGK3-PROTAC1 
On the basis of the experiments in section 3.4, I selected SGK3-PROTAC1 for further cellular 
characterisation, and for use in probing SGK3 biology in an array of cell lines. A cellular 
degradation assay confirmed that from 0.1 M SGK3-PROTAC1 markedly reduced SGK3 in 
HEK293 cells after 8 h treatment, however cisSGK3-PROTAC1 did not induce any loss of SGK3 up 
to 3 M. As observed previously, no degradation of S6K1 was observed at concentrations below 
1 M (Figure 3.11A). It was also of interest to study the impact of SGK3 degradation on 
phosphorylation of its physiological substrate NDRG1 at Thr346 (Sommer et al., 2013). As this 
site is also phosphorylated by Akt, all conditions were treated with the Akt inhibitor AZD5363 (3 
M) 1 h before lysis. At 0.1-0.3 M SGK3-PROTAC1, phosphorylation of NDRG1 was markedly 
reduced. At these concentrations cisSGK3-PROTAC1 had no effect, however at higher 
concentrations cisSGK3-PROTAC1 lowered NDRG1 phosphorylation (Figure 3.11A). This can be 
explained by the fact that although this compound does not bind VHL, the 308-R derived SGK-
binding head will still bind and inhibit SGK3. 
To fully characterize the compound, I performed timecourse analysis of SGK3-PROTAC1 induced 
degradation of SGK3. In HEK293 cells, 0.3 M SGK3-PROTAC1 induced 50% degradation of SGK3 
within 2 h, and maximal degradation was achieved after 8 h (Fig 3.11B). To demonstrate that 
SGK3-PROTAC1 induced SGK3 degradation is reversible, HEK293 cells were treated for 24 h with 
SGK3PROTAC-1, then washed 3 times with DMEM before replacing with fresh DMEM without 
PROTAC compound. Recovery of SGK3 expression was then tracked by Western Blot. This 
experiment revealed that increased SGK3 expression began after 1 h, with normal protein levels 
returning after 10 h (Fig 3.11C). SGK3-PROTAC1 is therefore a potent tool for the rapid and 
reversible degradation of SGK3 from cells, and manipulation of downstream signaling. As 
previously observed with DAT1, SGK3-PROTAC1-mediated degradation of SGK3 was also 






Figure 3.11 Mechanistic characterization of SGK3-PROTAC1. 
A. HEK293 cells were treated for 8h with 0.03-3 µM SGK3-PROTAC1 and cisSGK3-PROTAC1. Cells were also 
treated 1 h before lysis with 3 µM AZD5363, and protein levels measured by immunoblot. B. HEK293 cells 
were treated for up to 48 h with SGK3-PROTAC1 (0.3 µM), and lysates analyzed by immunoblot. C. HEK293 
cells were treated for 24h with SGK3-PROTAC1, cells washed 3 times with DMEM to wash out compound 
and recovery of protein analyzed by immunoblot D. HEK293 cells were pretreated with the indicated 
inhibitors before treatment for 6 h with 0.3 µM SGK3-PROTAC1, and lysates analyzed by western blot for 
SGK3 expression 
The aim of this project was to develop a tool with which I could study the removal of SGK3 from 




inhibition. I therefore characterized SGK3-PROTAC1 in 2 such cell lines, CAMA-1 and ZR-75-1 
(Bago et al., 2016). As in HEK293, in these cells concentrations of >0.1 M SGK3-PROTAC1 
induced degradation of SGK3, but not SGK1 or S6K1 after 8 h. Again, as expected, cisSGK3-
PROTAC1 had no impact on SGK3 expression (Fig 3.12A,B). Therefore SGK3-PROTAC1 is expected 
to be a good tool for interrogation of SGK3 signaling in these cells. It is also interesting to note 
that in these cancer cell lines, degradation of SGK3 is more potent than in HEK293, possibly due 
to increased expression or activity of VHL in these cells. A western blot analysis of VHL protein 
levels revealed higher protein expression in these cancer cell lines than in HEK293 (data not 
shown). 
HEK293, ZR-75-1 and CAMA-1 cells all contain much higher levels of SGK3 than they do SGK1. In 
order to confirm that SGK3-PROTAC1 mediated degradation is specific for SGK3 and does not 
induce degradation of endogenous SGK1, I additionally screened these compounds in the JIMT-
1 cell line. This cell line has previously been demonstrated to express high levels of SGK1, and 
cell growth and metabolism is largely driven by SGK1 in these cells (Sommer et al., 2013). 
Concentrations of up to 3 µM SGK3-PROTAC1 failed to induce degradation of SGK1, whereas 
SGK3 expression was reduced from 0.1 M as observed in other cells lines (Fig 3.12C). As 
previous attempts to generate SGK3-specific inhibitors have so far been unsuccessful, due to 
high homology of the SGK kinase domains (Gong et al., 2018), it is surprising that SGK3-PROTAC1 
degradation is so specific for SGK3. This also places SGK3-PROTAC1 as an important tool in 
studying SGK3 function and delineating between the roles of SGK3 and SGK1. The specificity of 





Figure 3.12 Characterization of cellular activities of SGK3-PROTAC1 and cisSGK3-PROTAC1 in cancer cell 
lines. 
CAMA-1 (A), ZR-75-1 (B) and JIMT-1 (C) cells were treated with 0.03-3 µM SGK3-PROTAC1 and cisSGK3-
PROTAC1. Lysates were subjected to immunoblot analysis with the indicated antibodies. 
3.6 Effect of SGK3-PROTAC1 on SGK3-dependent mTORC1 activation 
Previous work has shown that prolonged treatment of breast cancer cell lines such as CAMA-1 
and ZR-75-1 cells with PI3K or Akt inhibitors resulted in upregulation of SGK3 leading to the 
activation of mTORC1 signaling, mediated by SGK3 phosphorylating TSC2 at the same sites as 
Akt (Bago et al., 2016). Therefore, once I had confirmed that SGK3-PROTAC1 dramatically 
reduces protein levels of SGK3 in these cell lines, I aimed to investigate the effect that SGK3-
PROTAC1 treatment would have on this resistance pathway. In particular, I was interested to 




In order to investigate the effect of SGK3-PROTAC1 under these conditions, I treated CAMA-1 
(Figure 3.13A,C) or ZR-75-1 (Figure 3.13B,D) for 5 days with either a Class IA PI3K inhibitor 
(GDC0941, 1 µM) (Folkes et al., 2008) or the Akt inhibitor AZD5363 (1 µM) (Davies et al., 2012). 
These treatments induce increased expression and activity of SGK3, and a rescue of NDRG1 
phosphorylation at Thr346 and mTORC1 activity, as measured by S6K1 phosphorylation at 
Thr389 and S6 protein phosphorylation at Ser240/244 (Bago et al., 2016). To determine the 
impact of SGK3 degradation on this resistance pathway, I cotreated cells with SGK3-PROTAC1 or 
cisSGK3PROTAC-1 (0.3 µM), either at the start of treatment, or 8 h before lysis, once resistance 
had already developed. 
SGK3-PROTAC1 substantially reduced SGK3 expression in both the CAMA-1 and ZR-75-1 cells 
within 8 h, and SGK3 degradation was maintained after 5 days of treatment (media and 
compound replenished after 72 h). Consistent with SGK3-PROTAC1 blocking mTORC1 activation, 
we found that these treatments also suppressed mTORC1-mediated phosphorylation of S6K1 at 
Thr389 resulting in a moderate reduction in S6 protein phosphorylation. In contrast, cisSGK3-
PROTAC1 had no significant effect on SGK3 protein level or phosphorylation of TSC2, S6K1 or S6 
protein. 
In parallel, I also treated these cells with the non-PROTAC SGK inhibitor 14H (1 µM) (Halland et 
al., 2015). I chose this compound instead of the source inhibitor 308-R, as 14H is more specific 
in targeting SGK kinases, and therefore was the better control. I observed in these conditions 
that, in both CAMA-1 and ZR-75-1 cells, SGK3-PROTAC1 inhibited mTORC1 signaling more than 
the inhibitor, suggesting degradation of SGK3 has a greater effect than mere inhibition of its 





Figure 3.13 SGK3-PROTAC1-mediated degradation of SGK3 inhibits Akt-independent activation of 
mTORC1 in cancer cell lines treated with Akt or PI3K inhibitors. 
CAMA-1 (A, C) or ZR-75-1 (B, D) were treated for 5 days with 1 µM GDC0941 (A, B) or 1 µM AZD5363 (C, 
D). Cells were treated with the compounds indicated for either 5 days, or 8 h before lysis, cells were treated 
with the compounds indicated. Cell lysates were subject to immunoblot analysis with the indicated 
antibodies 
3.7 Effect of SGK3-PROTAC1 on cancer cell growth 
In section 3.6 I demonstrated that degradation of SGK3 by SGK3-PROTAC1 treatment can inhibit 




PROTAC1 impacts on proliferation of cancer cell lines in the context of PI3K-Akt pathway 
inhibition. 
I first sought to determine any effect of SGK3-PROTAC1 or cisSGK3-PROTAC1 treatment on 
CAMA-1 or ZR-75-1 cells under basal conditions, with no inhibition of PI3K or Akt. Treatment of 
CAMA-1 or ZR-75-1 cells with SGK3-PROTAC1 alone had no effect on growth (Figure 3.14A,C), 
consistent with previous work undertaken with high doses of conventional SGK inhibitors (Bago 
et al., 2016; Castel et al., 2016). This reconfirms that growth of these cells under basal conditions 
is not mediated by SGK3 and suggests that PROTACs are not exhibiting any off-target toxic or 
anti-proliferative effect. I also measured sensitivity and toxicity of the compounds by Sytox 
Green assay. Sytox Green is a fluorescent nucleic acid binding reagent which exhibits >500-fold 
increased fluorescence on binding nucleic acids, however, is impermeable to live cells. 
Measuring fluorescence emitted by this reagent with or without cell permeabilization by 
Saponin provides a quantitative measure of live cell number. This assay can be used to quantify 
the impact of a compound on cell survival and proliferation. Sytox Green assay determined that 
these compounds were well tolerated up to 3 M. In contrast treatment with PI3K inhibitor 
(GDC0941) or Akt inhibitor (AZD5363) significantly impacted on CAMA-1 and ZR-75-1 cell growth, 






Figure 3.14 SGK3-PROTAC compounds have no effect on cell growth. 
CAMA-1 and ZR-75-1 cells were seeded in 96 well plates, allowed to adhere overnight, and treated as 
indicated in the figure. A&C. Confluency of CAMA-1 (A) and ZR-75-1 (C) cells was measured every 4h on 
Incucyte S3. B&D. Measurement of cell number by Sytox Green Assay. Surviving cells were measured after 
7 day treatment with the indicated concentration of compound. Remaining cells were quantified relative 
to DMSO treatment. Error bar = SD, n=3. 
I therefore studied the effect that SGK3-PROTAC1 and cisSGK3-PROTAC1 had on the growth of 
CAMA-1 (Figure 3.14A,C) or ZR-75-1 (Figure 3.14B,D) in the presence of GDC0941 (1 µM) or 
AZD5363 (1 µM). I studied this effect in long term assays over the course of about 30 days. As 
previously observed, treatment with GDC0941 or AZD5363 substantially reduced growth of 
these cells, however a reduced proliferation was recovered after 7 days treatment with the 
inhibitors (Figure 3.15). Cotreatment with SGK3-PROTAC1 (0.3 µM) further reduced the growth 
of these cells under conditions that cisSGK3-PROTAC1 had a minimal effect (Figure 3.15). I also 
studied in parallel the effect of conventional SGK inhibitor 14H (3 µM) on growth of the inhibited 
cell lines. In the presence of a Class IA PI3K inhibitor 14H further suppressed cell growth, as 
reported previously (Bago et al., 2016), however this was to a lesser extent than was observed 
with SGK3-PROTAC1. When 14H was combined with the Akt inhibitor, it suppressed growth to a 







Figure 3.15 SGK3-PROTAC1-mediated degradation of SGK3 further inhibits the growth of cancer cell 
lines treated with PI3K-Akt pathway inhibitors. 
CAMA-1 (A, C) or ZR-75-1 (B, D) were treated with compounds as indicated either as monotherapy or in 
combination, and confluency measured on the Incucyte S3 every 4 h for up to 4 weeks 
I was also interested in the impact of targeting the PI3K-Akt pathway and SGK3 sequentially, 
with SGK3-PROTAC1, cisSGK3PROTAC1 or 14H added to cells after growth recovery in response 
to GDC0941 or AZD5363. In these assays, I first treated cells with PI3K or Akt inhibitor, and then 
sequentially added the SGK3-targetting compound when growth had recovered to 40-50% 
confluency. In these assays, sequential addition of either the inhibitor or the PROTAC 
compounds had very little effect on proliferation of the cancer cell lines, with the exception of 
ZR-75-1 under prolonged treatment with AZD5363 (Figure 3.16). In this condition, an equal 
effect was seen from the inhibitor or PROTAC. Growth of the cells appeared to stop completely 





Figure 3.16 SGK3-PROTAC1-mediated degradation of SGK3 further inhibits the growth of cancer cell 
lines treated with PI3K-Akt pathway inhibitors. 
CAMA-1 (A, C) or ZR-75-1 (B, D) were treated with compounds as indicated either as monotherapy or in 
combination, and confluency measured on the Incucyte S3 every 4 h for up to 4 weeks. Sequential 
treatments (seq) were performed after recovery of cell growth. Arrowheads indicate timepoints of 
sequential treatment 
3.8  Impact of SGK3-PROTAC1 on a generated, AZD5363-resistant cancer 
cell line, CAMA-R 
In order to study resistance to the Akt inhibitor AZD5363, a CAMA-1 cell line highly resistant to 
AZD5363 has been generated by AstraZeneca, termed CAMA-R. To generate this cell line, CAMA-
1 cells were treated with increasing concentrations of AZD5363 and clonally selected, to produce 
a cell line which is now resistant to 5 M AZD5363. This cell line has acquired very high SGK3 
levels to mediate resistance to the Akt inhibitor. I was therefore interested to investigate the 
impact SGK3-PROTAC1 had in this cell line, and whether any of the results differ to the 5 day 
induction experiments described in sections 3.6 and 3.7. 
As in section 3.5, a cellular degradation assay was performed with increasing concentrations of 




lines, degradation of SGK3 was observed from 0.1 M SGK3-PROTAC1, while no degradation was 
observed with cisSGK3-PROTAC1 treatment up to 3 M. Studying NDRG1 phosphorylation at 
Thr346, a significant dephosphorylation of NDRG1 was observed from 0.1 M, whereas 10-fold 
more cisSGK3-PROTAC1 was required to impact on NDRG1 phosphorylation. Moreover, SGK3-
PROTAC1 at 0.1/0.3 M had a greater impact on NDRG1 phosphorylation than the non-PROTAC 
SGK inhibitor 14H (Fig 3.17A). 
I next investigated the effect of SGK3-PROTAC1 treatment on cell proliferation and survival of 
CAMA-R cells. In the context of maintained AZD5363 treatment, SGK3-PROTAC1 had a significant 
effect on survival and growth of CAMA-R cells, measured by proliferation by Incucyte 
measurements and also Sytox Green assay (Figure 3.17C,E). When AZD5363 was removed from 
the cells, SGK3 degradation had no effect (Fig 3.17B,D, “No Drug”). In a similar result to 
cotreatment of CAMA-1 cells with AZD5363 and SGK3 PROTAC/inhibitor, I observed that 0.1 M 
SGK3-PROTAC1 had a similar effect on growth to 3 M 14H. When treating CAMA-R cells with 
0.1 M 14H I saw no impact on growth. As expected, cisSGK3-PROTAC1 had no effect at this 





Figure 3.17 The impact on SGK3-PROTAC1 treatment on Akt inhibitor resistant cell line CAMA-R. 
A. CAMA-R cells were grown and seeded in the presence of AZD5363 (5 µM). SGK3-PROTAC1 or cisSGK3-
PROTAC1 were added to cells between 0.03-3 µM for 8h then lysed and subject to immune blot. Red 
asterisk highlights the effect of 0.3 µM compound treatment on substrate phosphorylation, as 
concentration was used in further experiments. B&C. Sensitivity of CAMA-R cells in the absence (B) or 
presence (C) of AZD5363 (5 µM) to increasing concentrations of SGK3 inhibitor 14H, SGK3-PROTAC1 or 
cisSGK3-PROTAC1, as measured by Sytox Green assay after 7 days of treatment. D&E. Sensitivity of CAMA-
R cells in the absence (D) or presence (E) of AZD5363 (5 µM) to SGK3 inhibitor 14H (3 µM), SGK3-PROTAC1 
(0.1 µM) or cisSGK3-PROTAC1 (0.1 µM) as measured by Incucyte S3 cell proliferation assay. 
However, when studying mTORC1 activity downstream of SGK3, SGK3-PROTAC1 treatment had 
little to no effect on downstream phosphorylation of S6K1 and S6 protein (Fig 3.15A). This was 
surprising as such a strong impact on NDRG1 phosphorylation, and CAMA-R cell growth is 
significantly impacted by 0.1 M SGK3-PROTAC1 treatment. I therefore decided to directly 
compare the pathway in CAMA-R cells against CAMA-1 cells with induced AZD5363 resistance 
after 5 day treatment with the inhibitor. I observed that SGK3 was upregulated in CAMA-R cells, 
and there was strong phosphorylation of S6K1 and S6 downstream of mTORC1. However, again 




(Figure 3.18). Surprisingly, despite activation of mTORC1, I observed very little, if any, 
phosphorylation of TSC2 at the Ser939 and Thr1462 sites, proposed to be phosphorylated by 
SGK3 in this resistance model (Figure 3.18). Therefore, although mTORC1 does appear to be 
reactivated in this cell line, it does not appear to be occurring through the predicted mechanism. 
TSC2 is phosphorylated on alternative sites by, for example, AMPK and the ERK1/2 kinases, 
which were not analysed in this experiment but would be important to study in future work. In 
addition, while SGK3-PROTAC1 treatment does inhibit the growth of CAMA-R cells treated with 
AZD5363, this does not appear to occur through modulation of the mTORC1 signaling cascade. 
It is important to consider that the CAMA-R cell line is expanded from 1 resistant clonal line, and 
therefore resistance may have occurred by a different mechanism. Further experiments would 





Figure 3.18 mTORC1 is reactivated in CAMA-R cells, but not through TSC2. 
CAMA-R cells, grown in 5 µM AZD5363 were treated and analyzed in parallel to parental CAMA-1 cells in 
the presence of absence of 5d AZD5363 treatment, with SGK3-PROTAC1 or analogue cisSGK3-PROTAC1. 
Activation of mTORC1 in CAMA-1 induced resistance and CAMA-R constitutive resistance was analyzed by 
western blot. 
3.9 Determining the specificity of SGK3-PROTAC1 in HEK293 cells 
An important consideration in the validation of SGK3-PROTAC1 is determining the global 
specificity of the compound. This is of interest as by western blot degradation of SGK3 was 
observed to be specific over the other SGK isoforms. Unknown off-target effects may be having 




I used a quantitative Tandem-Mass-Tag (TMT)-labelled approach to determine the global 
proteomic changes occurring after SGK3-PROTAC1 treatment in HEK293 cells. Cell lysis and 
sample preparation was undertaken after 6 h treatment with SGK3-PROTAC1 (0.3 µM), in 
comparison to the inactive cisSGK3-PROTAC1 (0.3 µM) or a mock treatment with DMSO. The cis 
epimer offers a much more appropriate negative control, and also helps identify any global 
proteomic changes caused by the inhibitory headgroup of SGK3-PROTAC1. 
Cells were treated in triplicate for 6 h with either SGK3-PROTAC1 (0.3 µM), cisSGK3-PROTAC1 
(0.3 µM) or DMSO, then harvested and lysed in Urea buffer. After trypsin and LysC enzyme digest 
samples were labelled with TMT reagents, pooled, and fractionated by high pH reverse phase 
fractionation. Sample analysis was performed in Proteome Discoverer v2.2 using the Mascot 
search engine. This allowed for the unbiased, relative quantification of 8766 proteins, of which 
377 were determined to have protein kinase activity or directly regulate protein kinase activity 
(pantherdb.org). From this sample set, SGK3-PROTAC1 was revealed to be remarkably selective, 
with only SGK3 expression being significantly reduced (p value < 10-3) (Figure 3.19, 3.20). This 
provided higher confidence that the SGK3-PROTAC1 compound was highly selective in cells and 
that any biological changes should be a result of degradation of SGK3. Due to low expression in 
these cells, SGK1 and SGK2 were not detected in this analysis and therefore could not be 
compared. S6K1 and Akt, important possible off-target hits, were unaffected by SGK3-PROTAC1 
treatment. This analysis has also been performed in the biologically relevant ZR-75-1 cancer cell 





Figure 3.19 TMT Proteomic analysis of HEK293 cells treated with SGK3-PROTAC1. 
A. Workflow for Mass Spec analysis of SGK3-PROTAC1 specificity in HEK293. B. In cell lysates treated with 
SGK3-PROTAC1 for 8h, SGK3 levels were noticeably reduced. These lysates were used for mass 
spectrometry analysis of the global proteome. C. Volcano plot demonstrating global proteomic changes 
upon SGK3-PROTAC1 treatment in HEK23 cells. 
 
 
Figure 3.20 TMT Proteomic analysis of HEK293 cells treated with SGK3-PROTAC1 or cisSGK3-PROTAC1 
TMT-labelled proteomic analysis of HEK293 cells treated with A) SGK3-PROTAC1 compared to cisSGK3-
PROTAC1 and B) cisSGK3-PROTAC1 compared to DMSO. Data are represented as a volcano plot of fold-




3.10 Isoform specificity of SGK3 degradation over SGK1. 
Previously published studies have so far been unsuccessful in producing SGK3-specific chemical 
inhibitors, due to the high structural similarity of the kinase domains of the SGK isoforms, 
particularly in the ATP binding sites (Figure 3.21) (Gong et al., 2018). It was therefore very 
interesting that SGK3-PROTAC1 has been revealed as being exquisitely specific for degradation 
of SGK3 over SGK1. This is particularly surprising given that in in vitro kinase assays SGK3-
PROTAC1 inhibits these 2 kinases with a very similar IC50 (0.3 nM for SGK3, 0.22 nM for SGK1). It 
was therefore of interest to determine why degradation was specific for SGK3. 
 
Figure 3.21  Sequence alignment of SGK1 and SGK3 kinase domains. 
High sequence similarity is maintained between SGK1 and SGK3. In particular, regions of ATP and substrate 
binding are highly conserved. 
I first chose to study whether any structural features of SGK3 made this protein more amenable 
to degradation by SGK3-PROTAC1. SGK3 contains an N-terminal PX domain and is localised to 
endosomes, and in this way,  it differs from SGK1. I therefore expressed exogenous SGK3, either 
wildtype or with deletion or mutation of its PX domain, into SGK3 KO HEK293 cells and measured 
the ability of SGK3-PROTAC1 to degrade these proteins. I also expressed SGK3 with inactivating 
mutations in its T-loop (T320A), H-motif (S486A) or kinase domain (K191A) to determine 
whether activation of SGK3 influenced its susceptibility to degradation (Fig 3.22). I found that, 
in this overexpression system, SGK3-PROTAC1 induced about 50% degradation of wildtype SGK3. 
Mutation of the critical residues for SGK3 activity sites had very little effect, increasing SGK3 
degradation by an additional 10%. Although deletion of the PX domain had no effect on 
degradation efficiency, point mutations to inhibit PtdIns(3)P binding (R50A, R90A) and prevent 




mutant of SGK3 was less stable and expressed and much lower levels but appeared to be 
similarly targeted for degradation by approximately 50% (Fig 3.22). 
SGK1 also differs from SGK3 in that SGK1 carries an N-terminal degron motif, which leads to its 
ubiquitylation by Nedd4-2 and degradation via the proteasome. As this mechanism of SGK1 
leads to its rapid turnover and a half-life of ~30 minutes and overlaps with the mechanism of 
action of the PROTAC, this motif may affect induction of SGK1 degradation by SGK3-PROTAC1. 
Typically, in our assays SGK1 is expressed with its first 59 amino acids deleted, for more stable 
expression. As expected, deletion of the residues resulted in a more stable, higher expressed 
protein, however also sensitised SGK1 to degradation by SGK3-PROTAC1 (Fig 3.22). Therefore, 
the endogenous turnover mechanism of SGK1 in cells may partially impact on SGK3-PROTAC1 
induced degradation. Alternatively, deletion of these residues may have revealed accessible 
lysine residues for ubiquitylation by CUL2VHL. 
 
Figure 3.22 Mutations in SGK3 and SGK1 alter their susceptibility to SGK3-PROTAC1 mediated 
degradation. 
A. SGK3 and SGK1, wildtype and kinase dead, were transiently transfected into SGK3 KO HEK293 cells, and 
treated for 8 h with SGK3-PROTAC1. B. Mutant forms of SGK3 were transiently transfected into HEK293 
cells and treated for 8 h with SGK3-PROTAC1. 
In order to further determine the reasons for SGK3 specificity, I would in future studies perform 
experiments to assess the ability of SGK1 and SGK3 to form stable ternary complexes with SGK3-
PROTAC1 and pVHL. I would examine whether there was a structural element of SGK3 allows 
the protein to form a more stable complex than SGK1. I would in future studies perform 




SGK1 and SGK3, and therefore identify any differences in the binding affinities of SGK3-PROTAC1 
to these proteins. In vitro kinase assays are very similar between the two proteins so we would 
expect similar binding, however subtle binding differences may be revealed by ITC to partially 
explain this finding. 
In addition, treatment with SGK3-PROTAC1 in combination with proteasome inhibitor MG132 
may further explain the specificity between these isoforms. For example, co-
immunoprecipitation of SGK isoforms with VHL in the presence of SGK3-PROTAC may reveal a 
stronger complex formed with SGK3 than SGK1. Also, studying ubiquitylation of target isoforms 
by immunoblot would demonstrate whether an active ternary complex is being formed. In 
addition, ubiquitylation mapping could be performed on SGK3, to determine where it is being 
ubiquitylated and whether these regions are conserved in SGK1.  
3.11 Discussion 
In this chapter, I describe the design and characterisation of the compound SGK3-PROTAC1. This 
compound is able to induce potent, reversible degradation of SGK3 from a variety of cell lines 
within 4 h, with a DC50 below 100 nM. 
Specificity of SGK3-PROTAC1 
Quantitative mass spectrometry in HEK293 cells revealed degradation of SGK3 to be highly 
selective, with SGK3 being the most downregulated protein. It is particularly interesting that 
SGK3-PROTAC1 was revealed to be remarkably isoform specific for SGK3, with the highly related 
SGK1/2 isoforms remaining unaffected. This was even observed in cell lines such as JIMT-1 which 
express high levels of SGK1 and relatively low levels of SGK3. Recent studies attempting to 
develop isoform specific chemical inhibitors of SGK3 have been unsuccessful, due to the high 
structural similarity of the SGK1 and SGK3 kinase domains, in particular in the ATP binding site 
(Gong et al., 2018). SGK3-PROTAC1 is therefore an important tool in modulating SGK3 biology 




previously been observed in PROTACs derived from the pan-BET inhibitor JQ1 (Zengerle, Chan 
and Ciulli, 2015; Gadd et al., 2017; Testa et al., 2018) and PROTACs derived from the 
promiscuous kinase inhibitor Foretinib (Bondeson et al., 2018) or TAE-684 (Huang et al., 2018). 
It has recently been shown that specificity and potency of PROTACs can be dictated by 
differential cooperativity and stability of ternary complex formation (Gadd et al., 2017; Hughes 
and Ciulli, 2017; Roy et al., 2019) as well as geometry/orientation of the recruited E3 ligase 
(Smith et al., 2019). Future work will investigate the extent to which these molecular recognition 
features contribute to the exquisite selectivity of SGK3-PROTAC1 for SGK3 induced degradation. 
Further, the rapid turnover of SGK1 through ubiquitylation and degradation may make it 
intractable to PROTAC mechanism of action. As the protein is already readily ubiquitylated and 
degraded, additional PROTAC-mediated ubiquitylation may have minimal effect. 
Rana et al recently described a CDK6-targeting PROTAC, which had exquisite CDK6 specificity, 
despite equal inhibition of CDK4 and CDK6 (Rana et al., 2019). While CDK4/6 have overlapping 
kinase functions, CDK6 is believed to carry a kinase-independent role in transcriptional 
regulation (Petrocca et al., 2013). Additionally, CDK6 amplification was proposed as a resistance 
mechanism to CDK4/6 inhibition (Yang et al., 2016). The isoform specificity of the PROTAC 
yielded an important tool in studying CDK6-mediated regulation of transcription. The authors 
argued that either a ternary complex could not be formed with CDK4, or rapid deubiquitylation 
occurred on this protein, however they did not study this finding further. 
Benefits of SGK3 degradation over kinase inhibition 
In a variety of assays using SGK3-dependent cancer cell lines, SGK3 degradation was 
demonstrated to have a more potent effect than inhibition of its kinase activity by the 
conventional 14H inhibitor. This finding provides a further example of the benefit of the PROTAC 
approach in targeting protein kinase signaling pathways with greater efficacy and selectivity 




that a BCR-ABL degrader displays more sustained inhibition of Chronic myelogenous leukemia 
cell growth after removal of compound than can be achieved by a conventional ABL kinase 
inhibitor (Shibata et al., 2018). I did not explore the restoration of growth after SGK3-PROTAC1 
washout in my experiments, however this would be of interest to explore in further work. Han 
et al  also recently determined that a potent androgen receptor (AR) degrader ARD-68 was >100 
times more potent than an AR antagonist in suppressing gene transcription in two different cell 
lines (Han et al., 2019) 
Further, Crews lab more recently published a PROTAC compound binding allosterically to BCR-
ABL which, although potent in decreasing cancer cell growth, was not more effective than the 
leading active site inhibitor imatinib. However, allosterically targeting kinases for degradation 
also has the additional benefit of allowing combination treatments of PROTAC with kinase 
inhibitor. The authors reason that combination of allosteric degraders and kinase inhibitors 
lower the dose of inhibitor required, and therefore reduce toxicity of ATP mimic compounds 
(Burslem et al., 2019). 
IRAK4 is a Ser/Thr protein kinase downstream of Toll-like Receptor signaling in immune 
responses. IRAK has been proposed to have kinase-independent roles in IL-1β signaling and 
cytokine release due to scaffolding functions (Qin et al., 2004), however degradation with 
PROTAC compounds showed no improvement over kinase inhibition in cytokine production or 
signal transduction (Nunes et al., 2019)  
Other mechanisms by which SGK3-PROTAC1 may inhibit cell growth. 
It is of particular interest that, although in the context of PI3K inhibition SGK3 degradation was 
superior, in the context of Akt inhibition both 14H and SGK3-PROTAC1 had similar effects of 
cancer cell growth. Future studies should follow up further pathways downstream of PI3K in 
which SGK3 may have a role, which may explain the difference between the conditions. In 




cell growth was inhibited by targeting SGK3, this growth inhibition was not occurring through 
phosphorylation of TSC2 by SGK3, as observed in previous models. This again suggests additional, 
as yet undiscovered, pathways in which SGK3 may play a role in PI3K-Akt pathway inhibitor 
resistance. In CAMA-R cells, mTORC1 activation may be mediated through TSC2 at alternative 
sites through the ERK pathway or AMPK. Additionally, targeting of SGK3 in PI3K-Akt pathway 
inhibition appeared to be more effective when treating in combination before resistance occurs. 
Sequential treatment with 14H or with SGK3-PROTAC1 had minimal effect. This data teaches us 
that when targeting SGK3 in cancer, SGK3 and PI3K/Akt should be targeted together in 
combination.  
As described in Chapter 1, Akt phosphorylates substrates in mTORC1-dependent roles which 
regulate cell growth and proliferation, for example in phosphoinactivation of FOXO transcription 
factors and the p27 and p21 cyclin dependent kinase inhibitors (Zhou, Liao, Xia, Spohn, et al., 
2001; Tran et al., 2003; Sekimoto, Fukumoto and Yoneda, 2004). Therefore, degradation of SGK3 
in the context of PI3K-Akt inhibition may also regulate these pathways, which have not been 
fully characterized in this thesis. 
Additionally, SGK3 may have a role in alternative pathways as yet undiscovered. Further, these 
roles may be kinase independent and therefore not revealed by kinase inhibition. In Chapter 4, 
I further investigate this possibility by global proteomic and phosphoproteomic analysis of SGK3-
PROTAC1 treatment in ZR-75-1 cells. This provides evidence for potential newly discovered roles 
of SGK3, which may mediate the resistant growth phenotype on PI3K-Akt pathway inhibition. 
In the BCR-ABL compound described above, degradation was observed to reduce the level of 
GAB2 phosphorylation downstream of BCR-ABL and upstream of MAPK signaling, however 
inhibition of its tyrosine kinase activity did not have the same effect. Further analysis revealed 




(Burslem et al., 2019). However, this comparison was performed against the allosteric inactive 
PROTAC, and not the active site inhibitor. 
Conclusion 
In this chapter I, in collaboration with the Ciulli lab, optimized and characterized SGK3-PROTAC1 
as an important tool in the study of SGK3 signaling in PI3K-Akt pathway inhibition. This 
compound provides many of the benefits associated with PROTAC-mediated targeting, such as 
isoform specificity for SGK3 over other family members, and additional potency in inhibitor-
resistant growth over conventional kinase inhibition. This compound will be an important 
addition to our armory of chemical probes to decipher the biological roles of the SGK3 signaling 
pathway including in mediating resistance to PI3K and Akt inhibitor therapy in cancer. In Chapter 
4, I will utilize this compound for quantitative global proteomic and phosphoproteomic analysis 
of ZR-75-1 cellular response to SGK3 degradation, revealing possible roles for SGK3 in cancer not 




4. Global response to SGK3-PROTAC1 treatment in ZR-75-1 
breast cancer cells suggests potential role for  SGK3 in 
cAMP signalling and mitochondrial Oxidative 
Phosphorylation. 
4.1 Introduction 
Throughout this study I have been interested in the biology and signalling of SGK3 particularly 
in the ER+ breast cancer cell lines ZR-75-1 and CAMA-1, which induce SGK3 expression and 
activity in response to inhibition of the PI3K-Akt-mTOR signalling pathway. In section 3.9, I 
demonstrated by Tandem Mass Tag (TMT)-labelled quantitative proteomics that SGK3-
PROTAC1-mediated degradation was highly specific for SGK3 in HEK293 cells. However, results 
may differ in a cell-dependent manner and I was interested to determine the specificity and 
impact of compound-induced SGK3 degradation in a relevant cancer cell line. It was therefore 
of interest to understand the global effects of SGK3 degradation in the ZR-75-1 cell line. 
4.2 Experimental Design - Global Proteomics and Phosphoproteomics in ZR-
75-1 cells 
In an identical method to that used for HEK293 cells in section 3.9, I treated HEK293 cells for 6 
h with SGK3-PROTAC1 (0.3 µM), cisSGK3-PROTAC1 (0.3 µM) or DMSO. In these cell lines I was 
also interested in phosphoproteomic changes on SGK3-PROTAC1 treatment, in order to 
potentially identify new substrates or signalling pathways impacted by SGK3 degradation. 
Therefore, alongside analysis at the proteomic level, I additionally performed TiO2 enrichment 
of phosphopeptides from these lysates and performed complementary phosphoproteomic 
analysis. After treatment with the indicated compounds, cells were harvested, lysed in Urea 
buffer and digested by LysC and Trypsin digestion. Before mass spectrometry analysis, I 
confirmed by western blot that SGK3 had been substantially degraded upon SGK3-PROTAC1 
treatment, but not cisSGK-PROTAC1. The resulting peptides were split for proteomic or 




proteomic samples were pooled and fractionated by high pH reverse phase fractionation for 
analysis. For phosphoproteomic analysis, phosphopeptides were enriched before labelling and 
pooled for quantitative analysis (Figure 4.1). 
 
 
Figure 4.1 Experimental workflow for mass spectrometry analysis of SGK3-PROTAC1 treatment in ZR-
75-1 cells. 
ZR-75-1 cells were treated for 6 h with DMSO, SGK3-PROTAC1 (0.3 M) or cisSGK3-PROTAC1 (0.3 M). 




4.3 Global Proteomic Analysis of SGK3-PROTAC1 treatment in ZR-75-1 
reveals effects on mitochondrial respiration and cAMP signalling 
Global, unbiased analysis in Proteome Discoverer v2.2 identified relative quantification of 8167 
proteins. As observed in HEK293 cells, SGK3-PROTAC1 was observed to be highly specific, as 
SGK3 was identified as the most downregulated protein. A caveat of this analysis is that, as ZR-
75-1 cells express relatively low levels of SGK3 under basal conditions, relative quantification of 
SGK3 was based on one identified unique peptide, so it carries a relatively low p value, but was 
still determined to be significant (p value = 0.02). Other than SGK3, very few other proteins were 
identified as significantly downregulated. With the exception of Histone proteins that are likely 
trace nuclear contaminants, only 4 other proteins, PDE4D, TRAF3IP2, RPL14 and ZNF512B, were 
also detected as being downregulated in response to treatment, with a >45% reduction in 
protein levels (Figure 4.2 and Table 4.1). I also detected an unexpected upregulation of a host of 
mitochondrial proteins, which upon further analysis were revealed to all be components of the 
electron transport chain. Of 8167 identified proteins, 351 were determined to be significantly 
upregulated >2fold in response to SGK3-PROTAC1 treatment, in comparison to the inactive 
analogue cisSGK3-PROTAC1 (Figure 4.2 and Table 4.2, full list in Appendix Table 3). Of these 351 
upregulated proteins, 318 were identified by Gene Ontology (GO) analysis to be mitochondrial, 





Figure 4.2 Global proteomic analysis of SGK3-PROTAC1 treatment compared to inactive analogue.  
ZR-75-1 cells were treated for 6 h with SGK3-PROTAC1 (0.3 M) or cisSGK3-PROTAC1 (0.3 M) , and cell 
lysates subject to quantitative mass spectrometry analysis. Data are presented as a volcano plot 
 Analysis of SGK3-PROTAC-1/DMSO revealed similar proteomic changes, and as a negative 
control, cisSGK3-PROTAC1/DMSO has very little global effects (Tables 4.1, 4.2 and Figure 4.3). 
These controls confirm that these effects are dependent on SGK3-PROTAC1s ability to induce 
ubiquitylation and subsequent proteasomal degradation. 
 
Figure 4.3 Total proteomic changes on treatment with A) SGK3-PROTAC1 or B) cisSGK3-PROTAC1 in ZR-
75-1 cells. 
ZR-75-1 cells were treated for 6 h with SGK3-PROTAC1 (0.3 M),  cisSGK3-PROTAC1 (0.3 M) or DMSO, 
and cell lysates subject to quantitative mass spectrometry analysis. Data are presented as a volcano plot 




Table 4.1 List of proteins significantly downregulated on SGK3-PROTAC1 Treatment 
After removal of contaminants, identified proteins were filtered for an abundance ratio for SGK3-PROTAC1/cisSGK3-PROTAC1 <0.55 and p value <0.05.  
 
  
Accession Gene Description Unique Peptides Coverage 
# % Abundance Ratio p-value Abundance Ratio p-value Abundance Ratio p-value
Q96BR1 SGK3 Serine/threonine-protein kinase Sgk3 1 2 0.343 0.0486 0.225 0.0259 1.149 0.4726
Q96KM6 ZNF512B Zinc finger protein 512B 13 17 0.374 0.0329 0.41 0.0206 1.154 0.7151
Q08499 PDE4D cAMP-specific 3',5'-cyclic phosphodiesterase 4D 5 6 0.44 0.0001 0.446 0.0008 0.988 0.7399
P50914 RPL14 60S ribosomal protein L14 6 27 0.477 0.0404 0.447 0.0040 1.122 0.5306





Table 4.2 List of top 40 proteins significantly upregulated on SGK3-PROTAC1 Treatment. 
After removal of contaminants, identified proteins were filtered for an abundance ratio for SGK3-PROTAC1/cisSGK3-PROTAC1 >2 and p value <0.05. 351 proteins were 
identified meeting these criteria and the full list is available in Appendix Table 2. 
 
Accession Gene Description Unique Peptides Coverage 
# % Abundance Ratio p-value Abundance Ratio p-value Abundance Ratio p-value
P09669 COX6C Cytochrome c oxidase subunit 6C 3 21 2.25 0.0573 3.83 0.0328 0.99 0.5293
P56134 ATP5J2 ATP synthase subunit f, mitochondrial 2 26 3.51 0.0863 3.62 0.0472 0.80 0.7629
Q9H3K2 GHITM Growth hormone-inducible transmembrane protein 6 15 2.29 0.0271 3.55 0.0119 0.85 0.2732
Q6UWS5 PET117 Protein PET117 homolog, mitochondrial 2 31 2.74 0.0907 3.46 0.0461 0.92 0.9826
Q00325 SLC25A3 Phosphate carrier protein, mitochondrial 16 41 2.49 0.0437 3.31 0.0140 0.86 0.6578
P08574 CYC1 Cytochrome c1, heme protein, mitochondrial 12 42 2.24 0.0570 3.31 0.0168 0.92 0.7776
Q9NWR8 MCUB Calcium uniporter regulatory subunit MCUb, mitochondrial 3 9 3.61 0.0800 3.26 0.0389 0.97 0.6884
O75964 ATP5L ATP synthase subunit g, mitochondrial 5 53 3.03 0.0747 3.19 0.0417 0.84 0.7890
Q6UW78 UQCC3 Ubiquinol-cytochrome-c reductase complex assembly factor 3 3 46 2.25 0.1100 2.93 0.0326 1.22 0.8168
Q6NUK1 SLC25A24 Calcium-binding mitochondrial carrier protein SCaMC-1 26 57 2.05 0.0603 2.89 0.0111 0.94 0.8774
Q9Y2R0 COA3 Cytochrome c oxidase assembly factor 3 homolog, mitochondrial 4 36 2.35 0.0522 2.89 0.0260 0.93 0.8314
P00403 MT-CO2 Cytochrome c oxidase subunit 2 7 31 2.61 0.0536 2.89 0.0216 0.88 0.9554
Q99643 SDHC Succinate dehydrogenase cytochrome b560 subunit, mitochondrial 1 5 3.39 0.0481 2.89 0.0224 0.91 0.6842
O43674 NDUFB5 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial 5 25 2.18 0.0420 2.88 0.0217 0.92 0.6201
P00846 MT-ATP6 ATP synthase subunit a 1 4 3.26 0.0608 2.87 0.0253 0.91 0.6719
O95169 NDUFB8 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial 5 36 2.97 0.0499 2.86 0.0405 1.15 0.4244
O60830 TIMM17B Mitochondrial import inner membrane translocase subunit Tim17-B 5 37 2.84 0.0523 2.81 0.0355 0.95 0.8799
Q9UJS0 SLC25A13 Calcium-binding mitochondrial carrier protein Aralar2 19 46 2.24 0.0543 2.78 0.0147 0.88 0.8598
Q16891 IMMT MICOS complex subunit MIC60 49 62 2.09 0.0636 2.78 0.0158 0.88 0.8163
Q9Y6M9 NDUFB9 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 8 50 2.46 0.0604 2.77 0.0354 1.02 0.8594
P56385 ATP5ME ATP synthase subunit e, mitochondrial 6 67 2.19 0.0409 2.77 0.0363 0.90 0.4006
P53007 SLC25A1 Tricarboxylate transport protein, mitochondrial 13 45 2.46 0.0568 2.77 0.0281 0.89 0.8677
P05141 SLC25A5 ADP/ATP translocase 2 8 52 2.26 0.0550 2.76 0.0223 0.89 0.7942
Q5RI15 COX20 Cytochrome c oxidase assembly protein COX20, mitochondrial 3 23 2.81 0.0360 2.73 0.0077 1.23 0.9285
O95167 NDUFA3 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3 4 50 2.49 0.0489 2.73 0.0249 1.01 0.7860
Q96IX5 USMG5 Up-regulated during skeletal muscle growth protein 5 3 45 2.22 0.0833 2.73 0.0376 0.86 0.6991
Q9H300 PARL Presenilins-associated rhomboid-like protein, mitochondrial 5 11 2.48 0.0653 2.70 0.0251 0.92 0.9593
O43819 SCO2 Protein SCO2 homolog, mitochondrial 10 43 2.41 0.0437 2.70 0.0224 0.86 0.7113
Q96TA2 YME1L1 ATP-dependent zinc metalloprotease YME1L1 20 26 1.95 0.0677 2.69 0.0180 1.03 0.7877
Q9HA92 RSAD1 Radical S-adenosyl methionine domain-containing protein 1, mitochondrial 5 11 3.05 0.0148 2.69 0.0094 1.06 0.4686
P31930 UQCRC1 Cytochrome b-c1 complex subunit 1, mitochondrial 19 58 2.51 0.0592 2.68 0.0224 0.87 0.9920
A0A0B4J2F0PIGBOS1 Protein PIGBOS1 1 19 1.31 0.2455 2.67 0.0403 0.81 0.6948
Q6PML9 SLC30A9 Zinc transporter 9 9 14 2.01 0.0663 2.67 0.0279 0.98 0.9282
P13073 COX4I1 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial 8 40 2.20 0.0424 2.67 0.0238 0.93 0.7219
Q8N8Q8 COX18 Cytochrome c oxidase assembly protein COX18, mitochondrial 3 8 2.37 0.0920 2.66 0.0115 0.89 0.8118
P22695 UQCRC2 Cytochrome b-c1 complex subunit 2, mitochondrial 18 48 2.73 0.0668 2.65 0.0290 0.79 0.8595
Q6P1K1 SLC48A1 Heme transporter HRG1 1 8 3.28 0.0766 2.65 0.0472 1.13 0.4946





4.3.1 PDE4D is downregulated in response to SGK3-PROTAC1 treatment 
In order to determine the specificity of SGK3-PROTAC1, and whether other proteins were truly 
downregulated in response to PROTAC treatment, I analysed the expression of PDE4D, TRAF3IP2, 
RPL14 and ZNF512B by western blot, with commercially validated antibodies after 8h treatment 
with SGK3-PROTAC1, cisSGK3-PROTAC1 or 14H SGK inhibitor. In this analysis, I detected no 
observable change in expression of TRAF3IP2, RPL14 or ZNF512B, and these may therefore be 
false positives from the mass spectrometry procedure. However, PDE4D expression was 
determined to be downregulated in response to SGK3-PROTAC1, but not cisSGK3-PROTAC1, in 
ZR-75-1 cells by western blot (Figure 4.4). Importantly, this effect was not observed after 
inhibition of SGK3 by 14H, and therefore appears to be a degradation-specific effect.  
 
Figure 4.4 PDE4D is reproducibly downregulated on treatment with SGK3-PROTAC1. 
ZR-75-1 and CAMA-1 cells were treated for 8 h with SGK3-PROTAC1, cisSGK3-PROTAC1 or 14H. Target 
proteins were analysed by western blot. Results are representative of n=3 experiments. 
PDE4D is a cAMP-specific phosphodiesterase involved in regulation of Protein Kinase A (PKA) 




has also been linked to progression of a range of cancers and resistance to cancer therapy (Lin 
et al., 2013). Therefore, it would be extremely interesting if PDE4D activity could be mediated 
by degradation of SGK3, thus providing a secondary mechanism of blocking resistance to cancer 
therapy.  
The PDE4D family of phosphodiesterases consists of at least 9 isoforms generated by alternative 
splicing of the PDE4D gene. All isoforms share a C-terminal catalytic domain and variable 
regulatory N terminal domains (Figure 4.5). The isoforms vary on the basis of their UCR1 and 
UCR2 domains, which are heavily decorated with posttranslational modifications and are 
believed to regulate activity of the enzyme. 
 
Figure 4.5 Domain structure of PDE4D isoforms. 
A. 11 PDE4D isoforms are transcribed by alternative splicing of the PDE4D gene. B-D. Domain structures 
of the PDE4D isoforms. Long isoforms contain full UCR1 regulatory domains. 
By Western Blot, the isoforms of PDE4D downregulated by SGK3-PROTAC1 treatment 
correspond to the <80 KDa ‘Long isoforms’ of PDE4D. In CAMA-1 cells, expression of these 
isoforms of PDE4D was undetectable by western blot, however the antibody did pick up a lower 




to SGK3-PROTAC1 or 14H treatment. Given that isoforms containing UCR1 are sensitive to SGK3-
PROTAC1 treatment, it would be interesting to explore in future work whether there is an 
interaction between SGK3 and the UCR1 domain of PDE4D. Additionally, the UCR1 domain 
contains RXRXXS/T Motifs predicted to be phosphorylated by Akt, however treatment with SGK3 
kinase inhibitor 14H had no impact on PDE4D levels. 
Further analysis in HEK293 cells revealed that PDE4D downregulation in response to SGK3-
PROTAC1 treatment is also observed in this cell line (Figure 4.6A). However, the effect is less 
robust than is observed in ZR-75-1 cells, which may be why the change was not observed in the 
previous mass spectrometry experiment (Section 3.9). Timecourse analysis of PDE4D expression 
in these cells showed a slight reduction in PDE4D expression within an hour, with 50% reduction 
in 4-8 h (Figure 4.6B). An important control is to determine whether this downregulation of 
PDE4D is occurring on-target through SGK3, or as an off-target effect of the compound. I 
therefore sought to use genetic approaches targeting SGK3 in order to validate PDE4D as a 
downstream effector of SGK3.  
I continued to study PDE4D levels downstream of SGK3 using an shRNA method to induce 
significant knockdown of SGK3. Using two different shRNA constructs, targeting the protein 
coding region (shSGK3#1) and 3’UTR (shSGK3#2), I induced significant downregulation of SGK3, 
and studied PDE4D expression in the presence of absence of SGK3-PROTAC1 treatment. I 
detected a reduction in PDE4D expression in response to the shRNA, and remaining PDE4D was 
less sensitive to SGK3-PROTAC1 treatment (Figure 4.6C). This preliminary data suggests that 





Figure 4.6 PDE4D expression is mediated downstream of SGK3 in HEK293 cells. 
A. SGK3-PROTAC1 treatment reduced PDE4D expression in HEK293 cells, but this was not replicated by 
cisSGK3-PROTAC1 or 14H treatment. B. Timecourse treatment with 0.3 M SGK3-PROTAC1 revealed 
reduced expression of PDE4D after 2 hours. C. SGK3 was knocked down by shRNA treatment, and 
transfected cells selected for by puromycin treatment. These cells were then treated for 8 h in the presence 
or absence of SGK3-PROTAC1, and protein levels of SGK3 and PDE4D measured by western blot. 
Quantification of PDE4D was performed using Image Studio Lite software. 
In order to confirm a mechanism of action through SGK3, I re-expressed in the shSGK3 cell lines 
either wildtype or kinase inactive (KI) shRNA resistant SGK3. Consistent with a kinase-
independent mechanism of action through SGK3, PDE4D expression was rescued by both 
wildtype and kinase-inactive SGK3 (Figure 4.7). In fact, KI SGK3 rescued to a greater extent than 




analogue had no impact on PDE4D levels, suggesting that PDE4D downregulation is a 
degradation-specific effect. 
 
Figure 4.7 Rescue of PDE4D expression by exogenous expression of SGK3 wildtype and kinase inactive. 
HEK293 cells were transfected for 24 h with shRNA against SGK3 or a scrambled control. After allowing a 
further 24 h for recovery, cells were transfected with shRNA resistant SGK3, either wildtype or the kinase 
inactive mutant. 24 h later, cells were treated for 8 h with SGK3-PROTAC1 (0.3 M), cisSGK3-PROTAC1 (0.3 
M) or 14H (1 M). Cells were lysed and subject to immunoblot analysis. 
As additional confirmation that reduction in PDE4D is SGK3-degradation dependent, I treated 
ZR-75-1 cells with a panel of inhibitors to probe different aspects of the pathway. First, I treated 
cells with an off-target PROTAC HaloPROTAC-E, described in more detail in chapter 5, and VHL 
inhibitor VH298 (Frost et al., 2016). These inhibitors showed no effect on PDE4D levels therefore 
this result is unlikely to be an effect of VHL inhibition or HIF1a stabilization as an effect of 




GDC0941 or VPS34 inhibitor VSP34-IN1, alone or in combination. These inhibitors were used to 
block activity of SGK3 and determine that this effect is not due to loss of SGK3 kinase activity, 
however this may be the result of a scaffolding effect (Figure 4.8A). I also performed timecourse 
analysis of PDE4D expression in these cells upon SGK3-PROTAC1 treatment and determined that, 
similar to HEK293 cells, downregulation of PDE4D occurs within an hour of treatment, with 
expression reduced 50% within 6h. 
 
Figure 4.8 Mechanistic validation of PDE4D downregulation in ZR-75-1 cells. 
A. ZR-75-1 cells were treated for 6 h with SGK3-PROTAC1 (0.3 M), cisSGK3-PROTAC1 (0.3 M), 
HaloPROTAC-E (0.3 M), VH298 (50 M), 14H (1 M), GDC0941 (1 M) or VPS34IN1 (1 M). Cell lysates 
were subject to immunoblot analysis with the indicated antibodies, and protein levels quantified in Image 
Studio software. B. ZR-75-1 cells were treated for up to 12 h with SGK3-PROTAC1 (0.3 M), or for 12 h with 
cisSGK3-PROTAC1 (0.3 M). Cell lysates were subject to immunoblot analysis with the indicated antibodies 




4.3.2 Mitochondrial proteins involved in the Electron Transport Chain are 
upregulated on SGK3-PROTAC1 treatment 
It was surprising on analysing the proteomic data to identify a global upregulation in 
mitochondrial proteins involved in oxidative phosphorylation. This effect was not observed in 
HEK293 cells, and no previous literature to our knowledge has connected SGK3 to mitochondria. 
Subsequent analysis by western blot revealed that this effect appears to be specific to the SGK3-
dependent cancer cell lines, as this result could be reproduced only in the ZR-75-1 and CAMA-1 
cells, and not HEK293 cells (Figure 4.9A and B) .Furthermore, analysis of a range of mitochondrial 
proteins revealed this upregulation is specific to members of the electron transport chain, as a 
selection of outer mitochondrial membrane (OMM) proteins were unaffected. Additionally, no 
increased cleaved of OPA-1 was observed on SGK3-PROTAC1 treated, therefore this effect was 
not due to an effect on mitochondrial membrane polarity (Figure 4.9A). 
 
Figure 4.9 SGK3-PROTAC1 treatment induces upregulation of the Electron Transport Chain in ZR-75-1 
cells. 
A. ZR-75-1 cells were treated for 6 h with DMSO, SGK3-PROTAC1 (0.3 M) or cisSGK3-PROTAC1 (0.3 M). 
Cells were lysed in urea buffer and subject to immunoblot analysis with the indicated antibodies. B. HEK293 
cells were treated for 6 h with DMSO, SGK3-PROTAC1 (0.3 M) cisSGK3-PROTAC1 (0.3 M) or SGK3 
inhibitor 14H (1 M ). Cells lysates were subject to immunoblot analysis with the indicated antibodies. ETC 
= proteins of the electron transport chain. OMM = proteins located on the outer mitochondrial membrane, 




Oxidative Phosphorylation (OxPhos), is a metabolic pathway in mitochondria which generates 
ATP by transport of electrons through complexes I, II, III and IV of the electron transport chain 
(ETC). This process allows protons to be pumped into the intermembrane space by complexes I, 
III and IV (Figure 4.10). This generates a high proton gradient across the inner mitochondrial 
membrane, causing protons to flow back to the mitochondrial matrix through complex V, ATP 
synthase, driving the synthesis of ATP. Interestingly, in my data set I observed upregulation of 
proteins involved in all 5 complexes, transcribed from both mtDNA and nuclear genes. 
 
Figure 4.10 Electron Transport Chain process. 
Electrons are transferred between ETC complexes I-IV, which also transport protons into the 
mitochondrial intermembrane space, generating a membrane potential. This membrane 
potential allows activation of ATP synthase, which produces ATP. 
As this mitochondrial effect was observed in response to SGK3-PROTAC1 treatment, but not the 
inactive cisSGK3-PROTAC1, it was important to verify that this response was occurring through 




figure 4.8, I  treated CAMA-1 cells for 6 h with a range of compounds to delineate the pathways 
involved in this upregulation. 
SGK3-PROTAC1 and cisSGK3-PROTAC1 treatment confirmed upregulation as a degradation-
specific effect of SGK3-PROTAC1 treatment. I also treated cells with the off-target PROTAC 
(HaloPROTAC-E, 0.3 µM) or the VHL inhibitor VH298 (50 µM), to determine whether 
mitochondrial upregulation was a PROTAC/VHL-dependent effect in these cells. I also treated 
cells with the 14H inhibitor (1 µM) to determine whether SGK3 inhibition had the same effect. I 
additionally treated with Class IA PI3K inhibitor GDC0941 (0.5 µM) or Class III PI3K inhibitor 
VPS34IN1 (1 µM), alone or in combination, to switch off different components of the pathway. 
Western blot for a range of mitochondrial proteins confirmed a robust upregulation of Electron 
Transport Chain on treatment with SGK3-PROTAC1, but not cisSGK3-PROTAC1. I also did not 
observe an effect of treating with HaloPROTAC-E or VH298, therefore suggesting this is not an 
off-target effect through VHL. Finally, while SGK3 inhibition by 14H had very little effect, there 
was a variable effect observed with inhibition of PI3K Class I or Class III, with upregulation of 







Figure 4.11 Expression of the Electron Transport Chain is upregulated on treatment with SGK3-PROTAC1, 
but not other VHL-targeting compounds. 
CAMA-1 cells were treated for 6 h with SGK3-PROTAC1 (0.3 M), cisSGK3-PROTAC1 (0.3 M), 
HaloPROTAC-E (0.3 M), VH298 (50 M), 14H (1 M), GDC0941 (1 M) or VPS34IN1 (1 M). Cell lysates 
were analyzed by immunoblot with the indicated antibodies, and protein levels quantified in Image Studio 
software. 
In order to further determine response to SGK3-PROTAC1 treatment, I analyzed expression of 
these proteins in response to SGK3-PROTAC1 (0.3 µM) over a timecourse up to 12 hours. This 
revealed an immediate response within an hour of treatment of MT-CO1 and GHITM expression, 
which increased up to the 8 h timepoint. After 12 h, protein expression was maintained but did 






Figure 4.12 Increased expression of ETC components is observed within 30 minutes, and maintained for 
12 hours. 
CAMA-1 cells were treated for up to 12 h with SGK3-PROTAC1 (0.3 M), or for 12 h with cisSGK3-PROTAC1 
(0.3 M). Cell lysates were subject to immunoblot analysis with the indicated antibodies and protein levels 
quantified in Image Studio software. 
The functional mechanism and impact of protein upregulation cannot be determined from the 
western blot data. The increase in protein levels could be due to hyperactivation of 
mitochondrial respiration, or inhibition of the pathway causing a compensatory increase in 
protein expression. In future work it would be important to determine what effect PROTAC 
treatment and ETC upregulation was having on mitochondrial respiration and metabolism. It has 
currently not been functionally characterized how SGK3 is impacting on mitochondrial proteins. 
As will be discussed further in section 4.5, SGK3 may be impacting on Nedd4L or another E3 






4.4 Phosphoproteomic analysis in ZR-75-1 cells reveals potential pathways 
regulated by SGK3.  
In parallel to the proteomic analysis described above, I also performed phosphoproteomic 
analysis of SGK3-PROTAC1 and cisSGK3PROTAC1 (0.3 µM) in ZR-75-1 cells, in comparison to 
DMSO. Phosphoproteomic analysis was performed to potentially reveal novel substrates 
phosphorylated specifically by SGK3, and not Akt. After splitting the peptide digest for global 
proteomic analysis, peptides were enriched for phosphopeptides by TiO2 enrichment, before 
TMT labelling and analysis by LC-MS/MS on the Orbitrap Lumos Mass Spectrometer. Identified 
mass spectra were then analysed in Max Quant (version 1.6.6.0, (Tyanova, Temu and Cox, 2016)) 
before further analysis in Perseus (Version 1.6.2.3, (Tyanova et al., 2016)). 
A previous phosphoproteomic study in HEK293 cells recently discovered Syntaxin7 and 
Syntaxin12 as specific SGK3 substrates, which are not phosphorylated by Akt (Malik et al., 2019). 
The study performed 2 phosphoproteomic screens, one comparing HEK293 wildtype cells with 
an SGK3-KO cell line, and the other comparing phosphorylation of substrates after treatment 
with the SGK inhibitor 14H. It was interesting to determine whether these substrates were also 
found in ZR-75-1 cells, or if further substrates could be identified. 
The phosphoproteomic analysis identified 29,215 unique phosphosites, of which 18,629 sites 
were Class I sites, as defined by >0.75 probability. Of these 18,629 sites, 1,152 were significantly 
downregulated (According to Two tailed Student’s T Test, p<0.05, FC<=-1.5) in the SGK3-
PROTAC1 condition v cisSGK3-PROTAC, while 215 sites were significantly upregulated (p<0.05, 
FC>=1.5). In comparing the SGK3-PROTAC1 and DMSO conditions, 2,806 sites were 
downregulated, and 147 sites were upregulated in response to the PROTAC. These data are 





Figure 4.13 Phosphorylation sites modulated upon SGK3-PROTAC1 treatment in comparison to DMSO 
in ZR-75-1 cells. 
ZR-75-1 cells were treated for 6 h with SGK3-PROTAC1 (0.3 M) or DMSO, and cell lysates subject to 
quantitative mass spectrometry phosphoproteomic analysis after TiO2 enrichment for phosphorylated 
peptides. Data are presented as a volcano plot 
Although there was substantial overlap, there were differences between the altered sites in the 
SGK3-PROTAC1vcisSGK3-PROTAC1 and SGK3-PROTAC1vDMSO conditions. These differences are 
likely due to the SGK-targeting moiety of the compound still having an inhibitory effect on 
certain sites (Figure 4.14A). Therefore, an additional control to the study was to compare the 
negative control cisSGK3-PROTAC1 to DMSO treated samples, which revealed 396 
downregulated and 34 upregulated sites (Figure 4.14B). Therefore, the majority of the 







Figure 4.14 Phosphorylation changes in SGK3-PROTAC1/cisSGK3-PROTAC or cisSGK3-PROTAC1/DMSO. 
ZR-75-1 cells were treated for 6 h with SGK3-PROTAC1 (0.3 M) or DMSO, and cell lysates subject to 
quantitative mass spectrometry phosphoproteomic analysis after TiO2 enrichment for phosphorylated 
peptides. Data are presented as a volcano plot. 
I next analysed the phosphoproteomics data for phosphomotif sites enriched in the dataset 
(Figure 4.15). 86.8% of detected phosphopeptides were phosphorylated on a serine residue, 
with 12.2% pThr and 1% pTyr. These ratios are typical for phosphoproteomic analysis using these 
digestion and enrichment methods. I then analysed which phosphomotifs were enriched in the 
dataset, and whether any of these motifs, for example the RXRXXS/T motif shared by Akt and 
SGK3, were enriched in the downregulated phosphopeptides after SGK3-PROTAC1 treatment. I 
found a large enrichment of pSP sites both in the whole dataset and enriched upon SGK3-
PROTAC1 treatment. However, while RXRXXS/T sites composed a large proportion of the dataset, 






Figure 4.15 Phosphosite analysis in ZR-75-1 phosphoproteomic dataset. 
A. Phosphosite analysis of entire dataset B. Motif analysis of phosphopeptides identified in the whole 
dataset. C. Motif analysis of phosphopeptides reduced upon SGK3-PROTAC1 treatment compared to 
cisSGK3-PROTAC1. 
4.4.1 Under basal conditions, much RXRXXS/T motif phosphorylation in ZR-75-1 
cells is not controlled by SGK3 
Under basal conditions, ZR-75-1 cells express relatively low levels of SGK3. Increased expression 
and activity is induced on 5 day treatment with PI3K-Akt pathway inhibitors. Instead, growth 
and signalling are primarily driven through the PI3K pathway via Akt. Therefore, any shared 
substrates of SGK3 and Akt were not expected to change. However, phosphoproteomic analysis 
may reveal specific substrates of SGK3 in ZR-75-1 cells. 
574 sites in total were identified lying within the RXRXXS/T motif. Of these, on comparison of 
SGK3-PROTAC1 to cisSGK3-PROTAC1 treatment, just 17 sites were detected to be significantly 
modulated (FC>1.5, p<0.05). 7 sites were upregulated in response to SGK3-PROTAC1 treatment, 






Figure 4.16 RXRXXS/T motif changes upon SGK3-PROTAC1 treatment, compared to cisSGK3PROTAC1. 
ZR-75-1 cells were treated for 6 h with SGK3-PROTAC1 (0.3 M) or cisSGK3-PROTAC1 (0.3M), and cell 
lysates subject to quantitative mass spectrometry phosphoproteomic analysis after TiO2 enrichment for 
phosphorylated peptides. Data are presented as a volcano plot  
When comparing phosphoproteomic changes between the SGK3-PROTAC1 and DMSO treated 
conditions, slightly more significant phosphosite changes were identified (Figures 4.17,18). 
These sites were determined not to be significant when comparing the active and inactive 
PROTACs, like due to slight inhibitory effects of the inactive compound. Only 6 significantly 
modulated phosphosites were shared between the 2 analyses (Figure 4.18) Only 2 consensus 
motif sites were observed to be downregulated in the cisSGK3-PROTAC1 sample in comparison 







Figure 4.17 RXRXXS/T motif changes upon SGK3-PROTAC1 treatment, compared to DMSO. 
ZR-75-1 cells were treated for 6 h with SGK3-PROTAC1 (0.3 M) or DMSO, and cell lysates subject to 
quantitative mass spectrometry phosphoproteomic analysis after TiO2 enrichment for phosphorylated 
peptides. Data are presented as a volcano plot 
Of the significantly modulated sites detected, there were several overlaps with 
phosphoproteomic analysis of HEK293 cells either carrying an SGK3 KO or with SGK3 inhibited 
using 14H. These are indicated  on the heatmap with a red (SGK3 KO) or green (14H treatment) 
asterisk (Figure 4.18). 
STX7 is a member of the Syntaxin family of SNARE proteins and, along with STX12, was previously 
identified in our lab to be phosphorylated by SGK3 at S126, both in vitro and in cells, confirmed 
by phostag analysis. Recent data from the lab shows that phosphorylation of STX7 and STX12 at 
this site impacts on binding to their SNARE complex partners (VAMP4 and STX6 for STX12) and 
cellular localisation (Malik et al., 2019). Phosphorylation of these sites is specific to SGK3 over 
Akt, which is reported to favour large, hydrophobic residues after the phosphorylated Ser/Thr. 




in vitro (Malik et al., 2019). This represents a possible bioinformatic tool for delineating between 
SGK3 and Akt substrates. 
 
Figure 4.18 Heatmap of phosphorylation changes in RXRXXS/T sites across all 3 conditions. 
Phosphoproteomic changes between SGK3-PROTAC1, cisSGK3-PROTAC1 and DMSO treatment were 
analysed by two-tailed t-test. Heatmap demonstrates significant (FC>1.5, p<0.05) changes in RXRXXS/T 
sites in each comparison. The log2 values of each of the RXRXXS/T phosphosite is Z-score normalized and 
generated the heat map using Perseus software. 
 
Phosphorylation of WDR7 at Ser1121 was identified on 14H treatment in HEK293 cells. And 




further analysis, it was determined to be phosphorylated by both SGK3 and Akt  in vitro 
(Karapetsas et al., unpublished). 
The majority of modulated RXRXXS/T sites occur within potential 14-3-3 binding sites. Akt is 
known to modulate the activity of a range of proteins by phosphorylation on these sites, leading 
to protein sequestration in particular regions of the cell. As SGK3 is localised to endosomes, I 
analysed my data for any significantly modulated RXRXXpS/T sites on proteins annotated to have 
endosomal localisation. Apart from the previously discussed Syntaxins and Intersectin 1 (ITSN1), 
the only other significantly modulated protein was Melanophillin (MLPH). Melanophillin (also 
known as Synaptotagmin-like protein 2a) is an effector of Rab27-GTP and may regulate 
membrane trafficking. Therefore, the functional relevance of this site may be interesting to 
follow up in future work. 
Only relatively minor changes in phosphorylation were detected in all these sites, with a  
threshold of 1.5fold change used for detection. However, at the basal level in ZR-75-1 cells SGK3 
activity is very low. It would be important to repeat this assay under conditions inducing SGK3 
activity, such as prolonged PI3K inhibition, in order to observe more profound changes in SGK3 
substrates. 
4.4.2 CCNY-CDK16 – a putative pathway downstream of SGK3. 
Although I did not observe many significant changes in RXRXXS/T in these samples, there were 
several interesting phosphosites either up- or downregulated on SGK3-PROTAC1 treatment. 
Therefore, changes in these sites may, although not directly phosphorylated by SGK3, be 
downstream of a pathway regulated by SGK3. 
The most significant and clear change in the phosphoproteomic data is a dramatic reduction in 
phosphorylation of CDK16 at Ser138. This phosphorylation occurs in a proline-directed pSP site 
typically phosphorylated by Cyclin Dependent Kinases (CDKs) or Mitogen activated protein 




as previous phosphoproteomic screens in HEK293 cells by former PhD student Nazma Malik, 
identified an SGK3-dependent phosphosite in the upstream effector CCNY. Therefore, my data, 
identifying a modulated site downstream of CCNY using a separate approach, reinforces a 
possible role for SGK3 in this pathway. It remains doubtful, however, that CDK16 is a direct SGK3 
substrate. 
In addition, both this experiment and previously performed phosphoproteomic analyses 
studying SGK3 knockout or 14H treatment identified a high number of modulated pS/TP sites 
(Figure 4.19), suggesting that signalling involving Cyclin Dependent Kinases is somehow 
modulated downstream of SGK3 knockdown or inhibition. In comparison of the SGK3-PROTAC1 
and cisSGK3-PROTAC1 treated conditions, I detected 483 proline-directed Ser/Thr to be 
significantly modulated (FC>1.5, p<0.05). Of these, 57 sites were upregulated in response to 
SGK3-PROTAC1 treatment, and 426 were significantly downregulated. 
In order to further investigate changes in putative CDK substrates, I analysed the data for 
changes within the typical CDK substrate motif (pS/T-P-X-K/R) and the CDK16 substrate motif. It 
was determined that CDK16 has a very different preferred substrate motif than other CDKs, 
preferring basic residues at the +2 and +4 positions, and a small aliphatic residue instead of 
acidic residues at the +2 site. Additionally, CDK16 has a significant preference for Ser over Thr 
(pS-P-K/R- ϕ-K/R/H) (Shehata et al., 2012). From this analysis I found just 6 putative CDK16 sites 





Figure 4.19 pS/TP motif changes upon SGK3-PROTAC1 treatment, compared to cisSGK3PROTAC1. 
ZR-75-1 cells were treated for 6 h with SGK3-PROTAC1 (0.3 M) or cisSGK3-PROTAC1 (0.3 M), and cell 
lysates subject to quantitative mass spectrometry phosphoproteomic analysis after TiO2 enrichment for 
phosphorylated peptides. Data are presented as a volcano plot 
 
4.5 Discussion 
Study of SGK3 degradation in ZR-75-1 cells revealed several possible novel roles for SGK3. The 
detection of PDE4D downregulation downstream of SGK3 was a surprising finding and may 
represent an exciting undiscovered axis by which PI3K signalling and the PKA pathway can 
interact. Although this was initially detected in ZR-75-1 cells, this effect could also be confirmed 
in HEK293 cells and appears to be a ubiquitous mechanism of PDE4D regulation. Conversely, an 
unexpected upregulation of Electron Transport Chain components was discovered to be specific 




Downregulation of PDE4D in response to SGK3-PROTAC1 
There are four subtypes of PDE4, namely PDE4A–PDE4D, which are highly specific for cAMP 
degradation but not for cGMP. PDE4 inhibition has been investigated as a potential therapeutic 
target in asthma, COPD and other inflammatory diseases (Li, Zuo and Tang, 2018). Inhibition of 
PDE4 results in accumulation of intracellular cAMP and activation of PKA, cyclic nucleotide gated 
ion channels and Epac1/2. Reactivation of the cAMP signaling pathway by PDE4D Inhibition has 
also been proposed as a novel druggable axis against tamoxifen resistance in ER+ breast cancer 
(Mishra et al., 2018). Therefore, regulation of PDE4D downstream of SGK3 degradation is 
potentially an important component to this signaling axis in chemo-resistant breast cancer. 
It is currently unclear from this data how PDE4D expression is reduced in response to SGK3-
PROTAC1. PDE4D activity is spatially and temporally controlled by both extensive post-
translational modification, and localization to ‘cAMP signalosomes’ in highly specific regions of 
the cell. Both methods of regulation are discussed regarding SGK3 degradation below. 
It is possible that PDE4D stability is altered in some way by SGK3 degradation. A phosphodegron 
motif has been identified in the C terminus of PDE4D, leading to its ubiquitylation and 
degradation by the proteasome. This dual phosphorylation motif is regulated by CK1 and GSK3β. 
The motif is protected from phosphorylation by Calcineurin (Zhu et al., 2010). Protein levels of 
PDE4D were not effective by SGK3 inhibition, and the phosphodegron motif lies outside of the 
RxRxxS/T SGK3 substrate motif, so it is unlikely to be a direct SGK3 substrate.  However, SGK3 
may act upstream on this motif, or alternatively act on another region of the protein. PDE4D 
expression can be induced in response to cAMP by cAMP response elements (CREs) in its gene 
promoter (Kim et al., 2019). It has not been tested whether alterations in PDE4D expression are 
as a result of transcriptional/translation regulation, however as expression is reduced within 2 







Figure 4.20 Domain structure of PDE4D and known regulatory posttranslational modification sites. 
From (Mika and Conti, 2016) 
The PDE4D gene generates at least 9 isoforms through alternative splicing. All isoforms contain 
a shared C terminal catalytic domain and differ in their variable N terminus and splicing of the 
regulatory UCR1 and UCR2 domains. It was interesting to observe that only longer forms of 
PDE4D containing UCR1 were downregulated in response to SGK3-PROTAC1 treatment. The 
UCR1 and UCR2 domains of PDE4D have been proposed to be regulatory domains controlling 
PDE4D activity. UCR2 regulates the enzyme activity by opening and closing over the active site, 
controlling access of cAMP (Mika and Conti, 2016). UCR1 also forms contacts with UCR2 to 
modulate this regulation. UCR1 has also been proposed to be required for dimerization of PDE4D 
isoforms (Richter and Conti, 2002, 2004). Interaction of SGK3 with this UCR1 domain may 
therefore impact on stability, reveal a degron motif or otherwise trigger downregulation of 
PDE4D. UCR1 is also extensively decorated by posttranslational modifications, modulating the 
activity of PDE4D, as shown in Figure 4.20 above. For example, phosphorylation of S54 by PKA 
increases activity by 60% in a presumed negative feedback loop (Sette and Conti, 1996; 
Hoffmann et al., 1998). 
Interrogation of the phosphoproteomic data revealed no global changes in PKA substrate 
phosphorylation, suggesting global cAMP signaling is not impacted by SGK3-PROTAC1 treatment. 
However, adaptor proteins such as RACK1, AKAPs and SH3 domain-containing proteins are 




This results in highly localized modulation of cAMP signaling through ‘cAMP signalosomes’ 
through combination with cAMP effectors such as PKA and Epac1/2 (Maurice et al., 2014). This 
results in spatially and functionally distinct pools of cAMP. Therefore, reduction in PDE4D may 
result in modulation of very localized cAMP levels, not identified by a global phosphoproteomic 
approach. 
PDE4D has been found in T-cells to be recruited to sites of PI3K activation through formation of 
a complex with Akt and B-arrestin (Bjørgo et al., 2010). Co-recruitment to PIP3 sites via the PH 
domain of Akt implicated PDE4D in shutting off T-cell activation signals. Similarly, in Cardiac Cells, 
PDE4D was recruited to sites of PTEN inactivation, and was involved in inhibiting calcium 
overload and mPTP opening upon cardiac ischemia, inhibiting necrotic cell death (Zheng et al., 
2014). No interaction has previously been demonstrated between SGK3 and PDEs. The 
interaction domain of Akt with B-arrestin was mapped to 429-441 of Akt and, while the majority 
of this sequence is well conserved between Akt and SGK3, the critical Tyrosine residue for 
binding in Akt is an asparagine in SGK3 (Bjørgo et al., 2010). While the Akt complex forms via B-
arrestin, phosphodiesterases are known to form complexes with several adaptors, therefore 
complex formation may occur via an adaptor other than B-arrestin, therefore not requiring this 
binding site. In future work, it would be interesting to determine whether SGK3 is forming a 
stable complex in cells with PDE4D, and whether downregulation of PDE4D is occurring through 
collateral ubiquitylation or destabilization due to loss of the complex.   
Upregulation of electron transport chain components in response to SGK3-PROTAC1 
While downregulation of PDE4D was reproducible across several cell lines, it was interesting that 
upregulation of mitochondria proteins was observed as a cancer cell line specific effect of SGK3-
PROTAC1 treatment and could not be reproduced in HEK293 cells. This suggests a mitochondrial 




Mitochondria are energy hubs to produce the majority of the cell’s ATP. They also have roles in 
regulating cellular calcium, apoptosis and synthesis of macromolecules. Increased glucose 
uptake and metabolism, coupled to mitochondrial dysfunction, has been traditionally 
considered a hallmark of the Warburg effect in cancer. However, the role of mitochondrial 
metabolism in cancer is much more complex, with many cancers in fact becoming 
mitochondrially driven with a high reliance on oxidative phosphorylation (Solaini, Sgarbi and 
Baracca, 2011). 
Mitochondrial function is known to be regulated downstream of PI3K. Akt phosphorylates Bcl2-
family proteins in order to block the release of cytochrome c from mitochondria, inhibiting 
apoptosis (Datta et al., 1997, 2000; del Peso et al., 1997). As described above, Akt may also 
mediate necrotic cell death through regulation of mPTP opening via PDE4D control of cellular 
calcium (Fujio et al., 2000; Murphy and Steenbergen, 2008). SGK1 has also recently been 
proposed to modulate mPTP opening through an interaction with mPTP and VDAC1, in a role 
not affected by PI3K inhibition and therefore possible a kinase-independent role of the SGKs 
(Zhou et al., 2019). Further, inhibition of SGK1 was coupled with vulnerability to redox 
dysregulation. After inhibition or downregulation of SGK1, the authors found an increase in ROS 
and cytotoxicity upon H2O2 stress, mediated through NRF2 target gene expression (Wang et al., 
2019). 
An increased expression of ETC genes, causing increased mitochondrial respiration, has been 
identified as a mechanism of resistance to BRAF inhibitors (Baenke et al., 2016). However, 
increased expression of mitochondrial enzymes is observed within 30-60 minutes of SGK3-
PROTAC1 treatment and therefore this effect is unlikely to be translational. Additionally, OxPhos 
proteins upregulated are transcribed from both mitochondrial and nuclear genes. Inhibition of 




cancers driven through mitochondrial metabolism become sensitized to combination treatment 
with metformin (Denise et al., 2015; Vellinga et al., 2015). 
 
Crosstalk between PDE4D and Mitochondrial Metabolism 
It is currently unclear whether the downregulation of PDE4D and the upregulation of ETC in 
cancer cell lines are linked. CAMA-1 cells presented the most mitochondrial sensitivity to SGK3-
PROTAC1 treatment; however they lack the longer PDE4D isoforms downregulated upon SGK3 
degradation. 
cAMP is not a freely diffusible molecule within the cytosol, and cAMP signalling is therefore 
compartmentalised in the cell under the regulation of adenylyl cyclases (ACs) and 
phosphodiesterases such as PDE4D. PKA is one of a variety of kinases which translocate to 
mitochondria to modulate mitochondrial function downstream of cAMP signalling. AKAPs 
relocate endogenous PKA and cAMP modifiers such as phosphodiesterases to distinct 
subcellular compartments to strategically enhance cAMP regulated signalling pathways. PKA can 
be recruited to mitochondria by associating with 3 different AKAPS to regulate mitochondrial 
dynamics, structures and respiration. AKAP1 splice variants import and dock PKA to the outer 
mitochondrial membrane, and are also involved in transport of nuclear-encoded mRNA 
encoding mitochondrial proteins (Ginsberg et al., 2003). Mitochondrial cAMP-PKA signalling has 
been shown to impact on OxPhos through phosphorylation of ETC components in complexes I, 
IV and V, impacting on both activity and protein stability. Therefore, via this mechanism 
downregulation of PDE4D may have an impact of PKA-controlled regulation of mitochondrial 
metabolism. 
One of the first described mitochondrial targets of PKA is the nuclear-encoded 18-kDa subunit 




with Hsp70 and its import into the mitochondria (Papa, 2002; De Rasmo et al., 2008). cAMP-PKA 
signalling also modulates the stability of complex I by modulating degradation of its subunits by 
mitochondrial proteases. Inhibition of the mitochondrial adenylyl cyclase sAC, reducing cAMP 
signal within mitochondria, induces a decrease of complex I subunits (De Rasmo et al., 2015). 
cAMP signalling triggered either in the cytosol or in the mitochondria both impact on complex 
IV stability and activity. During hypoxia, PKA phosphorylates complex IV subunits I, IV and Vb, 
inducing their degradation and decreasing complex IV activity (Prabu et al., 2006; Shinzawa-Itoh 
et al., 2007). Additionally, an increase in cAMP signalling induces tyrosine phosphorylation of 
complex IV subunit I (Lee et al., 2005), inhibiting the complex’s enzymatic activity. This effect 
has also been seen with the PDE4 inhibitor theophylline (Lee et al., 2005). Finally, complex V can 
be modulated by PKA through phosphorylation of ATPase Inhibitory Factor AIF1 on Ser39, 
preventing binding to complex V and relieving inhibition of ATP synthase (García-Bermúdez et 
al., 2015). Again, intramitochondrial cAMP signalling modulates complex V via mitochondrial 
proteases, as a depletion of cAMP in mitochondria decreases levels of complex V connecting 
subunits and complex V oligomerisation (De Rasmo et al., 2016). The above describe a range of 
mechanisms by which a reduction of cellular or mitochondrial cAMP downstream of 
phosphodiesterases may impact on the stability and activity of ETC components. In particularly, 
the upregulation of ETC protein expression in response to SGK3-PROTAC1 treatment may lie 
downstream of inhibiting mitochondrial proteases against complexes I, IV and V. 
Phosphoproteomic changes upon SGK3-PROTAC1 treatment 
Complementary phosphoproteomic analysis revealed very few changes in RxRxxS/T motif 
phosphorylation sites. This was expected, as PI3K signaling through Akt is the primary driver of 
growth in these cells, and SGK3 is expressed at lower levels under basal conditions. However, 
identification of sites previously identified in HEK293 cells confirmed on target activity of the 




SGK3-dependent substrates. Of the modulated sites, many lie within 14-3-3 binding motifs. Akt 
phosphorylation of many of its substrates provides docking sites for binding of 14-3-3 proteins 
(Chen et al., 2003), therefore phosphorylation of these sites by SGK3 may well provide docking 
sties for 14-3-3 proteins and modulate protein localization and function. 
However, despite a relatively low number of changes in RxRxxS/T sites, many proteins did 
appear to be modulated at alternative sites. The reason for these changes is currently unclear. 
It is possible that degradation of SGK3 is regulating downstream kinases or phosphatases. No 
remarkable changes in the protein level or phosphorylation status of any protein 
kinases/phosphatases were detected in the proteomics, however a mild (20-25%) decrease was 
observed in the cyclin dependent kinases CDK18 and CDK17, and the CDK inhibitor CDKN1A. 
Additionally, such a large shift in mitochondrial proteins may result in modulation of further 
metabolic enzymes. Alternatively, these sites could be due to a currently unidentified off-target 
hit of SGK3-PROTAC1, or an unidentified substrate motif which can be phosphorylated by SGK3. 
A large number of modulated (S/T)P sites were also identified in previous phosphoproteomic 
screens (Malik et al., 2019), therefore increasing confidence that these alterations are an on-
target effect. 
 p(S/T)P sites were the most enriched throughout the sample set, representing 28% of the 
dataset and 23% of modulated sites. The p(S/T)P motif is a common substrate motif for many 
kinases, including the mitogen activated protein kinases (MAPKs) and cyclin dependent kinases 
(CDKs). Phosphorylation of many proteins is under the control of CDKs throughout the cell cycle, 
therefore this broad change in p(S/T)P sites may be a result of an impact on progress through 
the cell cycle in response to SGK3-PROTAC1 (Swaffer et al., 2016). 
In particular, the most downregulated phosphosite in response to SGK3-PROTAC1 treatment 
was phosphorylation of CDK16 and Ser138, which lies within a pSP site. Previous work from PhD 




interaction between CDK16 and Cyclin Y (CCNY). CCNY phosphorylation at Ser326 was identified 
in HEK293 cells as being reduced downstream of 14H treatment (Malik et al., 2019). Their work 
has demonstrated that, in vitro, both SGK3 and Akt can phosphorylate CCNY at Ser326. Ser326 
lies within an RXRXXS/T site, and alongside Ser100 phosphorylation leads to 14-3-3 binding of 
CCNY. 14-3-3 binding is critical for CCNY interaction with CDK16 and its subsequent activation. 
(Ou et al., 2010; Mikolcevic et al., 2012; Shehata et al., 2012, 2015), (Karapetsas, unpublished) 
(Figure 4.22). Follow-up analysis in cells, however, revealed some possible functional 
redundancy, as the CCNY-CDK16 interaction was still present in SGK3 knockout cells, and 
treatment with the SGK3-PROTAC1 compound had only a partial effect. 
Phosphorylation of CDK16 at Ser138 has not been studied in the literature, and the functional 
relevance of this site is not known. It is possible that the site is an autophosphorylation site upon 
CDK16 activation, or it is phosphorylated by an alternative upstream kinase. It would be 
interesting in future work to determine the kinase of this site, as it is unlikely to be mediated by 
SGK3 itself, and whether this site has any functional relevance for the activation of CDK16. 
 
Figure 4.22 Current Model of CDK16 activation downstream of SGK3. Phosphorylation of Cyclin 
Y (CCNY) at S326 promotes binding and activation of CDK16. Ser326 phosphorylation occurs in 
an RXRXXS/T motif site and can be phosphorylated by SGK3 and potentially other kinases. 
Phosphorylation of CDK16 at Ser138 may be a result of autophosphorylation or an alternative 
upstream kinase. 
Conclusion 
Global proteomic and phosphoproteomic analysis of SGK3-PROTAC1 treatment in ZR-75-1 cells 
revealed several potential new roles for SGK3 in cancer metabolism. Downregulation of PDE4D 




in turn have a role in modulating the stability of electron transport chain components and other 
mitochondrial functions. As chemoresistance in cancer has been associated with mitochondrial 
function, knockout of SGK3 may target mTORC1 signalling and mitochondrial metabolism 
simultaneously, offering a therapeutic benefit over kinase inhibition alone. In further work, it 
would be important to further validate the mechanisms of PDE4D downregulation and ETC 
upregulation and determine whether these two processes are linked via SGK3. 
Phosphoproteomic analysis revealed very few changes in SGK3 substrate RxRxxS/T motif sites. 
This was likely due to the activity of Akt in these cells in combination with relatively low 
expression of SGK3 in the unstimulated conditions. In future work this experiment could be 
improved by inducing SGK3 expression and activity with prolonged inhibition of PI3K or Akt, as 
described in Chapter 3. However, the findings of previously identified substrates STX7 and ITSN1 
and WDR7 confirmed the success of SGK3-PROTAC1 in downregulating SGK3 substrate 
phosphorylation. Further the  confirmation of these substrates in a second cell line increases 
confidence in these SGK3 substrates. In addition, phosphorylation of CDK16 at S138 was the 
most significantly downregulated phosphosite in the experiment, and although this isn’t an SGK3 




5. HaloPROTACs – a generalisable, targeted protein 
degradation approach 
5.1 Targeting of proteins with no validated binding ligands 
In the previous two chapters of this thesis I developed and validated SGK3-PROTAC1 and used 
this compound to directly target SGK3 for degradation. This compound was developed using 
known inhibitors of the SGK isoforms. PROTAC design, however, requires a ligand capable of 
interacting with the desired target, and high–affinity ligands are lacking for the vast majority of 
human proteins. In addition, detailed structural and biophysical analysis of the interaction 
between ligand and target protein is key for rational design of PROTAC compounds. In the case 
of SGK3, although we had known inhibitors of the kinase domain (Halland et al., 2015), we 
currently lack information on protein structure, and how these ligands are binding. 
In order to circumvent these issues, alternative strategies have been developed that involve 
attaching various tags to target proteins, to enable these to be targeted by a compound capable 
of inducing interaction with an E3 ligase machinery. One of the first approaches made use of the 
plant E3 ligase TIR1, exogenously expressed in non–plant cells, to trigger ubiquitylation and 
degradation of target proteins fused to an Auxin–Inducible Degron (AID) tag on addition of the 
plant hormone Auxin (Nishimura et al., 2009; Natsume et al., 2016; Nora et al., 2017). A more 
recent approach exploits the ability of a phthalimide–based chimeric compound called dTAG-13 
to bind proteins fused with a F31V mutant FKBP12 tag and induce degradation via the cereblon 
(CRBN) E3 ligase (Erb et al., 2017; Weintraub et al., 2017; Brunetti et al., 2018; Nabet et al., 
2018). CRBN is endogenously expressed in most mammalian cells and therefore does not need 
to be overexpressed. Other methods include deGradFP and AdPROM, which rely on the 
overexpression of the von Hippel–Lindau (VHL) E3 ligase fused to a GFP binding nanobody 
capable of inducing degradation of GFP–tagged proteins (Caussinus, Kanca and Affolter, 2012; 
Caussinus and Affolter, 2016; Fulcher et al., 2016), or the Trim–AWAY method that enables the 




Another example of this is the recently published HaloPROTAC approach (Buckley et al., 2015). 
HaloPROTAC compounds contain a chloroalkane moiety conjugated to a ligand of an E3 ligase, 
typically VHL or cIAP1 (Buckley et al., 2015; Tomoshige, Hashimoto and Ishikawa, 2016). These 
compounds are then targeted toward a modified bacterial dehalogenase HaloTag7 fusion to the 
target protein (Los et al., 2008). HaloTag7 will covalently bind to the chloroalkane motif, and the 
fusion protein targeted for ubiquitylation and degradation (Fig 5.1). 
 
Figure 5.1 Mechanism of action of HaloPROTACs 
A. PROTACs are bivalent molecules, which bind to both the target protein of interest and an E3 ligase. 
These compounds function by recruiting the E3 ligase to the target protein, triggering polyubiquitylation 
and proteasomal degradation. B. HaloPROTAC compounds contain a chloroalkane motif which can be 
covalently targeted by HaloTag7. These compounds therefore target HaloTag7 fusion proteins for 
proteasomal degradation. 
At the time starting this study, previous HaloPROTAC studies had only been applied to 
exogenously overexpressed proteins, limiting their application to endogenous systems. In 
addition, the use of this method to degrade subcellularly localized proteins remains 
understudied. I therefore aimed to combine the HaloPROTAC approach with CRISPR/Cas9 to 
target endogenously labelled SGK3-Halo, and its upstream regulator Halo-VPS34. This project 




VHL ligands (Galdeano et al., 2014; Frost et al., 2016) with CRISPR/Cas9 to target and manipulate 
the endogenous hVPS34-SGK3 signalling axis. 
5.2 Generation of SGK3-Halo and Halo-VPS34 KI cell lines by CRISPR/Cas9 
In order to generate cell lines which could be targeted using the HaloPROTAC compounds, I first 
used CRISPR/Cas9 technology to endogenously knock in the HaloTag7 protein to the C-terminus 
of SGK3, or the N-terminus of VPS34 in HEK293 cells. The HEK293 cell line was chosen as these 
cells have previously been extensively used to study the hVPS34-SGK3 pathway (Malik et al., 
2018), and they are readily amenable to transfection and genetic alteration by CRISPR/Cas9, 
making them an ideal model cell line. The C-terminus of SGK3 was chosen as the protein contains 
an N-terminal Phox-homology (PX) domain critical for its localisation and activation, and SGK3 
has previously tolerated well a GFP tag on its C terminus (Malik et al., 2018). Similarly, VPS34 
has previously been successfully tagged on its N terminus with no impact on activity or 
localisation (Fulcher et al., 2016). VPS34 has previously been the subject of targeted degradation 
through the AdPROM system, which targets an exogenously overexpressed E3 ligase to a target 
protein via a fused nanobody. While this approach successfully degraded ~80% GFP-VPS34, the 
impact on SGK3 activity was only slight, although significant (Fulcher et al., 2016; Malik et al., 
2018). Further, the AdPROM system described was expressed through viral transfection, and 
could be inducible only if expressed under a tetracycline-inducible promoter (Fulcher et al., 
2016). 
Genome editing with CRISPR/Cas9 
The clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated 
protein 9 (Cas9) system evolved as a bacterial defence mechanism against phage infection and 
plasmid transfer. In recent years it has been repurposed in molecular biology as a RNA-guided 
DNA targeting platform for transcriptional perturbation, epigenetic modulation, genome 




For use in genome editing, the endonuclease enzyme Cas9 is targeted to a genomic target by a 
guide RNA (sgRNA). This sgRNA consists of a 20-nucleotide guide sequence within a scaffold 
which will bind to the Cas9 enzyme. The sgRNA guide sequence pairs with a DNA target directly 
upstream of a critical 5’-NGG adjacent motif (PAM site). The Cas9 enzyme then mediates a 
double strand break (DSB) ~3bp upstream of the PAM site (Ran, Hsu, Wright, et al., 2013). 
Following a DSB, the cell’s DNA repair machinery will repair the break by one of 2 mechanisms, 
non-homologous end joining (NHEJ) or homology driven repair (HDR). The more common 
mechanism of DNA repair is through NHEJ, which often leaves insertion/deletion mutations 
(indels) in the genome. Such indels in a coding exon can result in frameshift mutations and 
premature stop codons, resulting in gene knockouts if targeted toward the start of the gene 
(Perez et al., 2008). Alternatively, if a repair template is available, DNA repair may occur through 
HDR, although at a much lower frequency than NHEJ. HDR can be utilised to introduce defined 
modifications at the site of double strange breaks, for example specific point mutations, 
insertions, or addition of affinity tags such as GFP, RFP or HaloTag7. Repair templates consist of 
the desired DNA insertion flanked by short (~150bp) homology arms for integration into the 
target locus. Knock-in mutations mediated by CRISPR/Cas9 through HDR occur much less 
frequently than NHEJ knockout mutations, and HDR is generally only active in dividing cells 
(Saleh-Gohari and Helleday, 2004). Efficiency can also vary depending on cell type, and the 






Figure 5.2 Mechanism of CRISPR/Cas9 mediated genome editing. 
A. The Cas9 endonuclease enzyme is targeted to the desired genomic locus by a guide RNA (sgRNA). This 
sgRNA targets a 20nt sequence upstream of a PAM site, targeted by the Cas9 enzyme. Cas9 mediates a 
double strand break (DSB). B. Cas9-mediated DSB is repaired by either non-homologous end joining (NHEJ) 
or homology driven repair (HDR). These two repair mechanisms can be utilized to generate knock-out or 
knock-in mutations respectively. For HDR, a repair template is also expressed with homology arms to 
target the desired genomic locus. From (Ran, Hsu, Wright, et al., 2013) 
A common problem in CRISPR-Cas9 genome editing is the possibility of off-target genomic 
alteration by the Cas9 enzyme. In order the reduce this risk, in this study the D10A ‘Nickase’ 
form of Cas9 was utilised (Ran, Hsu, Lin, et al., 2013). The D10A mutation in the active site of 
Cas9 removes the ability of the enzyme to form double strand breaks in DNA, instead generating 
single strand ‘nicks’. Therefore combination of this form of Cas9 with 2 sgRNAs leads to more 
specific targeting of the desired locus (Ran, Hsu, Lin, et al., 2013). 
Despite improvements in the approach, knock-in (KI) efficiency by the CRISPR/Cas9 method and 
HDR is still fairly low (1-2%). Therefore, when generating SGK3-Halo KI clones, an IRES2-eGFP 
cassette was included in the SGK3-Halo Donor cDNA to increase the likelihood of selecting 
positive clones. The IRES2-GFP cassette encodes GFP expression downstream of a second start 




SGK3. Hence, cells could be positively selected for GFP expression when performing single cell 
sorting. For Halo-VPS34, the chosen sgRNAs have previously been shown to generate a 
surprisingly high KI efficiency (Fulcher et al., 2016), therefore these cells were selected by single 
cell sorting alone.  
 
Figure 5.3 Generation of HaloTag7 endogenous fusion proteins by CRISPR/Cas9. 
HEK293 cells were transfected with the D10A Nickase form of Cas9 and 2 sgRNAs and a HaloTag7 fusion 
donor targeted to each locus. The SGK3–Halo donor also included an IRES2–eGFP cassette, allowing 
successfully integrated cells to be selected for through FACs sorting for GFP positive cells. The Halo–VPS34 
donor contained HaloTag7 only. Cells were selected through single cell sorting. Clones were selected and 
lysates screened by Immunoblot analysis, using antibodies against the endogenous proteins and a mouse 
monoclonal antibody against HaloTag7. The clones were characterized by DNA sequencing. Clone wt (wild 
type) refers to parental HEK293 cells, and ko (knockout) refers to previously described SGK3–knockout cell 
line (Malik et al., 2018) 
To confirm successful, in frame integration of HaloTag7 to the desired genetic locus, the selected 
clones were analysed by DNA sequencing analysis. HEK293 cells are pseudotriploid (Bylund et 
al., 2004), and carry three copies of SGK3 and VPS34 (HEK293genome.org).Halo-VPS34 clone 56 
was selected as a homozygous knock-in cell line. SGK3-Halo clone 2 was selected for the SGK3 
studies. This cell line contained 2 alleles with in-frame insertions of the HaloTag7 protein to the 




3’ of the critical hydrophobic motif activation residue Ser486, and is therefore predicted to 
produce an inactive protein.  
Addition of HaloTag7 does not affect localisation or complex formation of SGK3 and VPS34 
SGK3 and VPS34 are both localised to endosomal structures. SGK3 binds to PtdIns(3)P via its PX-
domain, and VPS34 localises by forming a complex with VPS15, a PH-domain containing protein, 
which colocalises to the endosome. It was important to consider, before using these cell lines 
for further biological characterisation, whether the addition of a large 33kDa tag to these 
proteins would affect their localisation or complex formation. The colocalization of SGK3-Halo 
and Halo-VPS34 to early endosomal marker Rab5 was analysed by immunofluorescence, in 
comparison to wildtype HEK293 cells. These cells were seeded onto coverslips and stained with 
the HaloTag7-TMR ligand, which covalently couples the TMR fluorophore to HaloTag7 via a 
chloroalkane motif. This allows easy visualisation of HaloTag7 fusion proteins by fixed 
immunofluorescence or live cell imaging. Cells were then fixed with 4% Paraformaldehyde (PFA) 
and co-stained for the endosomal marker Rab5 (Figure 5.4). It was observed that both Halo-
VPS34 and SGK3-Halo colocalised to Rab5-positive endosomal structures. As a negative control, 
analysis of HEK293 wildtype cells revealed no endosomal staining. On treatment with VPS34-
IN1, which inhibits VPS34 and reduces endosomal PtdIns(3)P, SGK3-Halo became diffuse 
throughout the cell, as previously observed (Bago et al., 2014; Malik et al., 2018). Conversely, 
VPS34-IN1 treatment caused Halo-VPS34 to become more punctate on endosomal structures. 
This has not previously been observed and may give some further information on the 





Figure 5.4 Endosomal localisation of SGK3 and VPS34 is unaffected by HaloTag7 fusion. 
HEK293 wildtype (A), SGK3-Halo (B) and Halo-VPS34 (C) cells were treated with either DMSO or the VPS34 inhibitor VPS34-IN1. Cells were stained for HaloTag7 (TMR-594) 





VPS34 forms a stable complex with VPS15 and Beclin1, either in complex I with UVRAG on Rab5-
postive endosomes, or complex II with ATG14 on Rab7 positive endosomes. To ensure the 
stability of this complex was not affected by the tag on VPS34, I performed immunoprecipitation 
of VPS34 from wildtype and Halo-VPS34 KI HEK293 cells, and analysed coimmunoprecipitation 
of complex members by immunoblot. I observed that coimmunoprecipitation of VPS15, Beclin1, 
ATG14 and UVRAG was unchanged between the wildtype and KI cell line, suggesting the 
complex was unaffected 
 
 
Figure 5.5 VPS34 complex stability is not affected by N-terminal HaloTag7 fusion. 
Endogenous VPS34 was immunoprecipitated from HEK293 wildtype or Halo-VPS34 KI cells. Co-
immunoprecipitation of complex members was detected by western blot. 
Addition of HaloTag7 does not affect PtdIns(3)P production by VPS34 
The critical role of VPS34 is to produce PtdIns(3)P from PtdIns on endosomal membranes. It was 
recently reported that this production of PtdIns(3)P was mediated in response to growth factor 




HaloTag7, I compared and quantified the levels of PtdIns(3)P, measured by a previously 
published fluorescent probe binding PtdIns(3) via a recombinant 2XFYVE peptide from HRS, 
conjugated to an AlexaFluor-593 fluorophore. Again, in these cells, I observed no defect in 
PtdIns(3)P production, and the staining was sensitive to VPS34 inhibition by VPS34-IN1. 
 
Figure 5.6 VPS34-mediated production of PtdIns(3)P is unaffected by HaloTag7 fusion. 
HEK293 wildtype (A) and HaloVPS34 (B) cells were stimulated with IGF1, after treatment with or without 
the Class I PI3K inhibitor GDC0941 or VPS34 inhibitor VPS34IN1. PtdIns(3)P production in these cells was 
measured with the 2XFYVE-AlexaFlour594 probe, and colocalised to the early endosomal marker Rab5. C. 





SGK3-Halo cells have similar levels of NDRG1 phosphorylation to wildtype, and 
phosphorylation is sensitive to SGK3 inhibition. 
 In order to determine potential effects of the HaloTag7 fusion on SGK3 activity, I analyzed 
phosphorylation of the well characterized SGK3 substrate NDRG1 at Thr346 (Malik et al., 2018) 
in HEK293 wildtype, SGK3-KO and SGK-Halo KI cells. NDRG1 is also phosphorylated at this site 
by the Akt kinases, therefore I assessed phosphorylation upon treatment with a selective Akt 
inhibitor (3 M AZD5363 (Davies et al., 2012)) in the presence or absence of a selective SGK3 
inhibitor (1 M 14H (Halland et al., 2015)). This assay revealed that SGK3 mediated 
phosphorylation of NDRG1 in wild type and SGK3–Halo cells was similar and higher than 
observed in SGK3 knock–out cells (Fig 5.7). Taken together, this evidence suggested that the 






Figure 5.7 NDRG1 phosphorylation is equivalent in HEK293 wildtype and SGK3-Halo KI cells. 
HEK293 wildtype, SGK3 KO and SGK3-Halo KI cells were treated with SGK inhibitor 14H or AZD5363 and 
SGK3 substrate NDRG1 phosphorylation measured by Western blot. Quantification of NDRG1 
phosphorylation at Thr346 is shown above the blot. 
In vitro SGK3 kinase Activity is altered by a C-terminal HaloTag7 
In order to determine the effect that addition of a C-terminal HaloTag7 has on SGK3 kinase 
activity in vitro, I performed an immunoprecipitation experiment to purify endogenous SGK3 
from wildtype HEK293 and SGK3-Halo KI cells. The immunoprecipitated kinase was then subject 
to an in vitro kinase assay against the well characterised Crosstide peptide substrate. Efficiency 




assay revealed that the activity of SGK3 immunoprecipitated from SGK3-Halo KI cells was much 
lower than that of the wildtype. 
As described in figure 5.3, the SGK3-Halo KI clone #2 used in these experiments contained 2 KI 
alleles, and 1 allele harboured a predicted inactive truncation.  SGK3-Halo KI clones #3 and #4 
contained 1 and 2 KI alleles respectively, with the remaining alleles wildtype. I could therefore 
use these clones to determine whether the reduced activity in clone #2 is due to the HaloTag7 
fusion, which would produce a ‘dose-dependent’ effect on SGK3 activity in the different cell lines, 
or a clonal effect of that cell line specifically. I therefore assayed the activity of each of these cell 
lines on stimulation with IGF1. This revealed that each SGK3-Halo KI allele reduced SGK3 activity 
by about 30% (Fig 5.9). This confirmed that reduction in SGK3 activity was likely due to the 
proximity of the tag, and not a clone-specific effect of the selected fusion clone. However, 
treatment with HaloPROTAC-A did reduce measured SGK3 kinase activity in clones 3 and 4, 
suggesting SGK3-Halo fusion protein does maintain some activity in these clones. The published 
SGK3-GFP KI cell line did exhibit reduced SGK3 activity, however responded normally to 
stimulation and inhibition of the pathway (Malik et al., 2018). Therefore, the effect is likely due 
to a large tag being in close proximity to the critical hydrophobic motif activation residue Ser486, 
blocking phosphorylation of SGK3-Halo by mTORC2. Although in vitro activity was reduced, in 
figure 5.7, I have observed that SGK3-Halo KI cells maintain phosphorylation of NDRG1 at Thr346, 
which is sensitive to SGK3 inhibition. Therefore, it is possible that SGK3 activity is maintained in 
cells, however the protein in less stable when immunoprecipitated for an in vitro kinase assay, 
thus explaining this result. 
In order to determine whether the proximity of HaloTag7 was blocking activation of SGK3, I 
performed an experiment overexpressing forms of SGK3-Halo in SGK3-KO 293 cells, with 
extended linkers from 5xGly to 20xGly, to determine if expanding the distance between SGK3 




extension of the linker up to 15xGly,modestly improved the activity of SGK3-Halo (Fig 5.10). 
However, the improvements in activity were very slight, and additionally the 20xGly linker 
construct did not have improved activity, and this was not followed up further in the study. 
 
Figure 5.8  In vitro kinase activity of SGK3-Halo is substantially reduced. 
3mg lysate of HEK293 wildtype, SGK3-KO or SGK3-Halo cells were immunoprecipitated for SGK3 , and 
subject to  in vitro kinase assay against the Crosstide peptide, and incorporation of 32P -ATP measured. 





Figure 5.9 SGK3-Halo fusion causes loss of SGK3 in vitro kinase activity. 
HEK293 wildtype, SGK3 KO or SGK3-Halo clones were treated with or without HaloPROTAC-A for 24 h, then serum-starved in empty DMEM overnight. Cells were harvested 
within or without prior stimulation with IGF-1 (50 ng/ml, 15 min). SGK3 was immunoprecipitated from 3 mg lysate, and subject to  in vitro kinase assay against the Crosstide 





Figure 5.10 Extending the linker between SGK3 and HaloTag7 increases SGK3 in vitro kinase activity. 
A. cDNA constructs were designed for transient transfection of SGK3 either alone of tagged with Flag, GFP 
or HaloTag7 with extending glycine linkers. B. SGK3-KO cells were transiently transfected with 30ng SGK3 
cDNA described in B. SGK3 was immunoprecipitated from 3 mg lysate, and subject to  in vitro kinase assay 
against the Crosstide peptide, and incorporation of 32P -ATP measured. 1 unit of activity = incorporation 
of 1nmol -phosphate into substrate per mg lysate. Error bars = SD, n=3. 
5.3 Compound design and screening 
To generate novel HaloPROTAC probes, I collaborated with the Ciulli lab (BCDD, Dundee) to 
produce 6 new compounds. HaloPROTAC3, previously described by the Crews Lab, contained an 
isoindolinone–based VHL targeting group conjugated to the chloroalkane moiety (Fig 5.11a) 
(Buckley et al., 2015). Based on recent publications from the Ciulli lab providing extensive 
understanding of structure–activity relationships and structure–based design of VHL ligands 
(Galdeano et al., 2014; Frost et al., 2016), it was hypothesized that substitution of the 
isoindolinone moiety of HaloPROTAC3 with other groups, optimized for VHL binding affinity 




of HaloPROTAC3 was replaced with N–acylamides of L–tert–leucine on the left hand side of the 
molecule (as in VHL ligand VH032) (Galdeano et al., 2014), maintaining the chloroalkane linker 
attachment point at the phenyl ring on the right hand side (Fig 5.11c). Compounds A and B 
contained linkers of 15 and 21 atoms respectively. In a second compound set, the acetyl group 
at the left hand side was replaced with a  cyclopropylcyanoacetic moiety (as in VHL inhibitor 
VH298 (Frost et al., 2016)) in compounds E and F, while maintaining chloroalkane linkers of the 
same length as compounds A and B (Fig 5.11c). Additionally, we prepared two HaloPROTACs (C, 
D) having linkers of 16 and 22 atoms length respectively attached at the N–terminal acyl amine 
moiety of VH032. This conjugation pattern had been explored previously albeit with different 
linker lengths (13 and 19 atoms) (Fig 5.11d) (Buckley et al., 2015) 
 
Figure 5.11 Design of HaloPROTAC compounds. 
A. Chemical structure of previously published HaloPROTAC3 (Buckley et al., 2015). B. New VHL 
inhibitors published by Ciulli lab (Galdeano et al., 2014; Frost et al., 2016). C&D. New 
HaloPROTAC compounds derived from phenyl position (C) or acetyl position (D) of VHL ligands. 
To determine the efficacy of each HaloPROTAC compound for degradation of HaloTag7 fusion 
proteins, I treated both SGK3-Halo and HaloVPS34 HEK293 cell lines with increasing 
concentrations of compound for 48h. This revealed that HaloPROTAC-E was the most potent 




structure-activity relationship of the compounds was very interesting, with 15/16 atom linkers 
much more potent than the longer chain versions. Additionally, as observed in Buckley et al, the 
more potent compounds derived the chloroalkane moiety from the phenyl position of the VHL 
ligand. Finally, adaptation of  the acetyl group to a cyclopropylcyanoacetic moiety in 
HaloPROTAC-E made it the most effective compound. This correlates with previous data that 
VH298, containing this cyclopropylcyanoacetic group is a much higher affinity ligand for VHL 
(Frost et al., 2016). 
 
Figure 5.12 Cellular characterisation of HaloPROTAC compounds. 
A. SGK3–Halo and Halo–VPS34 cell lines were treated for 48h with increasing concentrations of each 
HaloPROTAC in parallel. Degradation of target protein measured by Immunoblot analysis for HaloTag7. 
B&C.  Quantification of Western Blot intensity from A for SGK3–Halo (B) or Halo–VPS34 (C). Protein 




5.4 Mechanistic characterisation of HaloPROTAC-E 
It was important to fully characterise the kinetics and mechanism of degradation of 
HaloPROTAC-E. The above experiments demonstrated that HaloPROTAC-E mediated 
degradation was dose-dependent in HEK293 cells. I next demonstrated that degradation was 
time-dependent by treating SGK3-Halo and Halo-VPS34 cells with HaloPROTAC-E for up to 4 
hours and measuring degradation of the target protein by western blot (Figure 5.13A). This 
revealed rapid degradation of both target proteins. 50% degradation of SGK3 was achieved 
within 30-40 minutes, and VPS34 within 1-2 hours. The slightly delayed degradation of VPS34 
may be due to increased expression of VPS34 over SGK3, or due to the fact that VPS34 exists 
within a heterotetrameric complex. I also demonstrated HaloPROTAC-E mediated degradation 
to be reversible, as washout of the compound after 24h treatment resulted in rescued SGK3-
Halo expression within 10h, nearing complete rescue within 24h (Fig 5.13b). 
As in chapter 3, I used inhibitors of the ubiquitin-proteasome system to validate that this 
degradation occurred, as expected, via the CUL2VHL E3 Ligase complex and the proteasome. I 
pre-treated cells with various inhibitors of the pathway and measured blockade of HaloPROTAC-
E induced degradation. In addition to the MLN4924 and MG132 inhibitors described in chapter 
3, I also pre-treated cells with the VH298 high affinity, specific inhibitor of pVHL, recently 
published by the Ciulli lab (Frost et al., 2016). As expected, pre-treatment with these inhibitors 






Figure 5.13 Mechanistic characterization of HaloPROTAC–E. 
A. SGK3–Halo and Halo–VPS34 cells were treated for up to 4h with 300 nM HaloPROTAC–E. Cells were 
lysed and probed by Western Blot for HaloTag7 and quantified for percentage of remaining HaloTag7 
protein. B. SGK3–Halo cells were treated for 24h with 300 nM HaloPROTAC–E. After 24h, cells were washed 
3 times with DMEM and replaced with fresh media for the times indicated. Recovery of SGK3–Halo was 
analyzed by Immunoblot C.  Halo–VPS34 cells were treated for 6h with 300 nM HaloPROTAC–E, after pre–
inhibition of Cullin Neddylation by MLN4924 (3 M for 3h) or Proteasome by MG132 (50 M for 30 
minutes). Cells were lysed and remaining HaloTag7 fusion protein was analyzed by Immunoblot. D. SGK3–
Halo and HaloVPS34 cells were treated for 6h with 300 nM HaloPROTAC–E, after pre–inhibition of VHL by 
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SGK3 and VPS34 are both endosomally-localised, as demonstrated in Figure 5.4. It was of particular 
interest whether these proteins could be easily degraded on the endosome, or if they were degraded 
in the cytosol. I therefore treated SGK3-Halo HEK293 cells with HaloPROTAC-E in the presence or 
absence of the VPS34 inhibitor VPS34-IN1. Inhibition of VPS34 results in a reduction of endosomal 
PtdIns(3)P and translocation of SGK3-Halo to the cytosol. Therefore, studying the degradation rates 
of SGK3-Halo in the presence of absence of VPS34-IN1 revealed whether this protein was more 
rapidly degraded when diffuse in the cytosol. I observed no difference between these two conditions 
(Figure 5.14), suggesting SGK3-Halo can be degraded on endosomes. 
 
Figure 5.14 SGK3 is degraded when localised both on endosomes and in the cytosol. 
SGK3-Halo HEK293 cells were treated for up to 24 h with HaloPROTAC-E, with or without treatment with 
VPS34-IN1 (1 M). Cells were lysed and subject to immunoblot analysis with the indicated antibodies. 
It was important to directly compare our new compound HaloPROTAC-E to the previously 
published HaloPROTAC3 (Buckley et al., 2015). The publication reported a DCmax of 90% could 
be achieved 625nM HaloPROTAC3, however this was performed against exogenously expressed 
HaloTag7 protein. Both timecourse analysis and dose-response curves demonstrated an 






Figure 5.15 Comparison of HaloPROTAC–E to previously characterized HaloPROTAC3. 
A. Halo–VPS34 cells were treated in parallel for 24h with 1–1000 nM HaloPROTAC–E or HaloPROTAC3. 
Cells were lysed and remaining HaloTag7 fusion protein was analyzed by Immunoblot. B. Halo–VPS34 cells 
were treated for up to 4h with 300 nM HaloPROTAC–E or HaloPROTAC3. Cells were lysed and probed by 
Western Blot for HaloTag7, and quantified for percentage of remaining HaloTag7 protein. 
5.5 Global proteomic analysis for specificity of compound 
The global specificity of HaloPROTAC-mediated degradation has yet to be determined in the 
published literature. Therefore, to answer this, I performed a quantitative Tandem-Mass-
Tag(TMT)-labelled global proteomic analysis of Halo-VPS34 cells, treated in the presence or 
absence of 300nM HaloPROTAC-E for 4 hours. This experiment was undertaken in quadruplicate, 
and analysis in Proteome Discoverer v2.2 using Mascot search engine allowed relative 
quantification of 9786 proteins. This unbiased approach revealed that HaloPROTAC–E was 
remarkably selective. Halo-VPS34 was the most substantially and significantly degraded protein, 
with a 70% reduction in detected protein levels. The only other proteins with a significant 
reduction in protein levels were the known regulatory subunits of the VPS34 complex. VPS15 
(50%), Beclin1 (20%), ATG14 (30%) and UVRAG (15%) were all reduced to a statistically 
significant value (p<10-4) (Figure 5.16a). This exquisite selectivity is a clear advantage of the 
HaloPROTAC approach. This reduction in associated complex members has previously been 




al., 2016; Malik et al., 2018), and was confirmed by Immunoblot analysis (Fig 5.16b). As 
HaloPROTAC-mediated degradation offers temporal control, I next analysed whether expression 
of these components was lost in parallel to VPS34, or followed at a later timepoint due to loss 
of complex stability. Time course analysis of VPS34 degradation revealed that at very early time 
points of 10–20 minutes, VPS15 was reduced at a similar rate to VPS34, whereas the reduction 
in Beclin1 expression was slower (Fig 5.16c&d). 
 
Figure 5.16 Degradation of HaloTag7 fusions is highly specific and has a biological impact. 
A. Volcano plot quantifying proteins significantly downregulated on 4h HaloPROTAC–E treatment in Halo–
VPS34 cells. B. Immunoblot analysis of lysates taken for Mass Spectrometry analysis C&D. HaloVPS34 cells 
were treated with 0.3 M HaloPROTAC–E for up to 4 hours. C. Immunoblot analysis of these lysates for 
VPS34 complex members. D. Quantification of relative protein levels of VPS34 complex members from 
5.16C. 
5.6  Biological impact of HaloPROTAC-E mediated degradation of target 
proteins 
The advantage of combining a HaloPROTAC approach with CRISPR/Cas9 is that these tools can 
be deployed to investigate the endogenous roles of a protein. Additionally, this approach can 




targeted degradation. I therefore investigated known roles of SGK3 and VPS34, and the impact 
on these pathways by targeted degradation. 
Degradation of SGK3-Halo and Halo-VPS34 results in reduced phosphorylation of the SGK3 
substrate NDRG1. 
The best validated substrate of SGK3 is phosphorylation of NDRG1 at its Thr346 residue. This 
site is also shared with SGK1 and Akt. VPS34 acts upstream of SGK3, generating PtdIns(3)P on 
early endosomal membranes, triggering SGK3 activation. I chose to investigate whether 
degradation of Halo-VPS34 or SGK3-Halo was able to downregulate the hVPS34-SGK3 signaling 
axis and inhibit the phosphorylation of NDRG1. In order to remove the effect of Akt activity on 
NDRG1 phosphorylation, all conditions were performed in the presence of Akt inhibitor 
AZD5363. A timecourse analysis of HaloPROTAC-E mediated protein degradation revealed that 
degradation of both proteins induced dephosphorylation of NDRG1. Degradation of SGK3 
reduced NDRG1 phosphorylation within 4 h, whereas dephosphorylation of NDRG1 through 
VPS34 degradation took up to 24h (Figure 5.17). 
 
Figure 5.17 NDRG1 phosphorylation is reduced on degradation of SGK3-Halo and HaloVPS34. 
SGK3-Halo and Halo-VPS34 HEK293 cell lines were treated for up to 24h with HaloPROTAC-E to induce 
degradation of HaloTag7 target proteins. In the final hour before lysis, cells were treated with Akt inhibitor 
AZD5363 (1 µM). Phosphorylation of the SGK3 substrate NDRG1 at Thr346 was measured by western blot. 
in vitro studies of SGK3 activity had revealed a significant reduction in SGK3 kinase activity on 




NDRG1 phosphorylation is still mediated by SGK3 activity, and degradation of SGK3 reduces 
phosphorylation of its substrate.  
Degradation of HaloVPS34 marginally impacts on known VPS34 functions 
VPS34 is known to play a number of important roles in the cell. It catalyses the phosphorylation 
of PtdIns in order to produce PtdIns(3)P on endosomal membranes. This PtdIns(3)P is critical in 
the formation of authophagosomal vesicles in autophagy, and also the recruitment of PX 
containing effector proteins such as SGK3, stimulating its activation. I therefore used my Halo-
VPS34 cells to investigate whether degradation of VPS34 via HaloPROTAC-E has an impact on 
these biological readouts 
First, I used Halo-VPS34 KI cells to assay the activity of SGK3 on degradation of VPS34. Inhibition 
of this lipid kinase with VPS34-IN1 results in a substantial reduction in SGK3 activity, as 
PtdIns(3)P is reduced on endosomal membranes (Bago et al., 2014). I therefore compared SGK3 
activity in the immunoprecipitation assay described above, on inhibition or degradation of Halo-
VPS34. I also combined these treatments with the Class I PI3K inhibitor GDC0941 (0.5 µM), to 
remove the effect of SGK3 activation through the Class I PI3K pathway (Malik et al., 2018). I 
unveiled a slight, although statistically significant, reduction in SGK3 activity on HaloPROTAC-E 
treatment, however not as great an effect as seen on inhibition (Figure 5.18). This is in line with 
what was previously observed when degrading VPS34 via the AdPROM system (Fulcher et al., 





Figure 5.18 SGK3 activation in response to growth factors is marginally reduced by Halo-VPS34 
degradation. 
HEK293 Halo-VPS34 cells were treated with or without HaloPROTAC-E for 24 h, then serum-starved in 
empty DMEM overnight. Prior to stimulation with IGF-1 (50 ng/ml, 10 min), cells were treated with DMSO, 
GDC0941 (0.5 µM) or VPS34IN1 (1µM). SGK3 was immunoprecipitated from 3 mg lysate, and subject to  in 
vitro kinase assay against the Crosstide peptide, and incorporation of 32P -ATP measured. 1 unit of 
activity = incorporation of 1nmol -phosphate into substrate per mg lysate. Error bar = SD, n=3. Statistical 
analysis 2-way ANOVA with posthoc Tukey multiple comparisons test. 
However, a caveat of this assay is that long-term degradation of VPS34 (24 h degradation before 
16 h serum starvation), was being compared to short-term inhibition (1 h inhibition before IGF-




VPS34 degradation, and whether the cells react and compensate for loss of VPS34. I also 
performed this assay under basal conditions to remove the effect of growth factor stimulation 
of the Class I PI3K pathway. I observed that 1 h degradation of VPS34 caused an immediate 
reduction in SGK3 activity, but that this activity was then recovered after 24 h. Further, I 
observed that co-treating with VPS34-IN1 in the final hour before lysis was now unable to further 
reduce SGK3 activity (Fig 5.19). This suggests that a compensatory mechanism, perhaps via Class 
II PI3K or lipid phosphatases, may be responsible for this SGK3 activity, and that activity was 
being mediated independently of VPS34. 
 
Figure 5.19 After prolonged Halo-VPS34 degradation, SGK3 activity is not mediated by VPS34. 
HEK293 Halo-VPS34 cells were treated with or without HaloPROTAC-E for 1 or 24 h. Prior to lysis, cells 
were additionally treated with VPS34IN1 (1 µM) for 1 h. SGK3 was immunoprecipitated from 3 mg lysate, 
and subject to  in vitro kinase assay against the Crosstide peptide, and incorporation of 32P -ATP 
measured. 1 unit of activity = incorporation of 1nmol -phosphate into substrate per mg lysate. Error bars 




Given this response in SGK3 activity, I decided to assess the impact of HaloPROTAC-E mediated 
degradation of HaloVPS34 on production of endosomal PtdIns(3)P, as described in section 5.2 
(Figure 5.6). However, I only observed a very mild decrease in PtdIns(3)P on treatment with 
HaloPROTAC-E. Whereas in the SGK3 activity assay I observed a resistance to VPS34IN1 
treatment after degradation, when analysing PtdIns(3)P I could observe phospholipid levels 
were still sensitive to VPS34 inhibition after 24 h of degradation (Figure 5.20). Therefore, 
PtdIns(3)P production is still under the control of the remaining ~15% VPS34 in these cells.  
 
Figure 5.20 Production of PtdIns(3)P on endosomes is marginally decreased on Halo-VPS34 degradation. 
A. HEK293 Halo-VPS34 cells were seeded onto coverslips and allowed to adhere overnight. Cells were then 
treated for 1 or 24 h with HaloPROTAC-E and treated with or without VPS34IN1 (1 µM) 1h before lysis. 
Production of PtdIns(3)P on endosomal membranes was measured with the 2XFYVE-AlexaFlour488 




Aside from the activation of SGK3, VPS34 is more commonly associated with an important role 
in regulating autophagy. PtdIns(3)P production in response to, for example, nutrient starvation 
is critical for the formation of autophagosomes. I therefore chose to investigate the effect of 
Halo-VPS34 degradation has on autophagic flux. This can be measured by inducing autophagy 
by total nutrient starvation with EBSS, and blocking fusion of autophagosomes to lysosomes 
with the inhibitor Bafilomycin A (Ohkuma et al., 1993). Under these conditions, levels of 
lipidated LC3 can be measured by Western Blot, as a measure of autophagosomes formed. 
Under these conditions, I was able to observe a slight decrease in lipidated LC3 on HaloVPS34 
degradation, however not as much as was observed upon VPS34 inhibition by VPS34-IN1 (Figure 
5.21). More specifically, while basal autophagy appeared to be substantially inhibited, induction 
of high levels of autophagy by serum and amino acid starvation with EBSS could still occur after 
VPS34 degradation. However, as with the previous kinase assay, this assay was performed after 
24 h of VPS34 degradation, in comparison to short term inhibition. Therefore, this pathway may 
have been subject to compensatory mechanisms. If repeated at earlier timepoints, a greater 





Figure 5.21 Autophagic flux is mildly inhibited on degradation of Halo-VPS34. 
HEK293 HaloVPS34 cells were treated for 24h with DMSO or HaloPROTAC-E to induce degradation of 
VPS34. 2h before lysis, cells were washed twice with EBSS and media replaced with either DMEM or 
EBSS to induce autophagy. At this point, cells were treated with out without VPS34IN1 (1 µM) to 
inhibit VPS34, and Bafilomycin A (50nM) to block lysosome fusion of autophagosomes. Autophagic 
flux was measured by quantification of lipidated LC3b (lower band). 
5.7 Mutation of surface lysines of HaloTag7 does not significantly impact 
on the rate of degradation 
Proximity-driven ubiquitylation occurs on surface lysines of the target protein. In an attempt to 
increase the rate of ubiquitylation and therefore proteasome-mediated degradation of SGK3, I 
generated several mutant forms of SGK3-Halo, in which positive surface residues were mutated 
to extra lysines on the surface of HaloTag7. These residues were selected by inspection of the 




the surface which were predicted to tolerate mutation to lysine without altering the properties 
of the protein surface (Figure 5.22). I also investigated swapping the 5XGly Linker between SGK3 
and HaloTag7 to 5XLys, to see if this would increase proteasomal degradation further. These 
proteins were overexpressed in HEK293 FlpIn cells by 24 h doxycycline induction, then rate of 
degradation measured after up to 16 h treatment with HaloPROTAC-A. These experiments were 
performed with HaloPROTAC-A as the final HaloPROTAC-E compound had not yet been 
optimised at the time of performing the experiments. It would be interesting to repeat these 
experiments with HaloPROTAC-E and determine any differences with an optimised compound. 
The exchange of a 5XGly linker for 5XLys showed no significant increase in the rate of 
degradation (Figure 5.23), in fact early timepoints of degradation were marginally slower. The 
first set of mutations, summarised as ‘MUT1’ partially increased the rate of degradation, and 
total degradation achieved within 16 h. However, any further mutations did not increase the 
rate of degradation. These mutations may have destabilized the protein or impacted on its 





Figure 5.22 Design of HaloTag7 surface mutants. 
A series of  SGK3-Halo surface mutants were designed by Alessio Ciulli (BCDD), to increase lysine residues 
on the surface of the protein. Residues were selected based on the crystal structure of HaloTag7 (PDB: 





Figure 5.23 Addition of surface lysines to HaloTag7 does not significantly increase the rate of HaloPROTAC induced degradation. 
HEK293 FlpIn cell lines were produced expressing SGK3-Halo with a range of modifications, with the aim to induce more rapid degradation of SGK3-Halo protein. These changes 
included exchange of the 5XGly linker for 5XLys, and a series of surface mutations to decorate the protein surface with lysines to increase potential ubiquitylation. Expression 
of SGK3-Halo was induced with doxycycline (0.1 µg/ml) and degradation induced with HaloPROTAC-A for up to 16h. Degradation of SGK3-Halo was measured (A) and 





In this chapter, I present the design and synthesis of a new, potent HaloPROTAC compound, 
termed HaloPROTAC–E. More specifically I generated CRISPR/Cas9 KI cell lines of both SGK3 and 
its upstream regulator VPS34, and show that HaloPROTAC-E induces the rapid and efficient 
degradation of both target proteins. HaloPROTAC–E induced potent degradation, with a DC50 
between 3–10 nM. Both SGK3 (20–30 min for 50% degradation) and VPS34 (1–2 h for 50% 
degradation), which forms part of a complex, were rapidly degraded. A direct comparison 
revealed the HaloPROTAC compound described in this study was more effective than the 
previously reported compound HaloPROTAC3. The design and publication of HaloPROTAC-E is 
therefore an important addition to the field for the validation of potential PROTAC targets. As 
SGK3 and VPS34 are both endosomally localised, I have demonstrated in this study that the 
HaloPROTAC approach is capable of inducing degradation of both endosomally localised and 
cytosolic proteins. Treatment of SGK3-Halo cells with VPS34-IN1, to reduce endosomal 
PtdIns(3)P and move SGK3 to the cytosol, had no impact on the rate at which SGK3-Halo could 
be degraded. This is of great importance to the field as it demonstrates that subcellularly 
localised proteins can be targeted for degradation.  
The goal of this project was to target the HaloPROTAC approach towards endogenous proteins, 
and therefore manipulate an endogenous signalling pathway. Phosphorylation of the SGK3 
substrate NDRG1 at Thr346 was substantially reduced on degradation of either SGK3-Halo or 
Halo-VPS34. This demonstrated the ability of this approach to target endogenous proteins, and 
act as validation for the selection of target proteins for PROTACs or other chemical modulation 
approaches. Quantitative mass spectrometry studies also revealed that degradation mediated 
by HaloPROTAC-E is strikingly selective, not degrading any other proteins in the Halo-VPS34 cell 
line other than Halo-VPS34 itself and its known regulatory subunits. Again, this is a clear strength 
for the use of this approach in understanding and manipulating endogenous systems. It is 




stability of the complex upon VPS34 degradation, a hypothesis that is supported by previous 
siRNA knock–down data (Itakura et al., 2008). Alternatively, these subunits could be degraded 
through a “by–stander” effect, receiving collateral ubiquitination by the VHL ligase as a result of 
being part of the same complex (Maniaci et al., 2017). 
While NDRG1 phosphorylation was clearly impacted on degradation of SGK3-Halo and Halo-
VPS34, other biological readouts of VPS34 activity gave only marginal or conflicting results on 
degradation of Halo-VPS34. Only a mild reduction in autophagic flux, measured by production 
of lipidated LC3b, was observed after Halo-VPS34 degradation. It is possible that this milder 
effect may be due to the remaining VPS34 being sufficient to carry out necessary functions. 
Alternatively, compensatory pathways could be activated on degradation of VPS34, for example 
generating PtdIns(3)P from PtdIns(3,4,5)P3 via the lipid phosphatases INPP4B and SHIP2 (Malik 
et al., 2018). As VPS34 is an essential gene and cannot be knocked out at the genome level, 
relatively little is known about compensatory pathways which may occur in the absence of 
VPS34. A mechanism for inducible reduction in VPS34 expression in cells is therefore a very 
powerful tool. 
Similarly, after 24h degradation of Halo-VPS34, in vitro SGK3 kinase activity was only marginally 
reduced. This was also observed when constitutively degrading GFP-VPS34 using the AdPROM 
system, which resulted in only a mild reduction in SGK3 activity (Fulcher et al., 2016; Malik et al., 
2018). However, an advantage of the HaloPROTAC system is temporal control of protein 
expression, as degradation is both inducible and reversible. Using shorter HaloPROTAC 
treatments, I was able to demonstrate that short-term loss of VPS34 significantly reduced SGK3 
in vitro kinase activity, however after 24 h SGK3 activity was rescued, and could no longer be 
modulated by VPS34 inhibition. However, conflictingly, I also demonstrated by western blot that 
SGK3-mediated phosphorylation of NDRG1 is not rescued at this timepoint, and by 




explanation behind these apparently conflicting results is still unclear, and merits further 
investigation. Perhaps, SGK3 activated independently of PtdIns(3)P is incorrectly localised for 
phosphorylation of its substrate NDRG1. Alternatively, an autoinhibition mechanism may inhibit 
its activity in cells, but kinase activity can still occur in vitro. 
Because the chloroalkane handle reacts covalently with HaloTag7, a potential limitation of the 
HaloPROTAC approach is that stoichiometric occupancy of the tagged protein is required to 
achieve complete degradation of the target protein. A key advantage to PROTACs bearing non–
covalent target ligands is that they can function catalytically at sub–stoichiometric 
concentrations relative to the target protein. Despite the clear strengths of non–covalent 
protein degradation modalities, potent ligands are often required and structure–guided PROTAC 
design requires structural information on ternary complexes (Gadd et al., 2017). Even with this 
knowledge, many variables affecting efficacy of PROTACs are still not thoroughly understood, 
and are highly target dependent. The HaloPROTAC approach removes these issues, allowing for 
exquisite selectivity and high affinity. 
A caveat to the HaloPROTAC approach is the size of the required HaloTag7 fusion onto the target 
of interest. Such a large tag may interfere with the activation, complex formation or function of 
a target protein. This study demonstrates that both N- and C-terminal fusions can be degraded 
using HaloPROTAC-E, and the kinetics of degradation was similar for both proteins. Therefore, 
for most proteins with a regulatory terminal domain this issue can be avoided. However, the 
addition of a large 33kDa tag may impact on protein function and should always be evaluated. 
In the case of SGK3-Halo, we observed a significant reduction in its in vitro kinase activity on 
addition of the HaloTag7 fusion. This is likely due to the proximity of such a large tag to the 
critical hydrophobic motif activating residue, therefore blocking SGK3’s phosphorylation by 
mTORC2. As both the N- and C- terminus are critical for SGK3 activation, this has limited the 




that extending the linker between SGK3 and HaloTag7 began to rescue the activity of SGK3, 
however this was not followed up in this study. For this reason, I therefore continued with the 
approach described in Chapter 4, with the development of an inhibitor derived PROTAC against 
SGK3, which interacts with the protein directly in its kinase domain. This approach requires a 
more intensive optimization of compounds, however removes the caveats of placing a large tag 
on the protein. An advantage of having tried both approaches is that HaloPROTAC-E could be 
used to determine the specificity and any off-target effects of SGK3-PROTAC1, by treatment of 
SGK3-Halo cells with both compounds. Overall this optimized HaloPROTAC approach, combining 
HaloPROTAC–E with CRISPR/Cas9 mediated endogenous protein tagging, has been 
demonstrated to provide a useful tool to interrogate an endogenous system and validate the 




6. How is SGK3 activated in the context of PI3K Inhibition? 
6.1 Activation of SGK3 by Class I and Class III PI3K 
In common with other AGC protein kinases, SGK3 is activated by phosphorylation on its 
hydrophobic motif by mTORC2, and T-loop by PDK1. This activation has been demonstrated to 
also be dependent on the PX domain of SGK3, which recruits the kinase to PtdIns(3)P on 
endosomal membranes. In the case of Akt, this activation mechanism is dependent on the 
activity of Class I PI3K generating PtdIns(3,4,5)P3 on the plasma membrane. Recent work 
published by the lab has demonstrated that SGK3 can be activated by Class I PI3K, possibly 
through the action of lipid phosphatases INPP4B and SHIP2 (Malik et al., 2018), however it can 
also be activated by alternate mechanisms in the context of prolonged PI3K inhibition. Bago et 
al., demonstrated that SGK3 is activated by the activity of Class III PI3K VPS34, which generates 
PtdIns(3)P on endosomal membranes (Bago et al., 2014, 2016). Malik et al went on to 
demonstrate that activation via VPS34 could be stimulated by growth factors, similarly to Class 
I PI3K. However, the mechanism by which VPS34 is activated by growth factors in yet to be 
determined, as the paper demonstrated IGF stimulation did not increase in vitro kinase activity 
of VPS34, or the amount of VPS34 localised to endosomal membranes (Malik et al., 2018). 
Therefore, as part of my thesis I decided to investigate how VPS34 was activated by growth 
factors, and consequently activated SGK3. 
VPS34 exists in the cell in 2 complexes. The core VPS34 complex of VPS34, VPS15 and Beclin1 
can be found in complex I, with ATG14 on Rab7 containing membranes, commonly involved in 
nutrient sensing and autophagy. Alternatively, Complex II contains UVRAG in the place of ATG14 
and is found primarily on Rab5 containing membranes. A number of more transient accessory 
interactors bind to these complexes and modulate VPS34 activity. I was interested to determine 
whether complex composition of VPS34 was altered on growth factor stimulation, and whether 
interaction with known or unknown effectors may be altered on IGF1 stimulation, impacting on 




approach, TurboID, to selectively biotinylate and identify interactors of GFP-VPS34 , in the case 
of serum starvation or IGF1 stimulation. 
Bago et al. demonstrated that when cancer cell lines activate SGK3 in the context of PI3K 
inhibition, this activation still occurs via mTORC2, as demonstrated by shRNA experiments 
against the mTORC2 component Rictor which blocked SGK3 activation (Bago et al., 2016). Under 
these conditions, mTORC2-dependent phosphorylation of SGK3 is observed, but not of Akt, 
which remained dephosphorylated at S473. This finding suggested differential mechanisms by 
which SGK3 and Akt can be recognised and phosphorylated my mTORC2, which would be an 
important mechanism to understand in preventing PI3K-inhibitor resistance in breast cancer. 
It was recently proposed by Liu et al that mTORC2 activity was determined by the complex 
member mSin1, in particular the PH domain binding PI(3,4,5)P3 on the plasma membrane (Liu et 
al., 2015). However, under conditions of Class I PI3K inhibition, SGK3 was targeted by mTORC2 
independently of PtdIns(3,4,5)P3. I therefore chose to investigate how SGK3 phosphorylation by 
mTORC2 was regulated, and how this regulation differed from Akt. I also chose to focus on mSin1 
as a regulatory component of mTORC2 and generated various truncations and mutants of mSin1 
to determine which elements were required for activation of Akt and SGK3 respectively.  
6.2 PI3K-independent activation of mTORC2 mediated by mSin1 
6.2.1 SGK3 activation is mediated by mTORC2, and reliant on mSin1. 
I first aimed to generate CRISPR/Cas9 knockout of mSin1 in HEK293 TREx and U2OS TREx cells. 
The purpose of this was to remove endogenous mSin1, therefore any activity of mTORC2 should 
be mediated by the mSin1 mutants introduced to the cells via the Flp-In™ T-REx™, Doxycycline-
inducible system. Using the D10A Nickase form of Cas9 described in Chapter 5, mSin1 gRNAs 
were designed targeting Exon 5. As generation of gene knockouts occurs by non-homologous 
end joining (NHEJ) rather than homology driven repair (HDJ) a donor template was not required. 




therefore all isoforms of mSin1 should be affected. Using this approach, I generated 9 mSin1 KO 
clones in HEK293 TREx cells, and 3 knockout clones in U2OS TREx (Figure 6.1). The entire gel was 
analysed to ensure no expression of truncated forms of mSin1 remained. All U2OS clones and 4 
HEK293 clones were confirmed by Sanger sequencing. 
 
Figure 6.1 CRISPR/Cas9 KO of mSin1 from HEK293 TREx and U2OS TREx cells. 
CRISPR/Cas9-mediated knockout of mSin1 was performed in HEK293 TREx and U2OS TREx cells by sgRNA 
targeting exon 5 of the MAPKAP1 gene. Successful knockout clones were subject to immunoblot analysis 
with the given antibodies before confirmation by Sanger Sequencing. 
I first studied the mSin1 KO cells in comparison to parental cells to confirm that knockout of 
mSin1, and therefore loss of mTORC2 activity, blocks phosphorylation and activation of SGK3. I 
used 2 HEK293 mSin1 KO clones and performed a comparison with the parental cell line. Cells 
were serum starved overnight then stimulated with IGF1 for 10’ at 50 ng/ml. This revealed 
strong activation of SGK3 and an increase in its phosphorylation at T320 on stimulation with IGF 




Similarly, phosphorylation of Akt at S473 which is also modulated by mTORC2 was fully blocked 
by mSin1 KO, and phosphorylation of the shared substrate NDRG1 was significantly reduced, 
although could still be partially induced by IGF1 stimulation. 
 
Figure 6.2 CRISPR/Cas9 knockout of mSin1 in HEK293 ablates activation of SGK3 and phosphorylation 
of its activation site. 
Parental U2OS TREx cell lines and 2 mSin1 KO clones were serum starved overnight and stimulated with 
50 ng/ml IGF1 10 minutes before lysis. SGK3 activity was measured by immunoprecipitation of SGK3 from 
3 mg lysate and in vitro kinase assay against a peptide substrate. Lysates and eluted immunoprecipitated 
proteins were also subjected to immunoblot analysis using the antibodies specified. Error bars = SD, n=3. 
6.2.3 Development of tools to study hydrophobic motif phosphorylation of 
SGK3 
In order to robustly detect and study phosphorylation of SGK3 on its hydrophobic motif, it was 
necessary to develop a set of tools to assay this function. I first tested and optimised antibodies 
against both (a) Total SGK3 (S848D) and (b) the S486 hydrophobic motif site of SGK3 (LGF*SYAP) 
developed with MRCPPU Reagents and Services. As hydrophobic motif phosphorylation is 




vitro kinase activity as well as phosphorylation of its substrates in cells. In addition, I optimised 
(d) an in vitro mTORC2 kinase assay, by co-immunoprecipitating mTORC2 via HA-mSin1, to 
determine whether mSin1 mutations altered the ability of mTORC2 to phosphorylate SGK3 
directly in vitro, or just in cells. 
a. Total SGK3 antibody S848D 
One of my first tasks in the lab was to develop a new polyclonal antibody against SGK3. The aim 
was to produce an antibody which could detect SGK3 by western blot, and also 
immunoprecipitate it from cells. In order to obtain an antibody specific for SGK3 over the other 
isoforms, the antibody was raised against a peptide corresponding to the N-terminal PX-domain 
of SGK3 (Residues 1-130, DU2034, Figure 6.3A). I tested the specificity of 7 bleeds of the antibody 
for western blot by comparing 10 μg HEK293 WT lysate with 10 μg lysate from SGK3-KO HEK293 
cells. I determined from this assay that the 6th Bleed of the S848D antibody gave a very clean, 
specific signal, which was stronger than the previous S037D antibody (Figure 6.3B). 
I also tested the ability of all bleeds to immunoprecipitate SGK3. Immunoprecipitation of SGK3 
is critical for detection of SGK3’s activation sites, T320 and S486 phosphorylation, and in vitro 
kinase assays against a peptide substrate. For each bleed of the antibody, I immunoprecipitated 
from 3 mg HEK293 lysate using a ratio of 1 μg antibody to 1 mg lysate. I compared the ability of 
these antibodies to immunoprecipitate SGK3 to the previous S037D antibody and a pre-immune 
IgG antibody as a negative control. I determined that all bleeds of the antibody were capable of 
immunoprecipitating SGK3 and, although none of the antibodies were able to fully deplete SGK3 
from the supernatant, the best immunodepletion was again from the 6th bleed of S848D (Figure 
6.3C). In this experiment I blotted with the panSGK antibody from Sigma Aldrich and found that 
only SGK3 was pulled down over the other isoforms, as expected. I also performed an in vitro 
kinase assay as a quantitative measure of immunoprecipitation and to confirm 




similar readouts, with substantially better activity than S037D (Figure 6.3D). I therefore used 
bleed 6 of the S848D anti-SGK3 antibody for the rest of this project.  
 
Figure 6.3 Characterisation of SGK3 antibody S848D. 
A. S848D was raised against residues 1-130 covering the PX domain of SGK3. B. 7 bleeds of S848D were 
tested for their ability to detect SGK3 in 10 μg HEK293 lysate compared to an SGK3-KO control. C. 7 bleeds 
of S848D were tested for their ability to immunoprecipitate SGK3 from HEK293. D. in vitro kinase assay of 







b. Hydrophobic Motif antibody 
To understand regulation of hydrophobic motif phosphorylation of SGK3, an antibody to detect 
phosphorylation of this site is critical for the progress of the project. Previous work in the lab 
has used a SGK1 pSer422 antibody to study this site, as after immunoprecipitation of SGK3 this 
antibody can cross-react to detect SGK3 phosphorylation. However, the cross-reactivity is very 
weak for SGK3, therefore this signal is not robust or reliable to assay hydrophobic motif 
phosphorylation. I therefore tested several antibodies against this site in order to generate a 
more robust readout of SGK3 phosphorylation. 
I first tested 2 commercial antibodies, 1 SGK1 pS422 antibody from Abcam, and a PDK1-docking 
motif antibody from Cell Signalling Technology. This PDK1-Docking motif antibody is designed to 
recognise the hydrophobic FXXpS/TY/F motif which docks into the PIF-Pocket of PDK1. I tested 
the ability of these antibodies to detect SGK3 phosphorylation after serum starvation, 
stimulation of SGK3 phosphorylation with IGF1 and blockade of SGK3 phosphorylation by 
treatment with mTOR inhibitor AZD8055. In parallel, I also overexpressed SGK3 and stimulated 
with IGF as a positive control. Testing these antibodies against either 10 μg lysate or after 
immunoprecipitation of SGK3 from 3 mg lysate, I determined that these antibodies detected 
overexpressed, phosphorylated SGK3, but not the endogenous protein (Figure 6.4). 
While the commercial antibodies were able to detect phosphorylation of overexpressed SGK3, I 
was interested in this project in analysing phosphorylation and activation of the endogenous 
protein. I therefore generated an antibody with MRCPPU Reagents and Services raised against 
the Hydrophobic motif site of SGK3. Antibody SA517 was raised against the sequence indicated 
in the sequence alignment below (Figure 6.5). In order to generate the antibody, 2 immunogenic 







Figure 6.4 Commercial antibodies tested do not recognise S486 phosphorylated endogenous SGK3. 
HEK293 cells were serum starved overnight, before stimulation with 50 ng/ml IGF1 for 15 minutes before 
lysis. mTORC2 activity was modulated by treatment with and without mTOR inhibitor AZD8055 (0.1 μM, 
1h) and IGF1 stimulation (50 ng/ml, 10 min). Ability of antibodies to detect immunoblot was tested from 
10 μg lysate or after a 3mg IP of SGK3. 
 
 
Figure 6.5 Sequence alignment of the SGK1 and SGK3 hydrophobic motif sites. 
Antibody SA517 was raised against the residues indicated in the alignment. 
The resultant antibody was then purified using either the N-terminally tagged Peptide A or the 
C-terminally tagged Peptide B. In order to determine the sensitivity and selectively of these 
antibodies, I first tested their ability to recognise overexpressed SGK3. As before, I serum starved 
cells overnight, then stimulated SGK3 phosphorylation by addition of IGF1, in the presence or 
absence of an mTOR inhibitor. Figure 6.6 shows the results for Bleeds 1 and 5. Antibodies were 
dissolved to 1 μg/ml in the presence of 10 μg/ml non-phosphorylated peptide. While all bleeds 
of the antibody were able to detect overexpressed SGK3, this detection was found not to be 





Figure 6.6 SA517 recognises overexpressed SGK3, however is not phosphospecfic. 
SGK3 was exogenously overexpressed in HEK293 cells for 24 h. Following transfection, cells were serum 
starved overnight before treatment with or without mTOR inhibitor AZD8055 (0.1 μM, 1 h) and IGF1 (50 
ng/ml, 10 min). Lysates were subject to immunoblot analysis with the indicated antibodies. SGK3 pS486 
antibodies were incubated with 10 μg/ml non-phosphorylated peptide corresponding to the phosphosite. 
It was possible that this lack of phosphospecificity was due to the large amounts of protein being 
detected, masking a phospho-specific signal. I therefore used the best antibody from this screen, 
Bleed 1 purified by peptide B, to probe the phosphorylation of endogenous SGK3. In this 
experiment I found that, even after immunoprecipitation, this antibody was unable to detect 






Figure 6.7 SA517 does not recognise endogenous phosphorylated SGK3. 
Endogenous or exogenously overexpressed SGK3 was immunoprecipitated from HEK293 cells, which had 
been starved of serum for 16 h. Before lysis, cells were treated with or without mTOR inhibitor AZD8055 
(0.1 μM, 1 h) and IGF1 (50 ng/ml, 10 min). Immunoprecipitated SGK3 and whole cell lysate were subject 
to immunoblot analysis with the antibodies shown. 
c. Substrate phosphorylation 
Another readout for studying the activation of SGK3 is through analysing phosphorylation of its 
substrates. NDRG1 phosphorylation at Thr346 has been extensively used in our lab as a readout 
of SGK3 phosphorylation, however use of this substrate is complicated by the fact NDRG1 




a readout in my assays however this will be confounded by Akt-driven phosphorylation. As 
described in Chapter 4, two members of the Syntaxin family, STX7 and STX12 appear to be 
specifically phosphorylated by SGK3, and PostDoc Athanasios Karapetsas has developed a robust 
PhosTag assay for detection of Syntaxin phosphorylation (Malik et al., 2019). This assay will 
provide a useful tool in assaying SGK3 activity, and therefore hydrophobic motif phosphorylation, 
and will be used in future assays. In addition, a phospho-specific antibody for detection of STX12 
phosphorylation by SGK3 is in development. I also measure in vitro kinase activity of SGK3 
against a peptide substrate Crosstide after immunoprecipitation from cells. 
d. mTORC2 in vitro kinase assay 
In order to determine whether mSin1 variations impacted on the ability of mTORC2 to 
phosphorylate SGK3, SGK1 or Akt in vitro, I developed an in vitro mTORC2 kinase assay via 
immunoprecipitation of HA-mSin1 constructs and incubation with recombinantly expressed 
substrate SGK3, SGK1 and Akt protein. 
To produce recombinant substrate protein, I expressed GST-tagged kinase inactive (KI) SGK3, 
Akt and SGK1 in HEK293 cells. Kinase inactive constructs were chosen to remove the chance of 
autophosphorylation of the site in in vitro conditions. To ensure full dephosphorylation of the 
hydrophobic motif site, I serum starved cells overnight and treated with mTOR inhibitor 
AZD8055 for 1 h before lysis. By GST purification I was able to produce large amounts of 





Figure 6.8 Substrate purification of GST-SGK3, GST-Akt and GST-deltaN SGK1. 
Kinase-inactive (KI) GST-SGK3, GST-Akt and GST-(60-end)-SGK1 were transiently expressed in HEK293 cells. 
24 h after transfection, cells were serum starved overnight, and treated with mTOR inhibitor AZD5363 (0.1 
μM, 1 h) before lysis, to remove any hydrophobic motif phosphorylation of the substrate protein.  
I then used Akt as a positive control substrate and was able to robustly detect phosphorylation 
of Akt after immunoprecipitation from HA-mSin1 cells, but not the mSin1 KO cells, as expected. 
This in vitro phosphorylation was also blocked by mTOR inhibitor AZD8055 (Figure 6.9A). 
Phosphorylation of Akt could be specifically detected by both the specific Akt p473 antibody and 
the pPDK1-Docking Motif antibody (Figure 6.9A). 
Using these same conditions against substrate SGK1 and SGK3, I was again able to produce 
specific phosphorylation of substrate protein at the hydrophobic motif site, as measured by the 
SGK1 p422 antibody from Sigma Aldrich. Unfortunately, the pPDK1-Docking Motif antibody 
displayed poor recognition of the phosphorylated SGK isoforms, and therefore could not be used 
as a readout for all substrate proteins (Figure 6.9B). However, it was evident from this 
experiment that detection of SGK3 phosphorylation with the pSer422 antibody was very weak, 
so I therefore optimized these blotting conditions and determined that a 1:1000 dilution of the 




phosphorylated SGK1 was better detected using a 1:2000 dilution of the antibody against 10ng 
substrate protein (Figure 6.9C).  
 
Figure 6.9 Development of an mTORC2 in vitro kinase assay. 
A. mTORC2 immunoprecipitated from HA-mSin1 expressing cells phosphorylated substrate Akt in vitro. B. 
in vitro kinase assay against SGK3 and SGK1 C. Optimisation of antibody concentration and protein loading 
for specific identification of substrate phosphorylation 
6.2.4 Reintroduction of mSin1 variants 
I next proceeded to generate a series of stable cell lines expressing mSin1 variants (described in 
Fig 6.10) from a doxycycline-inducible promotor in the TREx mSin1 KO cells. Information from 
these cell lines could determine the ability of mSin1 variants to activate mTORC2 against SGK3 
or Akt and therefore determine the functional role of different regions of mSin1.  
Several functional domains have been annotated within the sequence of mSin1, as shown in 
figure 6.10. Incorporation of mSin1 into mTORC2 is mediated by the N-terminal sequence (Yao 
et al., 2017). Evolutionary sequence analysis also revealed a Raf-like Ras-binding domain, with 




membrane and lipid binding (Schroder et al., 2007). The Conserved Region in the Middle (CRIM) 
domain is less well characterised, but may play a role in mTORC2 substrate recognition (Tatebe 
et al., 2017). 
I first introduced the 5 known transcript variants of mSin1. If activation of SGK3 in the absence 
of PI3K is mediated by mSin1, one naturally occurring form of mSin1 would theoretically be 
responsible. These transcript variants are shown in Figure 6.10. The most highly expressed 
variants of mSin1 are the full length TV1 and TV2, which contains a small deletion in the RBD. 
TV3-5 are less commonly expressed. All variants except TV4 are believed to be able to form a 
complex with mTORC2, whereas TV4 lacks the N-terminal domain critical for binding the 
complex. TV5 carries a C-terminal variant which lacks the PH domain proposed to be critical for 
activity of mTORC2 (Liu et al., 2015). 
I also generated point mutations and truncations designed to disrupt the RBD and PH Domain. 
The point mutations in the mSin1-PHmut construct are R393C K428A K464A, as described in Liu 
et al., 2015. These residues were predicted by modelling against the PH domain of Akt to disrupt 
binding to PtdIns(3,4,5)P3. The mSin1-RBD mutant sequence carries an R312L mutation, which I 
designed by sequence alignment and homology to the R89L inactivating mutant of cRAF (Zeng 





Figure 6.10 Transcript variants and mutants of mSin1 used in this study. 
Variants were incorporated in TREx cells with a C terminal HA tag. 
Figure 6.11 shows  the re-expression of these constructs under the doxycycline-inducible system 
in the U2OS mSin1 KO clone P1E7. With the exception of Transcript Variant 4 (TV4) which does 
not incorporate into mTORC2, all variants rescued turn motif phosphorylation of Akt, which 
occurs cotranslationally and is not under the control of growth factor signalling. I proceeded to 
use these cell lines to perform initial assays to survey the effects of each of the variants and 
mutants on SGK3 and Akt phosphorylation. 
As an initial screen of these mSin1 variants, and their ability to mediate phosphorylation of Akt 
and SGK3, all cell lines were stimulated with IGF1 following serum starvation and assayed for 
SGK3 kinase activity and Akt Hydrophobic motif phosphorylation (Figure 6.12).  This screen 
revealed a number of interesting results for further investigation. The full-length variant TV1 
and near-full length TV2 both showed activity comparable to the parental cell line. As expected 




with previous published data suggesting TV4 cannot integrate into an active mTORC2 complex 
as this occurs through the N-terminus of mSin1. 
 
Figure 6.11 Doxycycline-induced re-expression of mSin1 variants in U2OS mSin1 KO cells. 
Stable cell lines were generated to express mSin1 variants under a doxycycline-inducible promotor. Cells 
were stimulated in the presence or absence of 0.1 μg/ml Doxycycline for 24 h, and after lysis were subject 






Figure 6.12 Reexpression of mSin1 in KO cells rescues phosphorylation and activation of SGK3. 
The mSin1-HA variants were expressed in mSin1-KO U2OS cells by induction with 0.1 μg/ml Doxycycline. 
These cells, alongside parental (P) and mSin1-KO (KO) cells were serum starved overnight, before 
stimulation with or without IGF1 and cell lysis. SGK3 was immunoprecipitated from 3 mg lysate for in vitro 
kinase assay against Crosstide substrate, and immunopreciptates and whole cell lysate subject to 




Previous data from, for example Liu et al, suggested that the PH domain of mSin1 is critical for 
mTORC2 activity against Akt, and that this activity is mediated via PI(3,4,5)P3. However, in this 
assay, both Akt and SGK3 could be partially activated by the PH-domain deletion and binding-
mutant mSin1 cell lines, although not to the same extent as the full-length version. This suggests 
that a second mechanism aside from the PH domain may play a secondary role in Akt/SGK3 
activation. Another interesting result was that both TV3 and TV5 mSin1 were able to mediate 
activation of Akt, but not SGK3, suggesting a differing mechanism of substrate recognition of 
SGK3 and Akt by mTORC2. 
6.2.5 Full length mSin1 does not fully reactivate SGK3 
Although the initial screen using these cells revealed full phosphorylation and activation of SGK3, 
in this assay TV1 was very highly expressed in comparison to the parental cell line and many of 
the other mSin1 variants. In figure 6.13, I repeated this assay with expression of mSin1 
normalised to parental expression. I determined in this assay that full length mSin1 only partially 
rescues the phosphorylation and activation of SGK3. I also repeated this assay in 2 independent 






Figure 6.13 Reexpression of full length mSin1 does not fully rescue SGK3 phosphorylation in mSin1 
knockout cells. 
Full length mSin1-HA (mSin1-TV1) was expressed in mSin1-KO U2OS cells by induction with 0.1 μg/ml 
Doxycycline. These cells, alongside parental (P) and mSin1-KO (KO) cells were serum starved overnight, 
before stimulation with or without IGF1 and cell lysis. Endogenous SGK3 was immunoprecipitated from 3 
mg lysate for in vitro kinase assay against Crosstide substrate, and immunopreciptates and whole cell 





Figure 6.14 In 2 HEK293 mSin1 KO clones, re-expression of mSin1 only partially rescues the phenotype. 
Full length mSin1-HA (mSin1-TV1) was transiently overexpressed in 2 independent mSin1-KO HEK293 cells. 
These cells, alongside parental (P) and the relevant mSin1-KO (KO) cells were serum starved overnight, 
before stimulation with or without IGF1 and cell lysis. Endogenous SGK3 was immunoprecipitated from 3 
mg lysate for in vitro kinase assay against Crosstide substrate, and immunopreciptates and whole cell 
lysate subject to immunoblot analysis with the antibodies indicated. Error bars = SD, n=3 
However, I determined that when expressing mSin1-TV2 in these cells, SGK3 phosphorylation 
and activity was fully rescued. Interestingly, I also saw full rescue of activity from the mSin1-RBD 
binding mutant. This is interesting as mSin1-TV2 differs from the full length transcript of mSin1 
through a short deletion within the RBD. As mutation of this domain has the same effect on 
activity, this therefore suggests this region of the protien is important in regulating SGK3 
phosphorylation and activation. 
However, a caveat to this experiment is that both TV2 and RBD expressed much higher than 
parental levels and TV1 expression, and therefore cannot be directly compared. Akt rescue is 
also deficient in TV1 in this experiment but not rescues in Figure 6.13 and 6.14. Experiment 
ought to be repeated with equalised expression. An alternative to avoid unequal expression 






Figure 6.15 TV2 and RBD fully rescues SGK3 phosphorylation and activity. 
The indicated mSin1-HA variants were transiently overexpressed in mSin1-KO HEK293 clone P1A2. These 
cells, alongside parental (P) and mSin1-KO (KO) cells were serum starved overnight, before stimulation 
with or without IGF1 and cell lysis. Endogenous SGK3 was immunoprecipitated from 3 mg lysate for in vitro 
kinase assay against Crosstide substrate, and immunopreciptates and whole cell lysate subject to 




6.2.6 How is the mSin1 PH domain impacting on phosphorylation of SGK3. 
In my initial screen (figure 6.12) I identified that, although reduced, SGK3 and Akt 
phosphorylation and activation could still occur upon mutation or deletion of the mSin1 PH 
domain. This is in contradiction of previous literature (Liu et al, 2015), which proposed that PH 
domain binding to PtdIns(3,4,5)P3 was critical for activity of mTORC2 against Akt. I therefore 
repeated expression of mSin1-TV1, mSin1-PHdel and mSin1-PHmut in U2OS mSin1 KO cells to 
validate the result. Again, I found that, although phosphorylation was impacted, SGK3 
phosphorylation and activation could still occur. Conversely, Akt phosphorylation at its Ser473 
site was relatively unaffected (Figure 6.16). 
In this and future experiments, I also measured phosphorylation of mSin1 at T86 using a 
phospho-specific antibody. The role of this phosphorylation site is unclear, it lies within the 
canonical RxRxxS/T motif, and has previously been associated with positive feedforward 
phosphorylation by Akt or negative feedback regulation by S6K1 in different cell types (Liu et al., 
2014; Humphrey, Azimifar and Mann, 2015; Yang et al., 2015). I therefore was interested in any 
association with this phosphorylation site and SGK3 phosphorylation and activation downstream 
of mTORC2. In this experiment, I observed that T86 phosphorylation was reduced in the PH-
domain mutation and deletion mutants, which were deficient in SGK3 activation, despite fairly 
equal expression of mSin1. 
As these mutants are deficient for phosphorylation of SGK3 in cells, I decided to study the effect 
these mutations had on mTORC2 function in vitro. I therefore immunoprecipitated the same 
mSin1-HA variants from cells and performed an in vitro mTORC2 kinase assay against SGK3. In 
this in vitro assay, mTORC2 immunoprecipitated by these constructs showed no defect in 








Figure 6.16 PH deletion and mutation constructs still maintain partial activity against SGK3 and Akt. 
Full length mSin1 (TV1) and PH-domain deletion and mutation variants were re-expressed in mSin1 KO 
U2OS cells. SGK3 was immunoprecipitated from cells and assayed for its in vitro kinase activity, alongside 






Figure 6.17 PH deletion and mutation have no effect on ability of mTORC2 to phosphorylate SGK3 in 
vitro. 
mTORC2 was immunoprecipitated from mSin1 KO cells expressing full length (mSin1-TV1), or PH-domain 
deletion and mutation variants. Immunopreciptates were assayed against recombinantly expressed SGK3 
in an in vitro kinase assay. The resulting protein was blotted for phosphorylation on its hydrophobic motif. 
Immunoprecipitates from mSin1 KO cells not expressing mSin1-HA and mTOR inhibitor AZD8055 were used 
as negative controls 
6.2.7 How is the mSin1 Ras Binding Domain (RBD) impacting on activation of 
SGK3? 
Given that PH-binding deficient variants of mSin1 were still able to partially lead to 
phosphorylation of SGK3, I next tested whether this deficiency could be compensated for the 
Ras Binding Domain (RBD) of mSin1. Therefore, I generated a double mutant cell line carrying 
both the PH-binding point mutations and mutation of the Ras Binding Domain. Unexpectedly, 
instead of this second mutation further inactivating mTORC2 and reducing SGK3 activation, I 
discovered a recovery of activity upon inactivation of the RBD (Figure 6.18). This therefore 
suggests that the RBD may be a negative regulator of SGK3 phosphorylation by mTORC2 and 
warrants further investigation. Additionally, it will be interesting to measure the effect of PH-
domain mutations in mSin1 TV2, which carries a deletion of the Ras Binding Domain. It is possible 
that, without the Ras binding activity, TV2 is not reliant on the PH domain and is therefore not 
subject to PtdIns lipid regulation and may therefore be responsible for activation of SGK3 in the 
absence of Class I PI3K activity. Sequence analysis predicted the RBD of mSin1 to be a Raf-like 
RBD, which is able to bind to bind to activated Ras (Schroder et al., 2007). It has been previously 






Figure 6.18 Reexpression of TV1,PHmut and PH/RBD double mutant in mSin1 KO cells. 
U2OS mSin1 KO cells reexpressing mSin1 under a doxycycline-inducible system were analysed for their 
ability to activate SGK3. mSin1_TV1, mSin1_PHmut and mSin1_PHmut/RBDmut were expressed, cells were 
serum starved overnight and stimulated with 50 ng/ml IGF1 for 15 minutes, in the presence or absence of 
Akt inhibitor MK2206. SGK3 activity upon IGF1 stimulation was measured by immunoprecipitation and in 
vitro kinase assay. Error bars = SD, n=3 
Again, in this experiment I observed that T86 phosphorylation was reduced in the PHmut form 




with the Akt inhibitor MK2206 reduced T86 phosphorylation in these cells, suggesting in U2OS 
T86 is a substrate of Akt, and may mediate the observed downregulation of SGK3 activity in 
these cells upon MK2206 treatment. 
 
6.2.8 What is the significance of mSin1 T86 phosphorylation? 
As mentioned above, I observed in several experiments that phosphorylation of Thr86 of mSin1 
was substantially reduced in variants of mSin1 which are less able to induce phosphorylation of 
SGK3. This site lies within the canonical RxRxxS/T motif, and has previously been proposed to be 
phosphorylated by Akt and S6K1 in different cellular contexts (Liu et al., 2014; Humphrey, 
Azimifar and Mann, 2015; Yang et al., 2015). While I could observe a defect in phosphorylation 
of this site, it could not be determined from this data whether T86 phosphorylation was a 
necessary upstream regulator for SGK3 phosphorylation or was itself a substrate of SGK3. 
In order to answer these questions, I have generated cell lines expressing both mSin1-TV1 and 
mSin1-TV2 carrying T86A and T86E mutations. In future work it will be important to use these 
cell lines in order to study the effect of these mutations on SGK3 phosphorylation and whether 
T86 phosphorylation was required for activity. 
I additionally studied phosphorylation of mSin1 downstream of SGK3, by inducing SGK3 activity 
in ZR-75-1 cells with 5 day Akt inhibitor treatment (MK2206, 1 μM). As described in previous 
chapters, prolonged treatment of ZR-75-1 cells with MK2206 results in a transcriptional 
upregulation and activation of SGK3, and the protein kinase can substitute for Akt activity in the 
phosphorylation of substrates. 
Under basal and prolonged inhibitor conditions, I treated cells for 1 h before lysis with the 
MK2206 (1 μM) or the SGK inhibitor 14H. In basal conditions, as in the U2OS cells, treatment 
with the Akt inhibitor reduced phosphorylation of mSin1 at T86. However, treatment with the 




phosphorylated by SGK3 under these conditions. Upon 5 day treatment with MK2206, 
phosphorylation of mSin1 and the common substrate NDRG1 was recovered. Under these 
conditions I observed that Sin1 phosphorylation was not reduced by treatment with SGK3 
inhibitor 14H, whereas SGK3 substrate NDRG1 phosphorylation was affected (Figure 6.19). 
Therefore, mSin1 is likely not a direct substrate of SGK3. It would be of interest to further 
characterise this phosphorylation site in future work, to determine its relevance to 
phosphorylation and activation of SGK3 by mTORC2. 
 
Figure 6.19 mSin1 phosphorylation is not downstream of SGK3 in Akt inhibitor-induced ZR-75-1 cells. 
ZR-75-1 cells were treated for 5 days in the presence or absence of Akt inhibitor MK2206 (1 μM). 1 h before 
lysis, cells were treated with MK2206 (1 μM) or SGK3 inhibitor 14H ( 1 μM). Cell lysates were subject to 
immunoblot analysis with the indicated antibodies. 
6.2.9 Q68H mutation has no effect on SGK3 activation 
It has previously been reported that a Q68H mutation in mSin1 completely ablates 
phosphorylation of SGK1 but not Akt (Lu et al., 2011).This was proposed to be due to a direct 
interaction with SGK1 via this residue determining substrate specificity. I was therefore very 




mTORC2. I introduced this mutation in full length mSin1 and tested the ability of this construct 
to mediate SGK3 phosphorylation at S486 in comparison to mSin1-TV1 and mSin1-PHmut as a 
negative control. Immunoprecipitation and immunoblot of SGK3 for the T320 and S486 sites 
revealed no defect in phosphorylation of SGK3 upon Q68H mutation (Figure 6.20). 
 
 
Figure 6.20 Q68H mutation does not impact on hydrophobic motif phosphorylation of SGK3. 
A. Domain structure of Q68H and PH domain mutants of mSin1. B. Full Length (TV1), Q68H mutant and 
PH-domain mutant mSin1 were transfected into mSin1 KO cells. Cells were serum starved overnight then 
stimulated with IGF-1 (50 ng/ml). SGK3 was immunoprecipitated and blotted for S486 and T320 
phosphorylation. 
6.2.10 Localisation of mSin1 in U2OS 
I was interested to determine the cellular localisation of various mSin1 transcripts. Further, 




and inhibition of the PI3K signalling pathway. It was hypothesised that different variants or 
mutants of mSin1 may alter SGK3 activation by changing localisation of mTORC2 in the cell. It 
has been reported that mSin1 is localised to the plasma membrane, through binding of its PH 
domain to PtdIns(3,4,5)P3 generated in response to growth factors. I therefore expressed 
different transcript variants of HA-mSin1 and stained by immunofluorescence for HA and 
costained using Wheat Germ Agglutin (WGA) conjugated to Alexa Fluor 594 to identify the 
plasma membrane. mSin1 stably expressed in the TREx system revealed mSin1 to be largely 
cytoplasmic, with some localisation to the plasma membrane and intracellular vesicles (Figure 
6.21). This is in agreement with Ebner et al, who studied the localisation of GFP-tagged mSin1 in 
cells, and similarly determined that mSin1 was localised to the cytoplasm and endosomal 
vesicles. Transcript Variant 5 (TV5), which lacks a PH domain, was discovered to be primarily 
localised in the nucleus. It would be interesting to continue this analysis of the PH-domain 
mutant constructs, as presumably these mutations would affect cellular localisations. Further, 
mutation of the Ras Binding Domain or the T86 phosphorylation site may also have an impact 
on cellular localisation. 
As mSin1 Transcript Variant 2 (TV2) and others presented possible localisation to intracellular 
vesicles, I decided to study colocalization with early endosomal marker Rab5. In this experiment, 
I used a freeze-thaw method of permeabilization to remove cytosolic protein and therefore only 
membrane-bound proteins remained in the sample. I determined that HA-mSin1 did localise to 
internal membranes, however surprisingly did not colocalise with the Rab5 marker as expected 
(Figure 6.22). It would therefore be important to continue this analysis with further markers of 
internal membranes, such as EEA1 as another early endosomal marker, Rab7 as a late 
endosomal marker, as well as mitochondrial and lysosomal trackers. Surprisingly, the full length 





Figure 6.21 mSin1 variants are cytosolically diffuse through throughout cell. 
mSin1 transcript variants were expressed under a Doxycycline-inducible system in U2OS cells. Localisation of mSin1 was analysed by immunofluorescence and compared to 





Figure 6.22 mSin1 Transcript variants localised to intracellular membranes, which do not colocalise with Rab5. 
mSin1 transcript variants were expressed under a Doxycycline-inducible system in U2OS cells. Cells were subject to freeze-thaw permeabilization to remove diffuse cytosolic 





Additionally, these analyses were undertaken under basal signalling conditions. It would be 
interesting to use this assay to determine how localisation of various mSin1 variants differ upon 
stimulation with growth factors or inhibition of the PI3K pathway. 
Despite some information on subcellular localisation of cells, a large proportion of the mSin1 
protein was cytoplasmic. This is in agreement with previous literature (Ebner et al., 2017). If 
mTORC2 is present and active all over the cytoplasm, these localisation differences may not be 
as important. However, as this study, and previous literature, was performed using 
overexpressed proteins, it may be the case that this cytoplasmic localisation is an artefact of this 
overexpression system. However, during amino acid starvation mTORC1 is diffuse in the cytosol 
(Laplante and Sabatini, 2012; Jewell, Russell and Guan, 2013), therefore this may also be true of 
mTORC2. I have therefore generated endogenous GFP knockins to Rictor and mSin1 by 
CRISPR/Cas9 to investigate endogenous localisation in future work. 
6.3 Activation of VPS34 by growth factors 
6.3.1 Proximity-driven Biotinylation to identify interactors of VPS34 upon IGF1 
stimulation.  
Co-immunoprecipitation has been extensively used for identification of interactors of a protein 
of interest for decades. In this approach, a target protein is subject to immunoprecipitation and 
any co-eluting proteins measured by western blot or by mass spectrometry analysis. This 
powerful technique has led to a number of important discoveries and enhanced our 
understanding of major protein complexes such as mTOR and identification of high affinity 
binding protein kinase substrates. However, a caveat to this approach is that co-
immunoprecipitation relies upon a stable, high affinity interaction with effectors, as more 
weakly associated, transient interactors may not immunoprecipitate with the target protein, or 
may be lost through extensive wash steps during the purification process. Therefore recently, 
Proximity-based Biotinylation techniques, such as BioID, APEX2 and TurboID, have been 




interacting proteins (Burke et al., 2013; Han et al., 2017; Branon et al., 2018). These approaches 
work by either endogenously expressing a target protein in tandem with a biotin ligase or 
expressing a biotin ligase targeted to the endogenous target protein by, for example, a GFP tag 
(Branon et al., 2018). In this approach, activation of the biotin ligase, in proximity to the target 
protein, leads to biotinylation of any nearby, interacting proteins. Biotinylated proteins can then 
be isolated by streptavidin pulldown and identified by mass spectrometry. This approach has an 
advantage over classical co-immunoprecipitation for identification of interactors, as more 
transient interactors can be permanently biotinylated and identified, rather than relying upon a 
stronger, high affinity interaction.  
The hypothesis of this study was that, upon stimulation with growth factors, a transient change 
in VPS34 complex members could occur to increase the capability of VPS34 to phosphorylate 
PtdIns. The APEX2 approach allows for rapid labelling of interacting proteins within 1 minute, 
however is reliant upon Biotin phenol and requires activation with H2O2 (Han et al., 2017). This 
approach was unsuitable for study of VPS34, as previous work as shown that H2O2 leads to 
inhibition of lipid phosphatases and significantly alters proteins on the plasma membrane within 
1 minute (Cheung et al., 2007).  BioID uses Biotin as a substrate and does not require hydrogen 
peroxide for activation, however the labelling kinetics are very slow, requiring 18-24 hrs and are 
not suitable for dynamic processes such as VPS34 activation (Burke et al., 2013). TurboID was 
recently developed through targeted evolution as an optimized biotin ligase, with the simplicity 
of BioID, but with decreased labelling times. I therefore chose this technique for studying any 
rapid changes in VPS34 complexes in response to growth factors. 
I therefore generated cell lines stably expressing TurboID biotin ligase targeted against GFP-
tagged VPS34. I could therefore then stimulate these cells in the presence or absence of IGF1, 





Figure 6.23 VPS34 Complexes in cells. 
VPS34 is found in 2 stable complexes in cells. Both complexes contain VPS34, VPS15 and Beclin1, while 
complex I is formed with ATG14L and complex II is formed with UVRAG. Other transiently binding proteins 
interact with these complexes to modulate VPS34 activity. 
 
 
Figure 6.24 TurboID Mechanism of action. 
TurboID Biotin ligase is targeted to the substrate GFP-VPS34 by an anti-GFP nanobody (aGFP). Interacting 
proteins are biotinylated by the enzyme and can be isolated using streptavidin-conjugated beads. 
6.3.2 Viral generation of TurboID into GFP-VPS34 cell lines 
HEK293 cell lines expressing GFP-VPS34 had been generated in the lab previously by bachelor’s 
student Annika Hornberger. These were fully characterised and the GFP-tag demonstrated not 
to impact on VPS34 activity (Malik et al., 2018). I therefore chose these cells to virally transfect 
aGFP-TurboID, and study interactors of VPS34. 
The TurboID construct used in this study is targeted by a destabilised anti-GFP nanobody. 
Therefore, in the presence of GFP, the biotin ligase will be targeted towards GFP and stabilized 




of the cell not expressing GFP, the ligase will be unstable and rapidly degraded and turned over. 
This reduces non-specific off target biotinylation which could be observed when exogenously 
overexpressing a biotin ligase. I therefore transfected this construct into wildtype, 5 GFP-VPS34, 
and 3 Beclin1-GFP HEK293 cell lines, and selected for TurboID integration by puromycin 
resistance. Of these transfections, 2 Beclin1-GFP and 3 GFP-VPS34 cell lines survived 
transfections and expressed the TurboID Biotin Ligase. The wildtype cell line was designed to be 
a negative control to account for any remaining off-target biotinylation. 
Figure 6.25 demonstrates the resultant cell lines from this transfection and selection process, 
with or without stimulation with 500 μM Biotin. First, the untransfected wildtype, Beclin1-GFP 
and GFP-VPS34 cell lines are shown with only biotinylation of the native carboxylases recognised 
by Streptavidin-HRP. The wildtype TurboID transfected cell line presents with a smear of 
biotinylated proteins which is increased on addition of Biotin. The Beclin1-GFP cell lines did not 
have any appreciable increase in biotinylation, likely due to relatively low expression of GFP-
tagged protein and, upon streptavidin pulldown of biotinylated proteins, there was only weak 
detection of VPS34 complex members. Comparatively, GFP-VPS34 cell lines expressed increased 
general biotinylation. In addition, additional bands appeared in the streptavidin blot specifically 
in the GFP-VPS34 TurboID samples, representing target proteins which were specifically 
biotinylated when TurboID is targeted toward VPS34. Upon streptavidin pulldown, all core 
VPS34 complex members could be detected by western blot, with greater efficiency than the 
Beclin1-GFP TurboID cell lines. Further, both ATG14 forming complex I, and UVRAG forming 
complex II could be detected. While all complex members were identified by streptavidin 
pulldown, the VPS34 core complex forms a very tight high affinity complex, therefore this does 
not necessarily mean the entire complex is being biotinylated. Since GFP-VPS34 TurboID clone 







Figure 6.25 Screening of TurboID cell lines. 
TurboID constructs were transfected into wildtype HEK293 cells and Beclin1-GFP and GFP-VPS34 cell lines. 
Cells were stimulated with 500 μM Biotin and analysed for global biotinylation. Biotinylated proteins were 
isolated by Streptavidin-conjugated sepharose beads and eluted for analysis by immunoblot. Global 
biotinylation was also analysed in cell lysates using Streptavidin-HRP. Lysates and biotinylated proteins 
were analysed by immunoblot with the indicated antibodies. 
Optimisation of TurboID stimulation conditions 
In figure 6.25 above I used a 15 minute standard stimulation time with 500 μM Biotin to 
stimulate biotinylation of colocalising proteins by TurboID. However, in the cell line screen I 
noted only a slight increase in general biotinylation in the GFP-VPS34 cell line after stimulation. 
I therefore next tested a timecourse of Biotin treatments up to an hour to determine the best 
time point to detect specific biotinylation. I observed that, although non-specific biotinylation in 
the wildtype cell line increase over time, I only observed a slight increase in specific biotinylation 
at 15 minutes in the VPS34 cell line which did not increase further (Figure 6.26). This result was 
surprising, as the nanobody is stabilized in the GFP-VPS34 cell line, but not in the wildtype. 
However, this result is possibly due to the stabilized nanobody being highly localised to VPS34 




biotinylate more substrate proteins. This could be investigated further by immunofluorescent 
analysis either against FLAG to determine the localisation of the nanbody or with fluorescently 
labelled biotin to determine where biotinylation is occurring in the cell. 
 
Figure 6.26 Timecourse of Biotin stimulation in TurboID cell lines. 
HEK293 WT, Beclin1-GFP or GFP-VPS34 cells expressing TurboID Biotin Ligase were stimulated for up to 60 
minutes with 500 μM Biotin before cell lysis. Biotinylated proteins were isolated by Streptavidin-
conjugated sepharose beads and eluted for analysis by immunoblot analysis with the indicated antibodies. 
Global biotinylation was also analysed in cell lysates using Streptavidin-HRP. 
Biotinylation of substrate proteins by the TurboID biotin ligase is an ATP-dependent process. 
Therefore, it was important to determine, before moving further with the assay, whether serum 
starvation of cells or stimulation with IGF1 would impact on biotinylation efficiency. An increase 
in biotinylation efficiency on IGF1 stimulation could result in false positives, as increased 
biotinylation in the IGF1 stimulated samples would not necessarily represent increased 
interaction with the VPS34 complex. I therefore studied stimulation of wildtype and GFP-VPS34 
TurboID cell lines with IGF1, either from a serum starved or basal state, and assayed overall 
biotinylation by the Streptavidin-HRP blot, and also specific biotinylation of the VPS34 complex. 




starvation the complex could still be readily detected by streptavidin pulldown. In addition, IGF1 
stimulation did not impact on global biotinylation changes (Figure 6.27). 
 
 
Figure 6.27 Serum starvation and IGF1 stimulation do not impact on TurboID-induced biotinylation. 
 HEK293 WT or GFP-VPS34 cells expressing TurboID Biotin Ligase were either grown in serum or serum 
starved overnight. Cells were then stimulated for 15 minutes with 500 μM Biotin in the presence or absence 
of IGF before cell lysis. Biotinylated proteins were isolated by Streptavidin-conjugated Sepharose beads 
and eluted for analysis by immunoblot analysis with the indicated antibodies. Global biotinylation was also 
analysed in cell lysates using Streptavidin-HRP. 
6.3.3 Mass Spectrometry Analysis of Streptavidin pulldown 
Based on the results above, I set up an assay to compare GFP-VPS34 TurboID cells by TMT-
labelled Mass Spectrometry in triplicate, stimulated with or without IGF1 (50 ng/ml, 15 minutes), 
in parallel with 15 minutes Biotin Stimulation. These were compared to the wildtype TurboID 
cell line also stimulated with IGF1 as a negative control for off-target biotinylation. Cells were 
serum starved overnight, stimulated with IGF1 and Biotin and washed 5 times with PBS before 
lysis in RIPA buffer, to remove any exogenous Biotin which would reduce the efficiency of the 
streptavidin pulldown. I performed a pulldown of biotinylated proteins overnight from 500 μg 




digestion. The resultant peptides were then labelled using TMT labelling reagents for 
quantitative mass spectrometry. 
In order to determine the efficiency of the streptavidin pulldown ahead of TMT labelling, I 
performed a streptavidin blot on the lysates, supernatant and pulldown of this experiment. I 
determined that the pulldown was largely efficient with most biotinylated proteins removed 
from the supernatant (Figure 6.28). However, while in the lysate I observed slightly higher 
biotinylation levels in the wildtype cell line compared to the GFP-VPS34, upon streptavidin 
pulldown I noticed substantially higher levels of general biotinylation. However, IGF1 stimulation 
in the GFP-VPS34 cell line resulted in no noticeable changes in general biotinylation. 
 
Figure 6.28 Many more biotinylated proteins are detected in HEK293 WT TurboID cells than GFP-VPS34 
TurboID. 
HEK293 WT or GFP-VPS34 cells expressing TurboID Biotin Ligase were serum starved overnight, then 
stimulated for 15 min with 500 μM Biotin in the presence or absence of IGF1 stimulation before cell lysis. 
Biotinylated proteins were isolated by Streptavidin-conjugated sepharose beads and analysed by mass 
spectrometry. Global biotinylation in lysates, streptavidin immunoprecipitation and the resulting 




I also observed, upon analysis of the quantified mass spectrometry data, that many more non-
specific biotinylated peptides were identified in the wildtype samples compared to the GFP-
VPS34 samples (Figure 6.29). The excessive number of non-specific peptides impacted on the 
sensitivity of the mass spec approach, as only PIK3C3 (VPS34) and PIK3R4 (VPS15) were detected 
in the GFP-VPS34 samples. 
 
Figure 6.29 Comparison of Biotinylated proteins in GFP-VPS34 and WT TurboID cells 
Biotinylated proteins from HEK293 WT or GFP-VPS34 cells expressing TurboID were isolated using 
streptavidin-conjugated sepharose beads. Peptides were eluted from beads by Trypsin Digestion overnight 
and the resultant peptides analysed by TMT-labelled quantitative mass spectrometry. Data comparing 
GFP-VPS34 and WT HEK293 cells is demonstrated by Volcano plot. Full dataset available in Appendix Table 
5. 
This low sensitivity resulted in very few changes being observed when comparing the IGF1 
stimulated cell to serum starvation (Figure 6.30). I observed, as expected, that amounts of VPS34 
and VPS15 were not affected by IGF1 stimulation. This is in agreement with previous literature 
than VPS15 is an obligate dimer with VPS34 and this interaction is not impacted by external 




promising that I identified the autophagy-related protein ATG2B to be enriched in the serum 
starved condition in comparison to IGF stimulation.  However, changes were very slight due to 
low sensitivity of the experiment. This experiment should therefore be repeated without the 
wildtype control samples, as in this case the cell line does not serve well as a negative control. 
 
Figure 6.30 Comparison of Biotinylated proteins in GFP-VPS34 TurboID cells 
Biotinylated proteins from GFP-VPS34 cells expressing TurboID in the presence or absence of IGF1 
stimulation were isolated using streptavidin-conjugated sepharose beads. Peptides were eluted from 
beads by Trypsin Digestion overnight and the resultant peptides analysed by TMT-labelled quantitative 
mass spectrometry. Data comparing IGF1-stimulation and serum starvation in GFP-VPS34 cells is 
demonstrated by Volcano plot. 
6.4 Discussion 
In this chapter, I present preliminary experiments investigating how SGK3 is activated under 
prolonged Class I PI3K inhibition. Current understanding in the field is that SGK3 is recruited to 
PtdIns(3)P produced on early endosomes by VPS34 and is there phosphorylated by mTORC2 and 
PDK1 for its activation. However, questions still remain over how mTORC2 is directed to SGK3 




most literature relates its activity to PI3K activation. Additionally, our current data does not 
explain how VPS34 is activated by growth factor signals. 
In order to further understand mTORC2 activation and targeting towards SGK3, I performed 
genome level knockout of the critical mTORC2 component mSin1 in HEK293 and U2OS TREx cells, 
and re-expressed several isoform variants and mutants under a doxycycline-inducible promotor. 
I first confirmed that my knockout of mSin1 inactivated mTORC2, as observed by a loss of Akt 
phosphorylation at Ser473, and that this loss of mTORC2 activity resulted in lost SGK3 activation 
and phosphorylation of its activation loop residue T320 (published in Malik et al., 2018). This 
confirmed previously published data using shRNA knockdown of Rictor that demonstrated 
activation of SGK3 was reliant on mTORC2 (Bago et al., 2016). Re-expression of the 5 transcript 
variants of mSin1 also reproduced current literature proposing that transcript variant 4, carrying 
an N-terminal truncation, cannot integrate into and activate mTORC2, and as such SGK3 was not 
activated in response to IGF1 stimulation in this cell line. This increases confidence in my chosen 
model for studying SGK3 activation by mTORC2 as these results agree with current literature. 
A key limitation to this study was that the chosen antibody for detecting SGK3 hydrophobic motif 
phosphorylation, raised against pSer422 of SGK1, had limited sensitivity for detecting pSer486 
of SGK3, and therefore this assay was not robust enough for detection in every experiment 
described. Although Thr320 phosphorylation and SGK3 in vitro activity could be used as a proxy 
for hydrophobic motif phosphorylation, to truly study phosphorylation of SGK3 by mTORC2 an 
improved tool would be required to detect this site. In this study, I tested several antibodies 
against the hydrophobic motif site, however none offered any improvement over the current 
pSer422 antibody, including a sheep polyclonal antibody raised in house. The development of a 
PhosTag assay for monitoring the phosphorylation of SGK3-specific substrates by Athanasios 




In this model, phosphorylation and activation of SGK3 could be rescued by mSin1 with a deletion 
of binding mutations in the PH domain. This is in contrast with Liu et al., who published that the 
PtdIns(3,4,5)P3 binding was critical for activation of mTORC2 and phosphorylation on the 
hydrophobic motif of Akt. The model proposed in the paper was that the PH domain acts by 
autoinhibition of the kinase domain of mTOR, which is released upon PtdIns(3,4,5)P3 binding (Liu 
et al., 2015). Within this model, it would make sense for the PH deletion mutant to be active, if 
mislocalised, as this inhibition is released, however it does not explain the activity of the 
PtdIns(3,4,5)P3-binding deficient mutant, which would still be autoinhibitory in the mTOR active 
site. Additionally, the PH-domain is not performing any auto-inhibitory roles by in vitro kinase 
assay. My data also propose a possible inhibitory role of the Ras-Binding domain of mSin1. 
Mutation of this domain appeared to rescue the decreased activity of the PH-domain mutant, 
and additionally this mutation in the full-length protein further increased its activity. It is 
possible that transcript variant 2, lacking this region of the RBD is not affected by the 
autoinhibitory effects of the PH-domain, and therefore is capable of activating mTORC2 in the 
absence of PI3K signals. This would provide a mechanism by which SGK3 could be activated by 
mTORC2 under prolonged Class I PI3K inhibition, however further experiments would be 
required to validate this mechanism. In order to fully characterise these effects, I would further 
analyse the ability of Ras Binding mutant or Isoform 2 of mSin1 to initiate phosphorylation and 
activation of SGK3. This would include combinations of the PH-domain mutations in TV2 to 
determine if the mutations have an effect in this cell line. It would also be interesting if the Ras 
Binding domain mutation altered the localisation of full length Sin1, and whether this was 
affected by PH domain mutations. Sequence analysis predicted the RBD of mSin1 to be a Raf-
like RBD, which is able to bind to activated Ras (Schroder et al., 2007). This study also suggested 
the RBD acted as an inhibitor or Ras signalling. It would be interesting to follow up this work by 
comparing Ras-like effectors which bind the mSin1 in the presence or absence of IGF1 




Analysis of the cellular localisation of HA-mSin1 revealed a largely diffuse, cytoplasmic 
localisation of mSin1. However, it was unclear from these experiments whether this is 
representative of the true localisation of the endogenous protein or an artefact of the 
overexpression approach. mTORC1 has been shown to be diffuse in the cytosol upon amino acid 
starvation (Jewell, Russell and Guan, 2013). I therefore decided to generate endogenous 
CRISPR/Cas9 knockin cell lines of mSin1-GFP and GFP-Rictor, another mTORC2 component, and 
use these cells to study endogenous localisation. While these experiments do not allow the 
analysis of different variants and mutants of mSin1, they provide an overview of endogenous 
subcellular localisation, and the response to stimulation and inhibition of the pathway. 
Several recent papers have proposed mechanisms by which mTORC2 could be activated 
independently of PI3K, and propose independent pools of mTORC2 with differing sensitivity to 
modulation of the PI3K pathway. Ebner et al., used a fluorescent biosensor of mTORC2 activity 
tethered to different cellular compartments to investigate independent mTORC2 pools. They 
determined that mTORC2 activity was most prominent at the plasma membrane, followed by 
the late and early endosomes. It is therefore surprising that I did not detect any strong 
localisation to either the plasma membrane or Rab5-positive early endosomal membrane 
structures. Using this system they determined that pools of active mTORC2 are present on the 
plasma membrane and mitochondria which are unaffected by GDC0941 treatment and are 
therefore regulated in a PI3K-independent manner (Ebner, Sinkovics, et al., 2017). Two recent 
papers have suggested mechanisms by which mTORC2 can be regulated independently of PI3K 
activity. Further, Jia et al recently published data  suggesting that, as with mTORC1, lysosome 
positioning had an impact on reactivation of certain pools of mTORC2 after serum starvation (Jia 
and Bonifacino, 2019). Given evidence that pools of mTORC2 are regulated independently, it is 
reasonable that an endosomal pool of mTORC2 could be activated to phosphorylate SGK3 




be activated by phosphorylation of mTOR and Rictor by AMPK in response to a range of AMPK 
agonists (Kazyken et al., 2019). 
In this chapter I also set up an assay for studying how VPS34 is activated to produce further 
PtdIns(3)P in response to growth factor stimulation. Using the TurboID Proximity-based 
Biotinylation system. I was able to set up a cell line in which the VPS34 complex was specifically 
biotinylated in GFP-VPS34 cells. However, a high degree of background biotinylation limited the 
depth of analysis, and detection of specifically biotinylated peptides. Therefore, in future work 
this system can be used to modify conditions and determine changes in complexes in response 
to stimuli. Further controls should also be used to optimise the TurboID system before 
proceeding to mass spectrometry analysis. The increased biotinylation in the wildtype cell line 
may be due to increased viral load on transfection of these cells. Additionally, 
immunofluorescent analysis can be used to ensure correct colocalization of GFP-VPS34 and the 
Flag-aGFPTurboID. By a similar method, streptavidin staining can be applied to ensure 
biotinylation is colocalised to GFP-VPS34. 
 Additionally, a miniTurbo biotin ligase was also published to be 1.5-fold less active than TurboID 
but exhibit less labelling before addition of exogenous biotin. This construct would potentially 
allow for more precise temporal control of labelling in highly dynamic processes (Branon et al., 
2018). In my samples, biotinylation in the VPS34-TurboID cell line only slightly increased on 
biotin stimulation compared to labelling from endogenous biotin. Therefore, changes within a 
15-minute stimulation may not be detected as easily. Therefore, repeating this process with the 
miniTurbo construct may allow for more sensitive detection of any potential changes in 
response to growth factors. 
Another interesting area to study would be whether post-translational modification of VPS34 is 
affected by prolonged PI3K inhibitor treatment. For example, VPS34 activity is known to be 




downstream of Akt (Huang and Chen, 2005; Su et al., 2017). Additionally, Beclin1 is heavily 
decorated with posttranslational modifications which modulate VPS34 complex activity (Hill, 
Wrobel and Rubinsztein, 2019). It is therefore possible that phosphorylation or acetylation 
changes occur over prolonged PI3K inhibition which impact on VPS34 activity. To answer this 
question, I would perform acetylation mapping and phosphosite mapping of VPS34 from ZR-75-
1 cells in the presence or absence of Class I PI3K inhibition for 5 days. Any identified changes in 
acetylation or phosphorylation sites could then be followed up to determine whether they have 




7. General Discussion and Future Directions 
Prior to the start of my PhD, SGK3 had been demonstrated to lie downstream of PI3K signalling 
and play a key role in resistance to PI3K-Akt pathway inhibitors in breast cancer. It is therefore 
critical to develop tools to modulate and understand this resistance pathway. 
In this study I generated 2 tool compounds for studying the biology of SGK3. SGK3-PROTAC1 
rapidly and specifically induced degradation of SGK3 from a range of cancer cell lines allowing 
modulation of downstream signalling. Importantly, degradation of SGK3 was observed to have 
a greater effect on inhibiting growth of cancer cells in the context of PI3K-Akt pathway inhibition. 
PROTAC compounds have recently grown in use to study the non-enzymatic functions of 
proteins, for example studying the non-kinase functions of FAK or CDK6. That degradation of 
SGK3 can have a greater impact on PI3K inhibitor resistance than inhibition of its activity 
suggests that SGK3 may have cellular roles beyond its kinase activity. 
Further to this hypothesis, mass spectrometry analysis of SGK3 degradation in ZR-75-1 cells 
revealed surprisingly cellular effects not observed upon SGK3 inhibition. I first demonstrated the 
degradation of SGK3 resulted in reduced expression of the phosphodiesterase PDE4D. As PDE4D 
acts in signalling complexes to mediate highly localised pools of cAMP, it may therefore form a 
complex with SGK3 to mediate endosome-localised cAMP. Further work would be required to 
determine the functional impact and mechanism by which PDE4D is downregulated. I also found 
a surprising upregulation of proteins forming the electron transport chain complexes in 
mitochondria. This could represent an exciting role for SGK3 in mediating cancer cell metabolism 
and warrants further investigation in future work. Importantly, in this study I have not 
functionally characterised the mechanism leading to the upregulation of these proteins, and 
whether mitochondrial function is being activated or inhibited in response to SGK3 degradation, 
and this would be an important future experiment to follow up from this work. Overall, SGK3-
PROTAC1, developed and characterised in this thesis, is a powerful tool for the further 




In addition to the specific SGK3-PROTAC1, I worked with Alessio Ciulli’s lab to develop 
HaloPROTAC-E. This compound utilizes the bacterial dehalogenase activity of HaloTag7 to 
specifically induce degradation of any endogenously Halo-tagged protein. I demonstrated that 
HaloPROTAC-E was able to induce degradation of the entire VPS34 complex to impact on 
downstream biology. The compound can also be used in future work to determine the specificity 
and off-target effects of SK3-PROTAC1, by comparing the effects of both compounds on the 
SGK3-Halo cell line. This compound will be a useful tool within the unit and wider field to study 
proteins with no known ligands or validate target proteins for potential PROTAC development. 
I also set up assays to study the upstream regulation of SGK3 and determine how SGK3 can be 
activated in PI3K inhibitor resistance. I generated mSin1 KO cell lines and used these tools to set 
up a range of assays to study phosphorylation of SGK3 by mTORC2. The data generated from 
this model system demonstrated that the PH domain of mSin1 is dispensable for the 
phosphorylation and activation of SGK3, in contradiction with previous literature (Liu et al., 
2015). Additionally, the data suggests a negative regulatory role of the Ras Binding Domain of 
mSin1. Given that mTORC1 is regulated by the Rag GTPases it would be interesting if activation 
of mSin1 was regulated by G protein binding of the Ras Binding Domain of mSin1. Further work 
would involve further investigating the effect of PH domain and RBD mutations on the 
localisation of mSin1, and how these change in response to pathway stimulation and inhibition. 
It would also be interesting to combine my model with biosensors of mTORC2 activity such as in 
Ebner et al., 2017, to determine if stimulation and inhibition alters the activity of mTORC2 in 
particular cellular compartments. For the study of VPS34 regulation by growth factors, I have 
developed a proximity based Biotinylation assay to identify novel interactors of VPS34, and how 
these interactions change in response to growth factor stimulation. It is important to understand 
regulation of VPS34 as this is a key component in the activation of SGK3 in inhibitor resistance. 
The system I have set up in preliminary experiments will be an important tool in investigating 




To conclude, the aim of my PhD was to develop tools to dissect the roles of SGK3 in PI3K-Akt 
inhibitor resistance. As such, I developed 2 compounds, SGK3-PROTAC1 and HaloPROTAC-E, 
which were able to induce rapid, reversible degradation of SGK3 in a variety of cell lines. From 
this work, I identified 2 potential new roles for SGK3 in cancer cells, possibly modulating cAMP 
signalling through the phosphodiesterase PDE4D, and mitochondrial metabolism. Important 
future work would determine the functional impact of these alterations and whether they have 
a relevant regulatory role in cancer progression. I also developed tools to study the mechanisms 
by which SGK3 can be activated upon Class I PI3K inhibition. These tools will be useful to the 
field to further understand SGK3 activation and therefore determine methods to modulate its 




8. Appendix Tables 
Appendix Tables are held online and are available at: 
 https://benchling.com/s/etr-D7NWzXp03rRSWREFOqeH 
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